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The abundant nuclear enzyme poly (ADP-ribose)polymerase (P ARP) catalyses the 
formation of long homopolymeric chains of ADP-ribose, utilising NAD+ as a 
substrate, as the immediate cellular response to DNA damage. P ARP recognises a 
damaged section of DNA and initiates polymer synthesis, which is believed to act as a 
signal to effect the repair of the lesion. A selective, potent P ARP inhibitor could block 
the recognition, and hence repair, of DNA damage induced by cancer chemotherapy. 
Since increased DNA repair is regarded as a mechanism whereby tumour cells can 
become resistant to treatment, P ARP inhibitors have therapeutic potential as resistance 
modifying agents. From a study ofPARP inhibitors such as 3-hydroxybenzarnide (A), 
benzimidazole derivatives (B) were proposed as inhibitors of the enzyme, and the 
synthesis and biological evaluation of a series of such molecules has been achieved. 
0 
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OH HN-Z R 
A B 
Substituted 2-aryl benzirnidazoles have proved to be highly potent P ARP inhibitors (B; 
R= 4'-MeOPh, ICso= 59 nM), under a permeabilised cell assay the nitro phenyl 
derivative (B; R= 4'N02Ph) is the most potent compound reported to date (ICso= 19 
nM) . 2-Methyl benzirnidazole-4-carboxamide (B; R= Me) has been shown to 
p tentiate the in vitro cytoto ' icity of the antitumour agent temozolomide in L 1210 
ell , and the nthe is of benzimidazole inhibitor suitable for pre-clinical ;n vivo 
aluati n ha al 0 be n in tigated This the i demon trate that benzimidazole 
P RP inhibit r hay promi ing potential for clinical development a re i tan 
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1.1 ADP-Ribosylation 
About 30 years ago at the University of Strasbourg, France, a research group under Dr 
Paul Mandel (1908-1992) interested in transcription accidentally discovered a novel 
polymer. They were studying mRNA poly-adenine tail synthesis in nuclear extracts 
from hen liver but instead of the poly-A expected they isolated poly (ADP-ribose) . 
The enzyme responsible for this process was later shown to be poly (ADP-
ribose )polymerase or as it is more conveniently abbreviated : P ARP.1 
Since this observation there has been much research into the processes involved in 
ADP-ribosylation and the physiological significance of these reactions. Two such 
reactions have been identified; mono- and poly ADP-ribosylation and these are 
essentially post-translational protein modifications. More recently a cyclic (ADP-
ribose) molecule, an NAD+ metabolite, has been discovered and shown to be involved 
in cellular calcium signalling. A brief description of cyclic (ADP-ribose) and the mono 
ADP-ribosylation reaction follows; then the process of poly ADP-ribosylation and the 
enzyme, P ARP, that catalyses the reaction with which this thesis is concerned \ ill be 
co ered in greater detail . 
1.1.1 Mono ADP-ribo ylation2 
10no DP-ribo~ lation i di tinct from pol DP-ribo Jdation in a numb r of wa ' 
~1on P-rib lati n ration cur III a \ ide ariet · f IL from b th 
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prokaryotic and eukaryotic organisms. The reaction takes place in the cytoplasm and 
cell membrane, in contrast to poly ADP-ribosylation, which occurs exclusively in the 
nucleus of eukaryotes. The extent of the modification is small in mono ADP-
ribosylation since only one ADP-ribose moiety is transferred to a protein acceptor. 
which is an amino acid of a basic nature. Examples of mono ADP-ribosylation with 
arginine, asparagine and lysine residues have been identified. The ADP-ribosyl protein 
bond formed in this case is an N-glycosidic bond, whereas in contrast, the nature of the 
bond formed in poly ADP-ribosylations is O-glycosidic. Much evidence suggests that 
mono ADP-ribosylating enzymes are microbial toxins with targets in eukaryotic cells. 
For example, diphtheria toxin is a protein produced by Corynebacterium diphtheriae 
that catalyses the mono ADP-ribosylation of a factor involved in protein synthesis, thus 
inhibiting the process and leading ultimately to the death of the cell. 3 Although 
additional roles for mono ADP-ribosylation have been postulated, the use as a toxin is 
the most clearly defined. 
1.1.2 Cyclic ADP-ribose 
o 
II 
-O-P-O 
I 
o 
I 
-O-p-O 
" o 
OHOH 
OHOH 
N 
NJ 
Proposed Structure of Cyclic ADP-ribose 
Recently a new NAD+ metabolite that mediates calcium ion release has been isolated 
from sea urchin cells This was formed by a novel enzyme that released nicotinamide 
from NAD+, with production of cyclic (ADP-ribose) and not the expected mono/poly 
ADP-ribose The roIL' of cyclic (ADP-ribose) has now been confirmed to be that of a 
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second messenger. It is a potent mediator of Ca2,.. release in many species, and has 
been shown to be involved in mammalian insulin secretion.-+,5 
1.2 Poly (ADP-rihose)polymerase: PARP [ EC 2.4.2.30 ] 
The nuclear enzyme poly (ADP-ribose)polymerase is highly abundant in most 
eukaryotic cells, with approximately one million molecules present in the average 
mammalian nucleus. It has alternatively been known as poly (ADP-ribose)synthase or 
poly (ADP-ribose)transferase but PARP has become the most accepted form. The 
enzyme catalyses a post-translational modification of proteins whereby an ADP-ribose 
moiety is transferred from nicotinamide adenine dinucleotide (NAD+) to a suitable 
protein acceptor. The process is then repeated, adding ADP-ribose units sequentially 
to themselves to build up long polymeric chains. The formation of the polymer 
described has been demonstrated to be the immediate cellular response to DNA strand 
breaks which are a requirement for enzyme activity. 
P ARP has been detected in many different classes of animals from simple eukaryotes 
such as the slime mould Dictyostelium discoideum6 to higher species including 
humans. It has been readily purified from human placenta by affinity chromatography 
using a 3-aminobenzamide ligand. 7 Amongst many other species it has been isolated 
from Drosophila8, murine9, bovine lO and chicken ll cells, and this hints at the 
importance of the enzyme to many forms of life. 
PARP, and hence the process of poly ADP-ribosylation, has been shown to participate 
in many cellular processes including cell cycle control, cell differentiation, transcription 
and alteration of chromatin structure, although its precise role in many of these events 
is unclear 12.13 However, the most important of the postulated roles for P ARP is its 
involvement in the D0JA repair process and its apparent ability to recognise D0i.-\ 
9 
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strand breaks. This is almost certainly the major function of the enzyme and there is 
now an increasing amount of experimental evidence to enforce these view 
1.2.1 Structure of PARP 
P ARP is a 116 kd nuclear protein with 1014 amino acid residues. The function of any 
enzyme is intimately linked to its structure, both in terms of the three dimensional 
architecture and the linear amino acid sequence that defines it. P ARP is no exception 
to this rule. Kameshita et al. first showed that limited a.-chymotrypsin and papain 
proteolysis of the enzyme separated three important domains. 1-l The amino acid 
sequence of the human enzyme was first determined from the cDNA of fibroblast 
cells. 15 In order to reveal important amino acid sequences and deduce their function 
the amino acid profiles determined from several species have been superimposed, 
revealing some highly significant information. With the exception of Drosophila, 
P ARP from the higher eurkaryotes such as the mammals has a highly conserved amino 
acid sequence between species, with a 900/0 amino acid sequence homology. In 
contrast Drosophila has only a 61 % homology with human P ARP. The most highly 
conserved sequences of the enzyme occur in concordance with the important structural 
and functional regions. A sequence of 50 amino acids in the C-terminal, residues 859-
908, has a 1000/0 homology among vertebrates and is still highly conserved when other 
species are considered, showing a 920/0 homology. This region is considered to be the 
P ARP signature. 16 From the digestion studies a 46 kd N-terminal fragment, a central 
22 kd region and a C-terminal 54 kd polypeptide have been identified and their 
function determined. Further sub-domains, sometimes of unclear function, have been 
defined within the three major regions and this is summarised infigure 1.1.17 
The N-terminal domain has been identified as a DNA binding domain (DB D) PARP is 
a metalloenzyme and requires zinc to function. It is \vithin the OBO that two zinc 
tinger structures f I and f I I are located, and these are believed to be essential for 
P ARP to recognise and bind to damaged D~ A 18.19 
10 
Automodification 
DNA Binding Domain Domain 
H2N-1 II II 1 1 ID/ 
f 1 f 11 NLS 372 524 Zinc 
Fingers 
Figure J. J; Structure oj P ARP 
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Catalytic Domain 
i 1 ~C02H 
859 908 1014 
PARP 
Signature 
A zinc finger is a secondary protein structure where an atom of zinc, chelated by amino 
acids with suitable side groups, holds the linear peptide in a loop or finger. 
Figure 1. 2,' Zinc Finger Structure 
This region of the amino acid sequence has a number of conserved residues including 
two finger motifs consisting of -(Cysteine-X-X-Cysteine-X28 or 30-Histidine-X-X-
Cysteine)- where X represents any amino acid. 19 This is consistent with the existence 
of two zinc fingers although P ARP represents a novel class of enzyme containing such 
structures. I8 Interestingly, an extremely similar zinc finger motif has been discovered 
in DNA ligase III, an enzyme which also binds preferentially at DNA strand breaks.20 
The N-terminal region also contains a short amino acid sequence known as the nuclear 
localisation signal (NLS). This generally basic region targets the enzyme to the cell 
nucleus. 16 
I 1 
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Ogata et aI., while studying poly (ADP-ribosyl)ation in isolated rat liver nuclei, 
demonstrated that P ARP could act as an acceptor for polymer formation, identifying 
the central domain amino acid residues 372-524, as a region containing protein 
acceptors.21 When activated, P ARP can modify itself as well as other proteins, in a 
process known as automodification. This domain is particularly rich in glutamic acid, 
an acceptor amino acid with an acidic side chain which is important for polymer 
formation as will be discussed later. The carboxyl terminal was shown to be the region 
where NAD+ substrate binding occurred. 1-l This fragment of the enzyme alone carries 
out all the enzymic functions of the protein hence is termed the catalytic domain. 17 A 
common feature in the active sites of enzymes that utilise NAD+ is a secondary 
structure known as a Rossmann fold, that consists of an a helix-~ sheet-a helix 
sequence. The catalytic domain of P ARP from all species has many highly conserved 
regions and there exists suitable amino acid sequences for the formation of such an 
NAD+ recognising structure; this was partly used to identify this region as the NAD+ 
binding domain. 22 However, this motif remains to be identified with certainty, and 
although much is known about the linear amino acid sequence of P ARP, a lot less is 
known about the three dimensional structure of the enzyme. 
The understanding of the precise structure is certain to become clearer, however, with 
the report that the crystal structure of the catalytic domain of chicken P ARP has 
recently been solved. A P ARP inhibitor has been co-crystallised, bound to the active 
site of the fragment, and this important data is discussed fully in Chapter Two. 
1.2.2 Function of Poly (ADP-rihose)polymerase 
Havina discussed the structure of P ARP we can now examme the many possible ;:, 
cellular functions proposed, although in many cases the precise mechanism of action is 
far from clear. 
12 
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The fact that P ARP could playa part in cell differentiation was suggested as long ago 
as 1975, when it was observed that fluctuation of NAD+ levels occurred in the cell 
when embryonic chick cells differentiated to become either muscle or cartilage tissue. 
It was shown that the rate of poly (ADP-ribose) synthesis was correlated to the rate of 
differentiation. 23 More recently, the cardiovascular drug vesnarinone that weakly 
inhibits P ARP has been shown to induce differention in murine carcinoma stem cells, 
giving further possible evidence of the enzyme's involvement with this process. 13 
P ARP has been linked to RNA synthesis, since in studies involving avian oviduct cells 
that uniquely stimulate transcription, an increase in RNA production is accompanied by 
increased poly (ADP-ribose) synthesis. 2~ 
P ARP may be implicated in the early stages of cancer according to the studies of Miwa 
et al. who recorded that P ARP activity is higher in the nuclei of hepatoma and human 
leukaemia cells than in the corresponding normal liver cells and leukocytes. They 
showed that P ARP has up to a ten-fold higher association with chromatin in 
transformed cells. 25 
It was known that damage to DNA resulted in a lowered cellular NAD+ concentration 
and Durkacz et al. first demonstrated that there was an accompanying rise in the 
activity of P ARP, linking the enzyme to the repair of DNA. 26 This observation, and 
the deduction that if poly ADP-ribosylation facilitates cellular recovery then inhibition 
of the process may enhance the effects of cytotoxic agents, has fuelled much research. 
Probably more is now known about this function than any other. 
It is now established that the major use of P ARP in eukaryotic cells is its ability to act 
as a "mo/ecli/ar nick st.'nsor" and participate in the intricate response of cells to D:\:\ 
damage, a role made possible by the diverse structural features of the enzyme. 28 This 
process \vill he disl'llssed in detail in the follo\\ing section. 
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1.3 DNA Repair 
The integrity of DNA is vital not only to cell survival but, ultimately, to the longevity 
of the whole organism as well. DNA is the molecular blueprint through which 
information is passed from cell to cell, from one generation to the next. However, 
damage is constantly being inflicted upon DNA by a number of cellular and 
environmental factors including UV and ionising radiation, cellular endonucleases and 
electrophilic, alkylating chemicals. There are a number of common forms of DNA 
damage, including missing/altered/incorrect bases, and bulges in DNA due to insertions 
or deletion of bases. UV exposure can lead to the formation pyrimidine dimers causing 
kinks in the DNA, and damage can also occur to the phosphodiester backbone or the 
deoxyribose rings. The cell has developed mechanisms to counteract these potentially 
lethal events, and although many are unclear a few are well defined. 
1.3.1 Mechanisms of DNA Repair 
Photoreactivation of Pyrimidine Dimers 
It is well known that UV light catalyses a cycloaddition reaction between two adjacent 
thymine bases, forming a cyclobutyl adduct. 
DNA 
Backbone 
UVEXPOSURE 
Figure 1.3; FormallOl/ of··J Thrmine Dime,. 
l~ 
\ 
'. CH3 
\ 
\ 
\~----- Cyclobutyl Ring 
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Photo lyase is a flavin dependent enzyme that also utilises visible light energy to repair 
the adduct, restoring the intact bases. This type of damage can also be repaired by a 
nucleotide excision mechanism. 
Mismatch Repair 
In this case an incorrect base may be incorporated during DNA synthesis. Mismatch 
repair enzymes excise the mismatched base(s) and mediate DNA polymerase repair. 
Repair of lJ6-Alkylguanine Adducts 
Exposure to DNA alkylating agents such as N-methyl-N'-nitro-N-nitroguanidine 
(rv1NNG) , yields, among other products, highly mutagenic 06-alkylguanine adducts 
that can cause base inversion at subsequent replications. Both E. Coli and mammalian 
cells possess a repair protein, 06-methylguanine- DNA methyltransferase (MGMT) 
that transfers the offending alkyl group to itself. Since this has the effect of 
inactivating the protein, it cannot be considered an enzyme. 
Excision Repair 
In base excision repair a damaged base is recognised and removed by a DNA 
glycosylase. The rest of the backbone is subsequently removed by an endonuclease. 
DNA polymerase incorporates a new base and backbone and the strand is sealed by 
DNA ligase. This is depicted infigure 1.-1. A similar mechanism exists for the repair 
of nucleoside damage. 
15 
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Figure 1.4 Mechanism of DNA Excision Repair 
P ARP has been known for a long time to be associated with the process of excision 
repair,26 but more recently a direct involvement has been suggested with P ARP 
competing with excision repair enzymes for the site of DNA damage. 27 
1.4 PARP: Involvement in DNA Repair 
The synthesis of long ADP-ribose polymers by P ARP is recognised as an immediate 
response to DNA damage. The presence of a DNA strand break is an absolute 
necessity for this response. 29 The substrate required by P ARP for its function is 
NAD+ which acts as the source of the ADP-ribose moieties required for polymer 
synthesis. In this respect P ARP is of interest as the well known function of NAD+ is 
as a coenzyme for redox reactions, rather than as an active site substrate. 
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Figure 1.5. The Mechanism of NAD+ REDOX Reactions 
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o 
As shown in figure 1.5 the oxidation of ethanol to ethanal catalysed by an alcohol 
dehydrogenase utilises NAD+ as a cofactor, which is reduced to NADH by a hydride 
atom from ethanol. Similarly, a molecule ofNADH can give up a hydride atom when 
acting as a cofactor in an enzymic reduction. P ARP however has no such redox 
activity, and is unusual in this respect. 
1.4.1 The Recognition of Strand Breaks 
PARP is an extremely abundant protein tightly associated with chromatin. In 
eukaryotic cells DNA is not a naked molecule, but is tightly bound to a group of basic 
proteins called histones. These support the double helix of D:-'::\, forming a protein-
DNA complex known as chromatin, thus forming the familiar structures known as 
chromosomes. 
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P ARP can recognise both single strand and double strand breaks. When a break 
occurs in a strand of DNA, P ARP recognises it and binds to the broken strand at its 
amino, zinc finger containing terminus. Once bound the enzyme has been shown to 
symmetrically cover 7-8 nucleotide residues on each side of the break 30 and seems to , 
bind irrespective of amino acid sequence in the vicinity of the site of damage. 31 
Gradwohl and co-workers demonstrated that in a zinc-dependent manner, double 
strand breaks with blunt ends are recognised by P ARP with the greatest efficiency, 
followed by double strand breaks with overhangs and finally by single strand breaks. 
The fact that double strand blunt end breaks have the greatest effect on the rate of 
polymer formation is probably due to the simple fact that this is potentially the most 
lethal form of damage. This work also reaffirmed the role of the zinc finger structures 
in P ARP activity and also identified the second finger structure, f II, as the most 
responsible for DNA binding. It was proposed that the main function of the first, f I 
finger, was dimerization to another P ARP DNA binding domain, suggesting that the 
enzyme could function as a dimer. 30 
More elegant experiments have been carried out with DNA containing single strand 
breaks, and much more is known about the recognition processes involved. In 
common with double strand breaks, when a DNA single strand break occurs P ARP 
recognises this and binds to the break at its N-terminal domain. Le Cam and co-
workers investigated the recognition phenomena using electron microscopy.32 They 
took a 139 base pair DNA fragment that contained a single strand nick approximately 
in the centre of the molecule and incubated it with PARP. Electron microscopy 
visualised the broken DNA before and after the addition of the polymerase and 
demonstrated that the broken DNA duplex appeared as a \' -like structure. Following 
incubation P ARP was obser\'ed to bind to the apex of the \' shaped D\: A at the 
position of the nick. :\fter the enz\·me is bound there is a 10:° angle between the 
IX 
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strands and this binding angle is less than the 1220 binding angle in lone single strand 
broken DNA. This is demonstrated infigure 1.6. 
\ 
\ 
\ 
DNA Damaged 
\ 
\ 
\ 
\ 
-PARP 
Figure 1.6; Recognition of DNA Damage By P ARP 
PARP Bound To 
Site Of DNA Damage 
The implication of this result is that P ARP may actually 'see' the break as P ARP binds 
more tightly to DNA that is bent. This is now accepted as the mechanism by which 
P ARP achieves its affinity for DNA single strand breaks. 
1.4.2 Polymer Synthesis 
Once P ARP has recognised and associated with a site of DNA damage, it catalyses the 
synthesis of long, highly negatively charged, polymers of ADP-ribose, at the expense 
of depletion of NAD+ levels within the cell. The polymer itself consists of repeating 
ADP-ribose units covalently elongated from an adenosine 2'-OH to the I'-ribose 
carbon of the next repeat unit, forming long chains. The polymer also forms frequent 
branch points, where new ADP-ribose polymers initiate from the 2'-ribose hydroxyl to 
a I'-ribose carbon on the first ADP-ribose unit of a branch point. The overall effect is 
the formation of a large, branched polymer that is depicted in figure 1.7. Spectral 
studies also suggest that the polymer may have a helical conformation. ~3 
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Figure 1. 7; Structure of Poly (A DP-ribose) . 
P ARP can initiate polymer formation at two possible sites. Such protein acceptor sites 
as they are known, are amino acids located either in an adjacent histone or in the amino 
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acid sequence ofP ARP itself, in a region defined as the automodification domain. The 
nature of these protein acceptors is highly specific and P ARP requires an amino acid of 
an acidic nature, either in the side chain (jor example, glutamic acid) or at a carboxyl 
terminus. 2 To digress briefly, this is an interesting distinguishing point of poly (ADP-
ribosylation) verses mono (ADP-ribosylation), since mono (ADP-ribose)transferases 
exclusively modify amino acids with basic side chains (jor example, asparagine). 
The initial step in polymer formation is the transfer of an ADP-ribose moiety from the 
substrate, NAD+, to a suitable acidic amino acid acceptor either on a histone 
(heteromodification) or in the automodification domain of the enzyme itself. This is 
accompanied by the release of a molecule of nicotinamide. 34 A mechanism for this 
reaction has been proposed involving a single essential amino acid residue, glutamic 
acid 988 (Glu-988), in the catalytic domain of the enzyme. 35 Its participation was 
proposed because of similarities with toxin ADP-ribosylations and the observation that 
site-directed mutation of P ARP which involved replacement of the Glu-988 with a 
glutamine residue, almost completely inactivated polymer formation reactions. 35 It has 
been proposed that Glu-988 is involved in both initiation and elongation of the 
polymer, although it may playa slightly different role in each process. 
Polymer Initiation 
At the beginning of polymer formation an NAD+ molecule is bound to the catalytic 
domain of the enzyme. It is thought that the Glu-988 may hydrogen bond to an acidic 
group in the automodification domain positioning it to attack the NAD~ and 
eliminating a molecule of nicotinamide. The attacking carboxyl group should be 
inherently nucleophilic since it is predominantly ionised at neutral pH, while the Glu-
988 ser\'cs to bring about the correct spatial arrangement. This is pictured in !(I.turc 
1.S. 
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Figure 1.8. Proposed Mechanism of Polymer Initiation 
Polymer Elongation 
The next step to consider is elongation of the poly (ADP-ribose) polymer. The 
proposal involving the critical Glu-988 residue is that the glutamic acid now aids 
polymer formation by catalysing nucleophilic attack of the terminal adenosine 2'-OH to 
the ribose-nicotinamide bond of the NAD+ substrate, again releasing nicotinamide, see 
figure 1.9. 
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There is some dispute as to the exact details of the physical process involving ADP-
ribose transfer during polymer elongation and two possible mechanisms, distal addition 
or enzyme-proximal addition, have been proposed. 36 
Distal Addition 
In this mechanism the NAD+ monomers are simply added progressively to the 
adenosine 2'-OH distal end of the polymer. In the case of automodification one P ARP 
molecule would catalyse the modification of another. 37 
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Proximal Addition 
This alternative model suggests that new NAD+ monomers are attached to P ARP by 
their I'-ribose carbon with the release of nicotinamide and the adjacent polymer is then 
transferred to the adenosine 2'-OH. The extended polymer is then returned to the 
automodification domain, and fully formed polymers could be transferred later to other 
proteins, such as histone acceptors for example. 38 
Current studies have suggested that the model of distal addition is probably the correct 
one. P ARP seems to function as a catalytic dimer, and the distal automodification of 
one P ARP molecule by another appears to be the most significant ADP-ribosylation 
reaction occuring in cells. 34 
1.4.3 Polymer Degradation 
The rapid catabolism of the polymer IS carried out by poly (ADP-
ribose )glycohydrolase, and although the enzyme is poorly studied in comparison to 
PARP, it has been cloned and is known to be a 59 kd protein. The short half-life of the 
ADP-ribose polymer is due entirely to the high activity of this enzyme, which always 
occurs with, and appears to work in synergy with PARP)4 The eDNA of PARP has 
been expressed in Saccharomyces cerevisiae, an organism with no naturally occurring 
P ARP or glycohydrolase. The subsequent accumulation of poly ADP-ribose chains 
resulted in intolerable interference with cellular processes, leading ultimately to the 
death of the organism. 39 
During the life time of a DNA strand break the polymer is probably synthesised and 
degraded many times, demonstrating the synergy between P ARP and the 
glycohydrolase. Once the DNA strand break is sealed any polymers remaining are 
rapidly degraded by: the glycohydrolase, and P.c\RP is only reactivated when it re-
detects DNA damage 
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Poly (ADP-ribose)glycohydrolase hydrolyses the O-glycosidic bond between monomer 
units, liberating a free adenosine 2'-OH polymer end and releasing an ADP-ribose 
moiety. In the case of distal polymer elongation, P ARP and the glycohydrolase 
continuously compete for the same distal end of the polymer. If proximal polymer 
formation occurs then the glycohydrolase still attacks at the distal end whereas P ARP 
operates at the opposite end of the polymer since by this model elongation occurs from 
the start of the polymer. 36 
Poly (ADP-ribose)glycohydrolase degrades the whole polymer except the final 
remaining ADP-ribose moiety bonded to the protein acceptor. The nature of this bond 
(the result of the initiation step), is different, and hence requires a different enzyme, 
ADP-ribosyl protein lyase, to hydrolyse the linkage liberating the free acceptor. 2 
1.4.4 The Consequence of Polymer Formation 
The process of polymer formation is very rapid and polymers can develop up to 200-
300 residues in size in less than a minute. The short half life of the polymer arises 
owmg to the high activity of the metabolising enzyme poly (ADP-
ribose )glycohydrolase. 28 Although short lived there is a brief period when there is an 
extremely dense concentration of the highly electronegative polymer (there are two 
negative charges per monomer unit) in the close vicinity of the DNA strand break. 
This inevitably leads to a repulsion between the polymer and DNA, and probably 
causes the modified P ARP to dissociate from the strand break. This inactivates P ARP 
since it requires DNA as a cofactor, thus halting polymer synthesis. It had been 
demonstrated previously that ADP-ribose modified PARP could not bind to DNA 
strand breaks ill \'jlro; this proves the hypothesis in retrospect. ~OA 1 \\,ith no 
polymerisation occurring, the polymer is completely degraded by the glycohydrolase 
and suddenly PARP can again bind to the DNA strand break. As such it is suggested 
that a dynamic existence occurs at the damage site. ~~ 
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Recall that P ARP can also heteromodify histones. It has been demonstrated that many 
histones, including the lysine rich histone HI can act as protein acceptors and poly 
ADP-ribosylation can also occur at this site. Interestingly, it is a terminal carboxyl 
residue that has been identified as an acceptor of ADP-ribosylation in the very basic 
histone H1.2 It has been proposed that such modifications introduce structural and 
conformational changes to the histone, causing a relaxation in the chromatin structure, 
an effect which has been observed under an electron microscope. 28 This forces P ARP 
to diffuse from the site of damage36 and, as described above, the polymer undergoes 
the familiar degradation followed by rejoining of the DNA damage site and new 
polymer synthesis. 
The overall effect of P ARP binding to damaged DNA, modifying itself, diffusing away 
from DNA and then rejoining DNA as a result of glycohydrolase activity has been 
described as a shuttle mechanism. 40 Its relevance to strand breaks is unclear but there 
have been several attempts to explain its purpose. 
Competition For Strand Breaks 
The simplest model suggests that at the site of DNA damage, P ARP and eXCISIon 
repair enzymes compete for the nicked strand, and P ARP is particularly efficient at the 
recognition of DNA strand breaks. Once attached, automodification commences 
causing electrostatic repulsion and the diffusion of the now inactive P ARP away from 
the DNA. This effectively allows the DNA lesion repair enzymes access to the site and 
the break is sealed. P ARP is reactivated by the action of poly (ADP-
ribose )glycohydrolase. 27 
The Histone Shuttle 
The histone shuttle model of P ARP involvement in excision repair is a more elegant 
attempt at explaining the function of ADP-ribosylation. Experimental evidence has 
shown that chromatin structure plays all important role in D\::\ repair. but the tight 
26 
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association between DNA and histone protein could possibly hinder the access of 
repair enzymes during excision repair. It is known that during excision repair the tight 
association between histones and DNA is locally disrupted; furthermore nuc1eosomes 
are unfolded as the damaged DNA is incised and removed. Complex experiments have 
suggested that the automodification reaction of P ARP may shuttle histones off and 
back onto DNA, thus facilitating the access of excision repair enzymes. 
The long branched polymers of ADP-ribose are highly acidic, more so than DNA, 
since the polymers have two negative charges per monomer compared to only one per 
nucleotide of DNA. All histones, especially HI, are highly basic, and P ARP competes 
with DNA, preferentially binding to a section of histones which subsequently 
dissociates from DNA. This allows the access of DNA repair enzymes to the site of 
damage. Following a now familiar mechanism the reassembly of the DNA-histone 
complex is effected by poly (ADP-ribose)glycohydrase. The degradation of the 
polymer reduces the acidic nature of the modified P ARP to such an extent that the 
now more acidic, and repaired DNA, successfully rebinds its histone core. 3-l,-l2 .. l3 
Cell Signalling 
One proposal suggests that the physical process of poly ADP-ribosylation constitutes a 
signal to the cell that informs it of DNA damage. This signal may well involve the 
ADP-ribose polymers or their degradation fragments, but there are also other unusual 
small molecules present such ADP-ribose and nicotinamide (from polymer 
formation).28.3-l Could one or more or these molecules act as a signal? 
Whatever mechanism is occurring at the site of DNA damage, it is certain that PARP is 
involved in the intricate response of the cell to strand breaks, and subsequent to the 
formation of ADP-ribose polymers, cellular excision repair enzymes are delivered to 
the site of damage 
27 
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1.5 P ARP and Cancer 
Poly ADP-ribosylation and P ARP has been linked to many different cellular functions 
and disfunction of any of these could potentially lead to disease. A recent study 
outlined the importance of such protein modifications in many varied conditions such 
as ageing, diabetes, HIY and AIDS and cancer. 44 
This thesis is concerned with the implication of P ARP in cancer, and more precisely 
the potentiation of DNA damaging agents used to treat cancer by inhibiting P ARP and 
hence excision repair in tumour cells. 26 A discussion of the human condition of cancer 
is needed to explain this involvement. 
1.5.1 Human Cancer 
Cancer is only second to heart disease in the cause of death in Western Europe and the 
United States, and it is probably the most feared. One in three people will develop it in 
some form in their lifetimes, and of these people half will die as a result. Cancer is not 
a new disease as commonly assumed, but has only comparatively recently been 
identified. 
A famous historical case is that of Katherine of Aragon, the first of Henry VIII's six 
wives. She died in 1536, the victim of poisoning by her enemies the medieval post-
mortem ruled. The 'poison' had caused a large black growth to attack her heart and 
heads rolled as a result! In recent examinations of the records surgeons have 
concluded that she almost certainly died of a tumour of the heart tissue, but given the 
political feelings and lack of knowledge of the time, such a gro\V1h could only have 
been the result of treachery. 
Fighty' \cars ago cancer caused less than 10°0 of deaths in the UK, the major killer 
being infectious disease :\s advances have been made in the treatment of bacterially 
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induced disease, the death rate from cancer has risen to over 200/0. The condition is 
characterised by uncontrolled cell proliferation. Many different types of cancer exist 
effecting many parts of the body. The main cause of cancer is now accepted as 
exposure to an increasing amount of environmental factors such as natural and 
synthetic chemicals, radiation and viruses. Additionally, there are occupational 
hazards, the best know example is probably lung cancers in construction workers 
exposed to large amounts of asbestos. Life style and diet can also effect cancer, 
smoking accounts for 30% of cancer deaths, and a high fat diet has been linked to 
colon cancer. Rarely, cancer can be inherited from ones parents, but more commonly 
some people have a genetic susceptibility, 'breast cancer families' are well known 
examples. Cancer is however very much a disease of the elderly, a result of increasing 
longevity of life, and a greater exposure to cancer causing agents. 
Cancer begins as a single damaged or altered cell that divides becoming a benign 
neoplasm ('new-growth') or tumour. For solid cancers, for example, this is small, and 
confined to the region of its origin. The slow growth of the tumour is generally not 
life threatening, but if allowed to continue it becomes a malignant neoplasm, and at 
this stage the condition is usually considered as cancer. In contrast to benign cells, the 
older tumour loses the appearance and function of the cells of its origin, can establish a 
blood supply, and aggressively invade neighbouring tissue, spreading throughout the 
body via a process known as metastasis. The condition becomes threatening when 
secondary tumours invade vital organs. P ARP has a possible association with the 
condition of cancer, probably at the initial stages of the disease. It has been 
demonstrated experimentally that pulmonary epithelial cells exposed to asbestos and 
cigarette smoke extracts show increased activation of the enzyme. ~5 
I.S.2 Treatment of Cancer 
The current treatments for cancer are surgery, radiotherapy and chemotherapy If 
surgery removes all the tumour mass the condition can be cured completely, but 
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usually once the tumour is large enough to detect and operable, it is invariably 
metastatic. Early detection is essential for surgery to be effective. Radiotherapy is 
also a localised treatment, often used in combination with surgery. Radiation directed 
at a tumour can kill cancer cells, and is useful if surgery is difficult to perform, but is of 
limited use once metastasis has occurred. 
Cancer Chemotherapy 
Since most cancer cases are diagnosed after the primary tumour has metastasised, a 
treatment involving chemotherapy is essential to remove microscopic secondary 
tumours from other parts of the body. Chemotherapy is a systemic treatment that 
reaches the whole body, but unfortunately it has many side effects. Many anti-cancer 
drugs act by targeting DNA or interfering with DNA synthesis particularly in cancer 
cells, that divide rapidly. Unfortunately, other dividing cells in the body such as 
intestinal epithelium, bone marrow and hair follicle cells are also effected, leading to 
the toxic effects of chemotherapy that include nausea and vomiting, immune 
suppression and hair loss. A serious problem encountered with chemotherapy is the 
ability of tumour cells to become resistant to treatment, and much research has tackled 
the exact function of such mechanisms. Resistance can arise when DNA damaged by 
treatment has an increased ability to repair lesions. Since P ARP is implicated in this 
process it suggests a target for inhibition, and hence control over the mechanisms of 
cellular resistance to anti-cancer drugs. 
1.6 Drug Resistance46,47 
Resistance to chemotherapeutic drugs represents a major problem in cancer treatment, 
and can be classified as intrinsic or acquired. In the United States in 1988 half of new 
cancer patients had tumours that were intrinsically resistant to drug treatment. 
10 
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Intrinsic Resistance 
A cell that has had no pnor treatment and shows resistance from the outset of 
treatment is intrinsically resistant. A number of reasons for this status are possible, 
The drug may not even be reaching the target cell due to poor bioavailability, or may 
not be able to cross the cell membrane. Once within the cell, should the drug require 
activation, the lack of a suitable enzyme (in certain cells or individuals) could leave 
drug unactivated, or conversely an excess of metabolic enzymes could completely 
break down and excrete the drug. In cancer treatment most drugs are at their most 
active against rapidly dividing cells. Solid tumours, such as those found in the colon, 
exhibit relatively slow growth, with most cells in the resting, Go phase, of the cell 
cycle. This is an obvious source of resistance. 
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Acquired Resistance 
A cell has acquired resistance if it responded initially to the treatment but became less 
responsive as treatment progressed, The central mechanism of acquired resistance is 
believed to be genetic. mutations can alter receptor sites and protecti\'e genes may be 
amplified, Cancer drugs are frequently mutagenic themseh"es. and gi\'en the genetic 
'\ I 
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instability of cancer cells they could increase the frequency of mutations that lead to 
the development of resistance. 
Figure 1.11 attempts to display the important features of cellular resistance to drugs. 
Resistance can arise at the stage of drug entry into the cell. If the influx is passive the 
physicochemical properties of the cell membrane are important, and if the transport is 
active a mutation in the mechanism may lead to resistance. Similarly an increased 
efficiency of the drug efflux could be detrimental to treatment. Overexpression of drug 
metabolising enzymes will inactivate the drug. This could be a response induced by 
over exposure of the cell to the drug so varying treatments can be important. A 
mutation in the structural gene of the drug target, even by one amino acid, could 
significantly reduce affinity for the drug rendering it less active, or an overexpressed 
structural target gene could increase the concentration of target sites with the effect 
that function is still maintained since a lower proportion of receptors are inhibited. An 
important mechanism is that of resistance to alkylating agents used in chemotherapy, 
and involves the repair of damage to the target site, in this case the repair of damage 
caused to DNA. MGMT has been reported to be implicated in alkylating agent 
resistance, and its mechanism of action has been discussed in a previous section. 
1.6.1 Multidrug Resistance48 
Another major problem is that of so-called multidrug resistance (MDR), where 
exposure to one drug induces resistance to a broad range of structurally and 
functionally unrelated drugs. MDR also occurs in a broad range of cell types, and it 
involves alterations to drug transport systems, the best studied example being the 
involvement of a membrane protein, P-glycoprotein. 
This 170 kd protein spans the cell membrane and its thought to constitute an acti\'e 
membrane efflux pump that removes many anti-cancer agents from the cell In mam' 
types of tumour the gene for P-gl~'coprotein is overexpressed It is important to note 
~, 
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that multi drug resistance does not significantly effect alkylating agents or platinum 
drugs. 
1.6.2 Overcoming Drug Resistance 
Many attempts have been made to overcome the problem of resistance of tumours to 
treatment, and much research has been devoted to understanding the mechanism 
involved. Novel classes of drugs have been identified and tested to determine if they 
exhibit resistance properties. In some cases changing the dose regime of a drug can 
have an effect on its potential for inactivation. 
It has been proposed that multidrug resistance could be overcome by targeting P-
glycoprotein with channel blocking agents. The cardiac drug verapamil reduces drug 
efflux and hence resistance in vitro but clinical trials were unsuccessful since the high 
concentrations ofverapamil required caused cardiac toxicity.-t7 
Resistance to alkylating agents and cisplatin occurs through a different mechanism 
based on the increased capacity of the cell to repair DNA damage. The initial 
recognition and incision of DNA in excision repair activates P ARP allowing access of 
DNA polymerase and other enzymes in a manner previously described. Masuda et al. 
demonstrated that induced resistance to cisplatin was associated with cross resistance 
to a classical alkylating agent melphalan (L-phenylalanine mustard) and was not 
attributable with the overexpression of P-glycoprotein. They also reported that 
aphidcolin a known specific inhibitor of DNA polymerase a, increased the cytotoxicity 
of cisplatin to a human ovarian cancer cell line. They concluded that increased DNA 
repair is involved in resistance and suggested that an inhibitor of this process could 
modulate resistance. They proposed that aphidocolin succinate could be used in 
combination with cisplatin to treat o\'arian cancer.-t9 
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PARP Inhibitors as Resistance Modifying Agents 
P ARP plays an equally important role in excision repair to that of DNA polymerase, so 
if inhibitors of P ARP reverse resistance, they could potentially modulate the repair 
process as well. It has been observed that mutant cells with depleted P ARP, showing 
170/0 of wild-type activity, have an increased sensitivity to alkylating agents.50 If 
P ARP could be inhibited by chemical means then such an observation should be 
reproducible. 
As will be discussed fully in Chapter Two, many inhibitors of P ARP have been 
identified. One of the simplest is 3-aminobenzamide, 3-AB, and this has been used 
extensively as a benchmark inhibitor for investigative experiments in this field. 
Durkacz et al. first showed that levels of DNA damage induced with dimethyl sulphate 
was increased by a number of P ARP inhibitors including 3-AB. If the cells were 
deprived of NAD+ a similar effect was observed. 26 Since that initial discovery, 
inhibitors of P ARP have been shown to potentiate the DNA damaging effects of a 
number of chemotherapeutic agents. The cytotoxic agent temozolomide methylates 
the 0 6 position of guanine, inducing single strand DNA breaks. Incubation with 
several P ARP inhibitors have led to the potentiation of this agent. 51,52 A similar result 
was obtained when bleomycin, an antitumour agent that induces DNA strand breaks, 
was incubated with 3-AB.53 Ionising radiation is commonly used to treat cancer by 
causing DNA damage leading to cell death and tumour shrinkage, and 3-AB has been 
shown to potentiate lethal levels of damage in X-ray irradiated Chinese hamster cells. 5~ 
Since the toxicity of these varied treatments can be potentiated by modulating 
resistance, potential clinical uses of P ARP inhibitors administered in combination with 
existing treatments have been proposed. 52 ,55 However, many of the kno\vn PARP 
inhibitors suffer from problematical physical properties such as poor solubility and 
many lack high potenc~' and specificity The design of better P ARP inhibitors as 
resistance modit\ing agents is currently an area of research interest 56,57 and Charter 
Two discusses recent developments in this field and the aims and rationale of the 
research presented within this thesis. 
1.7 PARP, p53 and DNA Repair 
Recent research has coupled P ARP's involvement with DNA repair to another 
important protein, p53, the implications of which will be discussed in this section. The 
protein p53 has Mr 53 000 and has been identified as the product of the p53 tumour 
suppressor gene. In a large number of common tumours including breast, colon and 
rectal cancer a mutation in the p53 gene leading to lack of expression of the protein is 
observed. In the event of DNA damage the cellular concentration of p53 is known to 
be elevated. 58 It was first shown that p53 regulated a protein known as p21, the 
expression of which inhibits cdk2 and cdk4, cyclin dependent kinases that are required 
for cell cycle progression from G 1 to S phase. In this manner p53 mediates a G 1 check 
point: if DNA damage occurs overexpression of p53 and hence p21 will cause cell 
cycle arrest and hence the death of damaged cells. 59 
Additionally, p53 has been demonstrated to be implicated in the cellular process of 
apoptosis, or programmed cell death, the mechanism first controversially introduced in 
the early seventies60 that allows certain cells effectively to commit suicide, and is in 
contrast to the other type of cell death, necrosis. It is now accepted that p53 is 
involved in apoptotic pathways and effects the regulation of two gene products, Bax 
and BcI-2. Overexpression of p53 in damaged cells down-regulates Bcl-2 which is a 
proto-oncogene product protecting the cell from apoptosis and up-regulates Bax, an 
apoptotic signal that initiates apoptosis and cell death. The Bax gene promoter has 
been shown to contain p5] binding sites59. 61 
Finally, there is good e\'idence that p5] is linked to 00: A repair processes Recently. 
the gL'I1C G:\OD-tS (Gro\\,th /\.rrest and DNA Damage) has been demonstrated to be 
.... 
induced by p53. The gene product IS known to promote excIsIon repaIr 
mechanisms. 59,62 
P ARP has been demonstrated to be involved in many of the processes described above 
and its link to apoptosis could well be via p53. Berger and co-workers demonstrated 
this by treating normal cells with etoposide (VP-16) a well known topoisomerase II 
inhibitor. This caused an increase in p53 levels, and gel electrophoresis of DNA 
produced the ladder pattern bearing the hallmarks of apoptosis and fragmented DNA. 
However, VP-16 treatment of cultured cells containing no N AD+, and hence no P ARP 
activity, showed no increase in p53 and no morphological changes associated with 
apoptosis. Further circumstantial evidence ofP ARP and p53 synergy was proposed by 
showing that while P ARP activity is an immediate response to DNA damage, 
measured in minutes, p53 is a much slower response in the order of hours. The 
authors suggested a sequential reaction and that P ARP may lie upstream from p53 in 
the response to DNA damage. 58,59 This is summarised in Figure 1.12. 
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PARP has been further linked to apoptosis with the discovery that it is cleaved and 
hence inaL,ti\'ated b!' a protease called apopain that is essential for mammalian 
apoptosiS. 63 Apoptosis can occur in a manner independent of p53 however, and this 
pathway may be functioning here. 64 
Although the current understanding in this area is far from the whole picture, there is 
considerable evidence that both P ARP and p53 participate in the cellular response to 
DNA damage. Both have been termed 'genetic policemen' or 'guardians of the 
genome' in recent literature. The mechanisms of p53 action are far less clear than 
those for P ARP but the suggestion that P ARP activity is upstream from p53 and may 
somehow induce its expression is now gaining acceptance. 
1.8 Summary 
Sadly, too many questions remain unsatisfactorily answered with regard to the role and 
function of this increasingly fascinating enzyme. Its involvement with many cellular 
processes, especially DNA repair, is now more clearly established and inhibition of 
excision repair can effectively be achieved via P ARP. The participation of P ARP in 
apoptotic pathways proposes more questions concerning its function, and P ARP 
inhibitors could potentially be used experimentally and clinically to regulate 
programmed cell death. The importance of poly (ADP-ribose)glycohydrolase must not 
be forgotten since it is essentially as important as P ARP itself due to the synergy that 
exsists between these two enzymes, and further investigation of the glycohydrolase 
could aid our understanding of the process of poly ADP-ribosylation. From early days 
of P ARP research new molecular biology techniques have greatly enhanced the 
understanding of the enzyme and its function but there is still much to learn. Current 
advances include the availability of PARP 'knockout' mice, genetically engineered 
animals completely lacking the P ARP gene; and information regarding the crystal 
stmcture of the enzyme is becoming available These will hopefully aid continued 
research into the phenomena of ADP-ribosylation and help unlock the final secrets of 
PARr 
,-, 
2.1 Introduction 
The discovery of new drugs, and the development of these compounds, can occur in a 
number of ways. For centuries, ailments were treated with whatever could be found 
from nature and was available to hand. For many years people had used extracts of 
willow tree bark to relieve pain but it was only relatively recently that the compound 
having this effect was identified as a derivative of salicyclic acid . Subsequently, the 
highly important drug acetylsalicyc1ic acid, commonly known as aspmn has been 
developed as a result of this observation.65 This, and numerous other examples 
represent drugs that have been discovered from nature. Certain drugs have been 
discovered entirely by chance as in the well known example of the antibiotic penicillin. 
A common approach to new drugs is that of rational drug design. Once a molecule 
has been identified as an active lead the medicinal chemist can develop the compound 
into a useful drug. In terms of lead identification this field very much overlaps with the 
previous two . A new method currently being developed for drug disco ery i the 
technique known as combinatorial chemistry.66 Using automated technolo,:, parallel 
ynthesi can build up e, ceptionall large librarie of molecule and creening can 
i lat a ti mp und . It can al 0 be applied to the nthe i of man tructural 
analogu of a I ad omp Llnd 
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In this thesis it is the technique of rational drug development that will be discussed, and 
its use in the synthesis and development of novel P ARP inhibitors. 
2.2 Why Inhibit P ARP? 
Although more is now known about the structure, function and role of poly (ADP-
ribose )polymerase, and the process it catalyses, than ever before this was not always 
so~ even now there is still much to learn. The concept of inhibiting an enzyme, and 
hence the biochemical or physiological process it participates in, has long been a 
recognised technique for determining the function of an enzyme. As such, the first 
inhibitors of P ARP were used purely to block the function of the enzyme to investigate 
its mechanism of action. 36 
More recently there has been interest in the use of inhibitors of P ARP clinically as 
resistance modifying agents. 56,57 By their ability to block repair of cytotoxic damage 
to tumour cells, P ARP inhibitors administered in combination with existing drugs 
could potentiate the cytotoxicity of these treatments. An established anti-emetic drug, 
metoclopramide, has recently been identified as a chemo- and radio-sensitiser, and is 
believed to function by interaction with P ARP. ~~ 
Early observations, however, noted that many P ARP inhibitors while being reasonably 
active had little specificity, and interfered with other cellular reactions. 67 In the 
laboratory this can be misleading, but in the clinic such side reactions are unacceptable. 
The design of highly potent and hence specific P ARP inhibitors therefore represents a 
valuable research goal in all respects. 
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2.3 Development Of P ARP Inhibitors 
The first P ARP inhibitors were identified and used in the early 1970' s by several 
research groups, and nicotinamide 2 and 5-methylnicotinamide 3 were quickly 
identified as competitive inhibitors of the enzyme.68 Thymidine 4 was also shown to 
inhibit P ARP, and interestingly none of the other natural bases and nucleotides tested 
showed similar activity. Certain analogues of thymidine, such as 5-halogenated-2'-
deoxyuridines 5, did show considerable P ARP activity however. 69 
o o 
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These were shown to be competitive inhibitors, and the assumption was made that they 
were competing with NAD+ at the catalytic active site. However, nicotinamides are 
known to affect many N AD+ biosynthetic pathways in the cell, and may lead to a 
decrease in nucleotide synthesis.70 Thymidine is known to inhibit D01A synthesis by 
depleting cellular dCTP concentrations.69 Any alteration of cellular behaviour 
observed after treatment of cells with these compounds cannot therefore be attributed 
solei\" to PARP inhibition 
·w 
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2.3.1 Development of Nicotinamide Analogues 
Two nicotinamide isosteres, benzamide 6 and pyrazinamide 7, were reported as good 
inhibitors of P ARP in 1975. The similarities of activities between the three compounds 
2, 6 and 7 suggested the first structure-activity data, namely that the ring nitrogens 
where not important to inhibitory activity.71 Benzamide is an important inhibitor since 
although it is less water soluble than nicotinamide, its interactions with other systems is 
considerably less, making it a far more specific inhibitor. 
0 0 0 
N 
NH2 (I NH2 NH2 
N 
NH2 
6 7 8 
The development of benzamide inhibitors was pursued by Purnell and Whish. While 
attempting to discover more specific inhibitors of P ARP, they synthesised a number of 
3-substituted benzamides in the hope of improving the solubility characteristics of the 
parent molecule. They found that 3-aminobenzamide (3-AB) in particular, although 
slightly less active than benzamide, possessed greatly increased solubility and handling 
properties. 3-AB has since been accepted as the standard 'benchmark' inhibitor of 
P ARP. Importantly they also reported that 3-AB is highly physiologically specific. 72 
Structure-activity relationships of the nicotinamide analogues was fully investigated by 
Sims et al. who made a number of seminal observations with regard to the 
requirements for inhibition. A large number of nicotinamide isosteres were tested and 
a selection of these results are displayed. They concluded that the 3-position is optimal 
for the carboxamide group and replacement of this, for example with an acid group, 
abolishes activity Carboxamide X-substitution severel\' reduces acti\'itv The aromatic 
- --
ring conjugated to the carboxamide is a strict requirement since filll\' saturated 
~l 
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analogues are inactive. Of the compounds tested they observed that benzamide 6 and 
3-AB 8 where among the most active. Interestingly, they also reported that certain 
purine analogues were active as P ARP inhibitors, and that theophylline and the related 
derivative caffeine are good inhibitors, although they probably act at a different region 
of the NAD+ site to the nicotinamide analogues. 73 
In order to probe structure activity relationships further, a series of sulphur containing 
benzamide analogues as P ARP inhibitors were prepared by Cantoni et al. The short 
series from carboxamide 6, to thiobenzamide 9, to benzenesulphonamide 10, was 
designed to test an increase in dipole moment and steric hindrance against the active 
site of P ARP. Thiophene-3 -carboxamide 11 was included as a classical bioisostere of 
benzamide. Their results showed that inhibition (measured as % of control at 5 mM) 
was an inverse function of dipole moment and steric hindrance since all compounds 
were less active than benzamide. 74 
CONH2 CSNH2 S02NH2 CONH2 0 S 
6 9 10 11 
84% 61 % 32% 53% 
2.3.2 Conformationally Restrained PARP Inhibitors 
A new class of inhibitors was isolated by Banasik and co-workers in 1992. In addition 
to studying benzamide analogue activity they reported several polyaromatic 
heterocycles as extremely potent P ARP inhibitors. These included 4-amino-I,8-
naphthalimide 12, 2-nitro-6(5H)-phenanthridinone 13 and 2-methyl-4(3H)-
quinazolinone l·t The activities are expressed as % of a control at 1 mM. 75 
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>99% 93% 99% 
The important common structural feature for all of these inhibitors is that they possess 
a carboxamide group conjugated to an aromatic ring, but constrained within a six 
membered ring. These inhibitors were by far the most active isolated at the time, and 
so this structural feature seemed very important to inhibitory function. 
While conducting research aimed at producing therapeutically useful P ARP inhibitors 
Suto et al. also independently explored the concept of restricting amide rotation. The 
authors reasoned that if the orientation of the amide that is free to rotate in 3-AB, is 
important for optimal activity, if it could be restricted in some way then inhibitory 
activity would be enhanced.76 To explore this concept they synthesised a series of 5-
and 7- substituted dihydroisoquinolinones designed to mimic two possible rotational 
Isomers of a 3-substituted benzamide. 5-Amino- (15) and 7-amino-
dihydroisoquinolinone 16 shown below mimic two possible orientations of 3-AB. The 
activities of these compounds are expressed as an IC50 value; the concentration of 
inhibitor required to reduce the activity of an enzyme (P ARP) to 50% of control 
activity. This series was found to be highly active although, significantly, the 5-
substituted isomers were more active than the 7 -substituted isomers, suggesting that 
this represented a favourable carboxamide orientation. 
NH2 
15 
o 
o 
IC50 0.41 JlM 
8 
NH2 
16 
IC50 8 IlM 
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o 
17 
IC50 0.36 IlM 
The most active compound isolated from this serIes was 5-
methyldihydroisoquinolinone 17, otherwise known as PD 128763. It was found to be 
50 times more active than 3-AB 8, and data suggested that it had clinical potential as a 
resistance modifying agent. 77 
The importance of carboxamide orientation was confirmed by the computational work 
ofLi and Goldstein. They performed ab initio molecular orbital calculations on NAD+ 
and other carboxamide substrates that bind to hydrogenase and reductase enzymes 
dependent on an NAD+ cofactor. They demonstrated that for binding the 
carboxamide group can adopt two possible conformations which they defined as the 
carboxamide carbonyl group being either anti or syn to the ring 2-3 C-C (J bond. 78 
o NH2 
o 
anti Sl·/I 
Figure ~. I,' j'ossihle Stahle Conformations of PARP Inhihitors 
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Figure 2.i; Possible Stable Conformations of PARP inhibitors 
When these data are considered together with the results of Suto and co-workers it can 
be clearly surmised that the anti conformation of the carboxamide group In 
nicotinamide analogues is the required orientation for effective inhibition of P ARP. 
o 
s 
R 
Thienopyridinone Inhibitors 
Sulphur containing, conformationally restricted thienopyridinone P ARP inhibitors have 
been synthesised by Threadgill et al., who reported a reasonable level of activity for 
these compounds ( R = Me, >80% inhibition at 10 IlM).79 These compounds are 
isosteric to isoquinolone inhibitors previously reported to inhibit P ARP. 76 
2.3.3 Mechanism Based Inhibitors Of P ARP 
An interesting class of potential P ARP inhibitors are carbocyclic analogues of NAD+ 
that block the metabolism of the cofactor. Carba-NAD+ 18 is a so-called mechanism 
based inhibitor. 80 
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In order to discuss the mechanism of action of these compounds it is first needed to 
consider the mechanisms by which NAD+ is degraded. 
NAD+ Metabolism 
Although the precise mechanism ofNAD+ hydrolysis is still a matter for debate it has 
long been accepted that it is driven by the exothermic hydrolysis of the C-N 
pyridinium-ribose bond. 81 The reaction is catalysed by NAD glycohydrolases, causing 
loss of nicotinamide and is facilitated by the formation of an oxocarbenium ion 
intermediate. It is believed that NAD+ adopts a specific conformation within the 
active site of such enzymes, allowing for the stabilisation of this intermediate. 82 
ADP 
I 
I 
0, ,d .. 
.... H' 'H .. 
o 
+ ~NH2 
N 
'0 0 
'( 
enz 
Figure 2.2; Proposed Mechanism Of Intermediate Stabilisation 
Carba-NAD+ Inhibitors 
Carba-NAD+ 18 resembles NAD+ 1 in terms of overall charge and shape but a 
methylene group has replaced the ribose oxygen molecule. This simple replacement 
renders the compound resistant to NAD+ hydrolytic enzymes since the oxocarbenium 
intermediate is unable to form and the C -N bond is effectively uncleavable. As 
expected, however, the analogue is still able to function as a hydride acceptor in redox 
reactions, and is recognised as a substrate by yeast and horse liver alcohol 
dehydrogenases which reduce it to carba-NADH. The 'unnatural' isomer \l/-carba-
NAO+ 19, \vas not a substrak for dehydrogenases. 
~7 
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Diasterisomeric carba-NAD+ was found to inhibit (ADP-ribose) transferase enzymes 
as expected since the action of these enzymes requires the fission of the ribose to 
nicotinamide bond. Interestingly, the greater inhibitory activity was found to reside 
with \jJ-carba-NAD+ when the diasterisomers were separated.83 
Although the results of these experiments are of interest, these analogues do not act as 
P ARP inhibitors, and since they have low specificity demonstrated by their ability to 
interact with many other NAD+ requiring enzymes, are not a good lead for the 
development of P ARP inhibitors. 
2.3.4 Interassay Differences Of Inhibitory Activity 
In the many experimental systems reviewed there has been an inconsistency concerning 
the assignment of values of inhibitory activity to common inhibitors such as benzamide 
and 3-AB. This can be attributed to the different conditions, materials and assay 
methods adopted by various research groups and may explain any minor discrepancies. 
This is summarised in the table below. 
Authors Assay % Inhibition By 
Benzamide 
Purnell and Whish 72 Pig Thymus Nuclei 96 
1980 
Sims el af.73 Permeabilised 96 
1982 Human Lymphocyte 
Cantoni el al. 7~ Pure Enzyme 84 
1987 
I 
Banasik el al. 75 Pure Enzyme 92 I 
j 
ll)92 
--- -~ 
Figure 2. 3,' JI1!C/,(lSS(~\' Differences 
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2.3.5 Development Of Heterocyclic Inhibitors 
In an attempt to explore further P ARP inhibition the established inhibitor 3-
hydroxybenzamide was chosen as a lead compound for analogue development. Hence 
a series of O-alkylbenzamides 20 and substituted benzyloxy benzamides 21 were 
synthesised and tested for inhibition of P ARP. 8~ In the O-alkyl series it was clear that 
relatively bulky groups were tolerated by the enzyme, although solubility problems 
were encountered. A number of 4-substituents differing in their electronic properties 
were introduced onto the benzyloxy aryl ring, but since the activities of the compounds 
were roughly similar across the series no clear structure activity data could be 
obtained. 
0 
.,/H 
.,/H N 
0 I N 
H I 
NH2 
0 
0, 
R 
R 
R 
20 21 22 
R= H 35% R=N02 26% R=H 82% 
R = n-C7HlS 26% R=OMe 580/0 
Activities Expressed as % of a Control at 10 pM 
F or this series of compounds the carboxamide group is still able to rotate, and as we 
have seen this may hinder efficient active site binding. If the orientation of the amide 
could be restricted in some way to the favoured anti conformation the activity should 
be increased accordingly. It was proposed that this could be achie\"ed by the addition 
of a 'bridging' nitrogen atom, forming an oxazole ring system. The additional nitrogen 
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atom could form an intramolecular hydrogen bond to an amide proton, hence forcing 
the group to adopt the anti conformation. The resulting benzoxazole compounds 22 
are analogues of the benzyloxy benzamide series, and proved to be more active P ARP 
inhibitors. They contain an electron rich heteroaromatic system conjugated to the 
carboxamide group, the carbonyl acting as a good putative hydrogen bond donor to an 
active site amino acid residue, and the amide is held in the important anti conformation 
by an intramolecular hydrogen bond. The benzoxazole also allows for structural 
elaboration of the inhibitor. Reassuringly, when 2-methylbenzoxazole was tested for 
P ARP activity as a control experiment it was completely inactive, and since 2-
methylbenzoxazole carboxamide is highly active, the activity must depend upon the 
presence of the amide functionality. When the amide of a benzoxazole carboxamide 
was mono methylated the resulting compound was inactive against P ARP. Since the 
remaining amide proton is involved in the hydrogen bond there is no free proton to 
interact with the active site, emphasising the importance of an unsubstitued amide, as 
first shown to be necessary by Sims et al. 73 
2.3.6 Inhibitor Active Site Binding 
Conclusive information with regard to inhibitor binding to P ARP was obtained when a 
PARP inhibitor, PD128763 17, was successfully co-crystallised with the active site of 
the catalytic region of chicken P ARP and the x-ray crystal structure solved. 85 The 
structure of residues 662-1010 incorporating PD 128763 was obtained at 2.4 A 
resolution and structurally analysed. The catalytic domain, which does not lose 
activity when isolated, was found to be similar in structure to the catalytic region of 
diphtheria toxin (see SectiOIl 1.1.1), and other microbial toxins, even though only a 
weak sequence similarity is observed between these proteins. 
The x-ray structure initially proves that P ARP inhibitors do bind to the catalytic region 
of P,\RP, almost certainly at the I\:AD-+- binding site. hence they must act as mimics of 
the substrate as proposed. ,>\nahsis demonstrated that PO 12S 763 binds to the active 
50 
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site via three hydrogen bond interactions; two bonds from the peptide backbone of 
glycine 863 to the lactame group, and another bond between the C 1 carbonyl oxygen 
and the side chain of serine 904. Further, non-polar interactions between the inhibitor 
and tyrosine 907, that lies adjacent to PD128763, have been identified. 
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The carboxylate group of glutamic acid 988, an amino acid highly conserved amongst 
species and demonstrated to be of vital importance to catalytic activity35 (see section 
1.-1.2), is at a distance of only 4 A from the inhibitor C9 methyl group. The C9 carbon 
of PD 128763 is structurally equivalent to C l' of NAD+, so from this location Glu988 
involvement with polymer initiation and elongation or with intermediate oxocarbenium 
ion stabilisation is certainly possible. 
The crystal structure data confirms the site and hydrogen bonding interactions 
predicted for P ARP inhibitors such as 17. This extremely encouraging result suggests 
that other P ARP inhibitors containing a conformationally restrained amide group could 
bind to the enzyme in a similar manner, resulting in the high levels of potency 
observed. 
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2.4 Benzimidazole P ARP Inhibitors 
Due to the large amount of research conducted in the field of P ARP inhibition a great 
deal of information is now available about the structure-activity requirements of the 
active site of this enzyme. The benzoxazole P ARP inhibitors, while showing good 
inhibitory capacity suffered from poor solubility and a lack of appropriate sites for 
further elaboration of the series. For this reason a series of novel benzimidazole 
analogues was proposed. 
2.4.1 Aims Of Benzimidazole Research 
Benzimidazoles are isosteric to benzoxazoles and have a similar electronic 
configuration, but the imidazole nitrogen allows an extra site for elaboration of the 
compound, provides an additional site for interaction with the enzyme and may also 
increase solubility. The intramolecular hydrogen bond essential for high activity is 
present. Otherwise the other structure-activity concepts determined previously should 
apply to these new P ARP inhibitors, as detailed infigure 2.5. 
Essential Anti Conformation 
For Amide-Enzyme Interactions 
Aromatic Ring ESSenti\ 
H-------Enz N/ 
Electron Rich 
Heterocycle 
I 
~ ",H 
N'" 
R,/
N- ij' " \ "-- Intramolecular Hydrogen Bond \;R 
Sites Of Structural Elaboration 
To Probe Active Site Requirements 
Figure 2.5; ,Structural Features of..4 Bl'Il::imida::ole Inhibitor 
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By the application of basic medicinal chemistry drug design principles it was hoped to 
extend the benzimidazole series, and develop a novel series of highly potent, selective 
P ARP inhibitors. A series of alkyl and aryl benzimidazoles were proposed, and the 
substituents within these series would be varied to attempt to establish a structure 
activity relationship for these inhibitors. As an aside, a brief description of these 
criteria for the design of more efficient drugs follows. 
2.4.2 Structure Activity Related Drug Design 
It was observed by Hammett in the 1930's that a linear relationship existed between the 
dissociation constants of substituted benzoic acids and the rates of alkaline hydrolysis 
of substituted ethyl benzoates.86 
2 
Rate Of 
Ester 
Hydrolysis 
log klka 0 
p-N02 
_24--L----------.-----------~ 
-1 0 1 
log KiKa 
Acid Dissociation Constants 
Figure 2.6: Plot of Acid Dissociation Constants Against Rate Of Ester Hydrolysis 
The electronic nature of the substitutents is responsible for this phenomenon since an 
electron \\'ithdrawing group will stabilise a carboxyl anion, thereby driving the 
hydrolysis more rapidly, whereas the opposite is true for electron donating groups 
53 
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Hammett introduced substituent constants to quantify the degree of electron 
withdrawing or donating ability for different functional groups. These were assigned 
crp and crm for para (4-) and meta (3-) substituents, respectively. This analysis was 
developed further for the application to drug design by Hansch. 87 When designing a 
drug, if it is known that a receptor or active site contains an electronegative region it 
will favour an electron deficient site in the drug molecule. An electron withdrawing 
group in close proximity could achieve the correct electronic requirements for binding 
but how powerful a group is optimal? The technique of quantitative structure activity 
relationships (QSAR) suggested by Hansch attempts to solve this problem. To 
develop the benzimidazole series, the degree of the electronic nature of aryl 
substituents may be important. In drug design, varying one factor and studying its 
outcome on activity can help to relate physicochemical properties to the efficacy of the 
drug. This project aims, initially, to vary aryl substituents electronically in the search 
for a structure activity relationship for these compounds, and as a guide the table 
below demonstrates the relative electron withdrawing and electron donating abilities of 
important functional groups. 
Figure 2. 7; Examples of op 
Substituent 
P-N02 
p-CN 
P-CF3 
H 
p-OMe 
p-OH 
P-NH2 
CJp 
0.78 
0.66 
0.54 
0 
-0.27 
-0.37 
-0.66 
Where CJp = Kx / Ko 
K = Dissociation Constant of 
x 
Benzoic Acid With x Substituent 
Ko = Dissociation Constant of 
Benzoic Acid 
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F or a complete study of structure activity relations other factors also need to be 
considered. Steric factors measure the bulkiness of a group, and may be related to the 
degree of contact between a drug and its target site. Partition coefficients can be 
calculated for a drug; the partition of a compound between water and octan-l-ol is 
used as a measure of lipophilicity. A combination of all these factors can lead to a 
comprehensive description of a drugs ability to react with its target. 
Isosteric Replacements 
A good drug is one that interacts preferentially over the natural substrate at a binding 
site. Potentially, a number of structurally similar molecules could achieve this, and a 
crude but effective technique for exploring such structure activity relations is that of 
isosteric replacement. 
Starting with a drug molecule, a region of the compound can be replaced with an atom 
or groups of atoms that contain a similar number of valence electrons and are 
approximately sterically equivalent. This is termed an isosteric replacement and such 
compounds can have very similar properties to the parent molecule. A benzimidazole 
can be considered an isostere of a benzoxazole, and other examples of isosteric 
replacements are shown below. 
Univalent Multivalent Other 
-NH2 -0- -C=C-
- CH3 
-N- -s-
H 
Figure ].8; Table of !sosfere.\· 
2.4.3 Su 111111 a I)' 
This thesis aims to demonstrate the rational de\'e1opment of novel. potent P .-\RP 
inhibitors based on the principles of drug design, \\'hile knowledge of the acti\'e site 
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structure of the enzyme is limited, application of the techniques discussed may be 
useful to build up a picture of what chemical functionalities are required for efficient 
inhibition. The direction of the synthetic strategy relies upon the feedback of 
biological activity data and each potent compound identified will be developed further 
as described. If these compounds are to be utilised in the clinic, consideration will be 
needed to be given to the clinical acceptability of each inhibitor, a concept that will be 
discussed more fully in Chapter Five. 
2.5 Other Benzimidazole Drugs 
Benzimidazoles form the basis of many drugs that are used to treat a diverse number of 
different conditions. The following is a brief outline of a few of the many examples of 
the wide uses of benzimidazoles in medicine. 
2.5.1 Anthelmintic Agents 
Helminth or worm infections of humans and animals, such as tapeworm and fluke, are 
extremely common, particularly In developing countries. Phenzidole, 2-
phenylbenzimidazole 23, was discovered as a sheep anthelmintic in the 1960's and 
subsequently much research as been devoted to this area, cumulating in a large number 
of such drugs being available, most being based on a substituted benzimidazole 
carbamate 24 core. 88,89 
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2.5.2 Angiotensin n Receptor Antagonists 
Compounds that interfere with the renin-angiotensin system are effective against 
hypertension and congestive heart failure, and hence form an important class of 
cardiovascular drugs. Angiotensin converting enzyme (ACE) inhibitors are currently 
used clinically to block the renin-angiotensin system, but a nonpeptide angiotensin II 
receptor has been identified as an additional target for inhibition of this system. A 
large series of benzimidazole compounds was developed as antagonists of the All 
receptor and the compound TCV -116 25, selected as a candidate for clinical trials. It 
is hoped that this class of compounds will be more specific than the existing ACE 
inhibitors captopril and enalapril. 90,91,92 
N 
EtO--< 
N 
25 
2.5.3 DNA Intercalating Antitumour Agents 
A series of 2-phenylbenzimidazole-4-carboxamides 26 has been reported to be 
cytotoxic by intercalation with DNA although these agents may not act via 
topoisomerase II. While these compounds have obvious structural similarities to the 
benzimidazole P ARP inhibitors, they are unlikely to show any activity since the 
carboxamide group is substituted. 93 
Compounds that alkylate in the minor groove of DNA are kno\vn to be particularly 
cytotoxic. Bis-benzimidazoles are known to be minor groove binders, and have been 
coupled to a mustard group }'ielding a minor groove targeted alkylating agent 27 9~ 
57 
2.6 Summary 
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From the study of a number of P ARP inhibitors developed from the simple compounds 
nicotinamide 2 and benzamide 6, it has been demonstrated that a P ARP inhibitor with a 
benzimidazole core is a likely candidate for a highly active compound. Benzimidazoles 
derivatives have been commonly reported as possessing useful pharmacological 
properties, and as such there many examples of their synthesis. The following chapter 
aims to discuss various preparations, and propose suitable starting materials for the 
synthesis of benzimidazole carboxamides as P ARP inhibitors. 
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3.1 Introduction 
F or the synthesis of a series of benzimidazoles carboxamides, starting materials that are 
easy and convenient to use need to be identified. The 1,2-diamino aryl nucleus is a 
common intermediate reported in the synthesis of many benzimidazoles molecules, 
although the required derivatives are not always available commercially. If this is the 
case then the synthesis of starting materials should be easy, high yielding and suitable 
for scale up. In an attempt to select suitable starting materials a study of the literature 
methods for benzimidazole synthesis was undertaken. 
3.2 Methods For Benzimidazole Synthesis ' 
3.2.1 Alkyl Benzimidazole Synthesis 
The traditional method of benzimidazole synthesis is from 1,2-diaminobenzene (ortho-
phenylenediamine) 28 and has become known as the Philips Method . Reaction of 28 
with formic acid and boiling aqueous hydrochloric acid (4M Hel) yields benzimidazole 
29 in good yield . Many 2-alkyl substituted benzimidazoles, including 30 and 31 can 
be prepared b reacting 28 \ ith the appropriate carboxylic acid in the pre ence of a 
mineral acid a atal t .9 -,96 
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HC02H, HCI QN / ~ I ) 29 ~ N H (JCNH2 CH3C02H , HCI (XN ~ I ~CH3 30 ~ NH2 ~ N 
28 H 
\ PhCH2C02H (XN ~ I h HCI ~ N Ph 31 
H 
Figure 3.1; Benzimidazole Synthesis 
This reaction typically gives yields of 60-80 0/0. In some cases the reacting acid, for 
example acetic acid, can be used directly as the solvent and reactant. This method still 
remains today one of the most frequently utilised methods of benzimidazole synthesis. 
There are, however, a few variations to this method. One or more of the required 
amino groups can be conveniently masked as a nitro group, which is more likely to be 
resistant to chemistry performed at other sites in the molecule. Subsequent reduction 
with, jor example, palladium/carbon and hydrogen followed by immediate treatment 
with a carboxylic acid can yield benzimidazole compounds. 97,98 
i. Pd/C, H2 
ii. R"C02H 0=N ----~~ I N~R" 
RlR' H 
Figure 3.]; Benzimidazole Preparation From Dinitro Compollnds 
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If an imidazole N-substituent is required, this can be added to the 1,2-diamino core 
before reaction with a carboxylic acid to yield the benzimidazole as demonstrated in 
figure 3.3. 99 
RX (XI NH2 ~ NH (XN I }-R' ~ N 
I 
R 
\ 
R 
Figure 3.3; Benzimidazole N-Substitution 
3.2.2 Aryl Benzimidazole Synthesis 
The synthesis of 2-aryl benzimidazoles is best achieved using polyphosphoric acid as a 
catalyst and solvent, and gives much higher yields of the benzimidazole than using 
HCl.lOO Polyphosphoric acid is commonly used in heterocyclic chemistry, although it 
is a viscous liquid when cold and some handling difficulties have been encountered. 10 1 
An alternative direct synthesis of 2-aryl benzimidazoles has been achieved via the 
oxidative condensation of 1,2-diaminobenzoic acids and aryl aldehydes using copper 
acetate. The insoluble copper complexes are treated with H2S to yield the desired 
benzimidazoles. 93 
Cu(OAcb 
OHC-o 
i. PhCN 
ii. NCS 
• 
~N 0--N>-Ph 
R H 
Figure 3. -I; A ,y/ Rel1:imida=o/e .. \rnlhesis 
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It is also possible to synthesise 2-aryl benzimidazoles starting from aniline derivatives. 
Reaction with an aryl nitrile yields an amidine that can be chlorinated with N-
chlorosuccinamide or sodium hypochlorite, and cyclised under basic conditions to a 
benzimidazole.88 
3.2.3 Other Methods of Benzimidazole Synthesis 
Although not strictly a method of preparation, arylbenzimidazoles have been observed 
as products of the photolysis of aromatic tetrazoles, and this reaction could potentially 
be utilised synthetically. 102 
Me N~N Me Me ., , \ N hv 
N--\ MeCN N N 
• )----Ph )----Ph Ph + 
C02Me N N \ \ C02Me Me 
19% 160/0 
Figure 3.5; Photolytic Benzimidazole Synthesis 
There are many possible routes for the synthesis of benzimidazoles a few of which 
have been discussed here. The synthesis of benzimidazole carboxamides as P ARP 
inhibitors was proposed from the common 1,2-diamino or 1-amino-2-nitro precursors, 
and so the synthesis of suitable derivatives was investigated. 
3.3 Synthesis Of Starting Materials 
Benzimidazoles with I N- or 2-substituents are well known whereas -i-substituted 
compounds are fairly uncommon in the literature. In order to svnthesise the desired 
benzimidazole--l-carboxamide series proposed, the commercially available 3-
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nitrophthalic anhydride was chosen as the precursor to the pivotal intermediates 2,3-
diaminobenzoic acid 32 and methyl 2,3-diaminobenzoate 33. 
3.3.1 2,3-Diaminobenzoic Acid As A Benzimidazole Precusor 
The use of 2,3-diaminobenzoic acid 32 as a precursor to benzimidazoles has been 
reported previously, and in both cases its method of preparation has differed. A 
preparation from 2-methyl-6-nitroaniline 34 has been reported. The aniline was 
acetylated and then oxidised to yield an acid derivative. Deprotection of the amino 
group followed by reduction yielded 2,3-diaminobenzoic acid 32.103 
o o 
i.5%HCI 
ii. KMn04 ii. SnCI2. HCI 
~ 
34 
Denny et al. used ethyl 2-carboxy-3-nitrobenzoate 35 as the precursor to 32. It was 
treated with thionyl chloride, followed by sodium azide, to yield an acyl azide 
derivative. Heating this in dilute acetic acid effected a Curtius rearrangement, 
producing an ester derivative that was hydrolysed with KOH. The resulting 2-amino-
3-nitrobenzoic acid 36 could be stored until needed and then reduced in situ (PdlC and 
hydrogen) at the start of their synthetic procedure. 93 
0 0 0 
i. SOCI2 i. ~AcOH 
OEt ii. NaN3 OEt ii. KOH OH 
.. .-OH N3 
N02 0 N02 0 N02 
36 
35 
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3.3.2 3-Nitrophthalic Anhydride 
3-Nitrophthalic anhydride 37 can be synthesised from phthalic acid with relative ease, 
although explosions have been reported in this synthesis.lO-l It was purchased since it 
was readily available and inexpensive. However, care has to be taken with the storage 
of this compound as it was found to be liable to decompose to 3-nitrophthalic acid if 
stored under unsuitable conditions. Maintaining a head of nitrogen on the bottle and 
storage in a desiccator seemed to solve this problem. 
3.3.3 Synthesis of 2-Amino-3-nitrobenzoic Acid 
2-Amino-3-nitrobenzoic acid (3-nitroanthranilic acid) 36 was prepared from 3-
nitrophthalic anhydride conveniently following the procedure of Chapman and 
Stephen. 105 Initially, reacting the anhydride with ammonia yielded 2-carboxamido-3-
nitrobenzoic acid (3-nitrophthalamic acid) 38 in good yield with no evidence for any 
competing reaction at the other carbonyl site. This demonstrates the ability of the nitro 
group to activate the ortho-carbonyl of 37 to nucleophilic attack. 
Still following the procedure of Chapman and Stephen the step to 2-amino-3-
nitrobenzoic acid proceeded via a Hofmann rearrangement, a carbon to nitrogen 
migration detailed in figure 3.6, and analogous to the Curtius rearrangement used by 
Denny.93 
H ArrF~'~ AryNH2 Br2 AryN'-. KOH 
~ Br ~ W Br 
0 0 
1 
H2O 
Ar-N==C==O Ar-NH2 ... 
FiK''''C 3.6: 711e H(imlllm Rearrangement 
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Traditionally, the Hofinann rearrangement is carried out in an aqueous sodium 
hypochlorite solution. Following these conditions a successful transformation was 
achieved, yielding the desired product 36 in good yield (approx. 600/0), using 
commercially available sodium hypochlorite solution. 
o 
NH3 (aq) 
37 38 
NaOe11 
KOBr (aq) 
.. 
o 
36 
It was envisaged that 36 would be used in large quantities to satisfy the demand for the 
important intermediates that could be synthesised with its use. In aqueous conditions 
sodium hypochlorite is essentially a solution of sodium hydroxide and chlorine and to 
make this reagent would be impractical due to the hazardous nature of handling 
chlorine in the laboratory. Carrying out the rearrangement using potassium 
hypobromite106 was investigated, since potassium hydroxide and bromine are readily 
available and convenient to handle. Generating a potassium hypobromite solution in 
situ, immediately adding the reactant 3-nitrophthalamic acid 38 and heating, achieved 
the Hofmann rearrangement in high yield (80-850/0). The success of this procedure in 
comparison with that previously used was considered to be due to the fact that the 
hypobromite solution had been prepared fresh as required. 
The hypobromite procedure has been successfully carried out on a scale ranging from 
19 to 40g of 3-nitrophthalamic acid 38, which can also be readily synthesised in large 
quantity. 
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3.3.4 Esterification of 2-Amino-3-nitrobenzoic acid 
The possibility of synthesising a benzimidazole directly from a 2-amino-3-nitrobenzoic 
acid derivative has been considered. 98 In order to carry out such a procedure it was 
necessary to improve the solubility characteristics of the molecule and this was 
proposed by simply generating the methyl ester of2-amino-3-nitrobenzoic acid. 
o o 
OH Hel, MeOH OMe 
~ 
36 39 
The preparation of methyl 2-amino-3-nitrobenzoate 39 was achieved by dissolving the 
acid 36 in methanol, saturating the solution with dry HCI gas, and refluxing overnight. 
Many variations of this procedure were attempted, but the optimum method involved 
cooling the reaction to -10°C before bubbling Hel gas through the solvent, and 
allowing the mixture to warm to room temperature before refluxing overnight. 
Anhydrous conditions were important but the use of dry methanol did not alter the 
yield, which although variable, was usually only 50-60%. It is a clean reaction, 
however, leaving only unreacted starting material that can be recovered and recycled. 
Hence, overall the conversion of the acid to the ester is essentially quantitative, after 
repeating the procedure. 
A number of other methods of esterification were attempted in order to improve the 
yields of this reaction. Para-toluenesulphonic acid (tosic acid) and concentrated 
sulphuric acid were both tried as alternative acid catalysts. Both reactions yielded less 
than 50% conversion. The reaction was also attempted using an excess of the 
methylating reagent diazomethane and although a very pure sample of 39 was isolated 
66 
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from the reaction, the overall yield was only in 44%. Of all the procedures attempted, 
the methanol Hel reaction remains the most effective method for the generation of the 
methyl ester 39. 
3.3.5 Synthesis of 2,3-Diaminobenzoic Acid Derivatives As Starting Materials 
2,3-Diaminobenzoic acid 32 and its methyl ester 33 were readily synthesised from their 
respective 3-nitro derivatives under the conditions of atmospheric catalytic 
hydrogenation. Using a 10% palladium on activated carbon catalyst and methanol as 
solvent, the reactions proceeded in high yields, typically 90-950/0. 
o 
36 
o 
39 
OH 
OMe 
Pd/C , H2 
Pd/C , H2 
HCI, 
MeOH 
o 
OH 
32 
o 
OMe 
33 
Care had to exercised in the storage and use of these diamino-compounds as they were 
found to be extremely light sensitive, and quickly darkened if left exposed to the light. 
While the reaction gave high yields the product \vas not ahvays obtained especially 
pure, probably due to impurities from the breakdown of the compound \vith exposure 
to light. Further purification at this stage was extremely wasteful and it was found that 
the purity of the compound was sufficient to proceed with the next synthetic step. 
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3.3.6 Starting Materials: A Summary 
The research described provided the basic starting materials for use in benzimidazole 
synthesis. The synthesis of the 2,3-diamino derivatives 32 and 33 has been 
investigated and optimised such that reasonable quantities of these materials can be 
readily made for use as the common intermediates for benzimidazole synthesises. It is 
also possible that the 2-amino-3-nitro benzoic acid derivatives (jor example 39) may be 
useful starting materials for benzimidazole synthesis. There are problems associated 
with the diamino precursors, however, due to their instability. Denny et al. avoided 
this by generation of a 1,2-diamino precursor in situ, but storage in the dark with 
refrigeration for short periods of time seems to be acceptable. 
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4.1 Benzimidazole Nomenclature 
Before a full description of benzimidazole chemistry is embarked upon, a mention of 
the nomenclature used for such systems is necessary. 
5(X4 ~~6' 5' I '\ 2 If ~ 4' 
6 ~ N -
1 2' 3' 
7 H 
23 
~N)<R 
~N H 
40 
Figure 4.1; Benzimidazole Numbering Systems 
o 
OMe 
3' 
4' 
I-H-Benzimidazoles such as 2-phenylbenzimidazole 23 possess a hydrogen atom 
bonded to an imidazole nitrogen, in contrast to the related 2-H-benzimidazoles 
(isobenzimidazoles) 40)07 The numbering in I-H-benzimidazoles starts from the I-H-
nitrogen and continues as shown infigure -1.1. If a substituted aromatic ring is present 
the numbers of this ring are primed. The benzimidazole precursors are numbered as 
derivatives of benzoic acid and are assigned as in the above figure if a ubstituted 
ar matic ring i pre ent This numeri al naming system \ ill be adopted throughout 
thi th i 
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4.2 2-Alkylbenzimidazole Synthesis 
The synthesis of benzimidazole derivatives from a 1,2-diaminobenzene (ortho-
phenylenediamine) derivative and a carboxylic acid, using a mineral acid as solvent and 
catalyst, was used in the first attempts made at the synthesis of simple alkyl 
benzimidazoles. 2,3-Diaminobenzoic acid 32 and a suitable carboxylic acid, were 
reacted together using 4M aqueous hydrochloric acid as a catalyst and solvent. 
4.2.1 Reaction With Formic and Acetic Acids 
The initial targets investigated were benzimidazole-4-carboxamide 43 and 2-
methylbenzimidazole-4-carboxamide 44. These represent the simplest P ARP inhibitors 
of the series. The synthesis of these compounds was proposed via the corresponding 
4-carboxylic acid, before conversion to the required amide. Following the methods of 
similar literature procedures,95,96 2,3-diaminobenzoic acid 32 was dissolved in 4M 
hydrochloric acid, formic acid was added and the reaction refluxed. The same method 
was carried out using acetic acid as the reactant. These procedures yielded the 
unsubstituted I-H-benzimidazole-4-carboxylic acid 41 (77010) and 2-methyl-l-H-
benzimidazole-4-carboxylic acid 42 (720/0), respectively, in good yield. 
0 0 0 
RC02H OH i. SOCI2 NH2 OH 4M HCI ii. NH3 
• • 
N N 
NH2 HN~ HN~ 
R R 
32 
41 R=H 77% 43 R=H 13° a 
42 R= CH3 72°'0 44 R=CH3 1-.+°0 
4.2.2 Amide Synthesis 
The benzimidazole carboxylic acids were readily converted to the amides \'ia the acid 
chloride, The compounds were refluxed in thionyl chloride, removal of \\'hich bv 
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distillation yielded the acid chloride, and this was immediately reacted with aqueous 
ammoma. Although the desired ami des were obtained in poor yield after purification, 
sufficient was obtained to allow characterisation and submission as the first 
benzimidazole carboxamide compounds to be tested for biological activity against poly 
(ADP-ribose)polymerase (PARP). An analytically pure sample of I-H-benzimidazole-
4-carboxylic acid 41 was also prepared as a control for the assay, since the lack of an 
amide group at the 4-position should render the compound inactive if our assumptions 
of the requirements for inhibitory activity are correct. 
4.2.3 2-Trifluoromethyl-l-H-benzimidazole-4-carboxamide 
The inhibitor 2-trifluoromethyl-l-H-benzimidazole-4-carboxamide 45 was proposed as 
a target for synthesis as the compound should be sterically similar to the 2-methyl 
benzimidazole 44 since hydrogen and fluorine have similar Van der Waals radii, and 
some enzymes are unable to distinguish between these two atoms, or groups 
containing these atoms, for example -CH3 and -CF3.108 Electronically however 45 is 
very different to 44 so comparison of the P ARP activity of these two inhibitors could 
furnish information regarding the nature of substituents tolerated within the enzyme's 
active site. 
Initially, the benzimidazole was synthesised by treatment of methyl 23-, 
diaminobenzoate 33 with trifluoroacetic anhydride in THF. It was reasoned that a 
mineral acid catalyst would not be required on this occasion since the activating effect 
of the trifluoromethyl group should readily promote ring closure to the benzimidazole. 
The trifluoroacetic acid produced could be removed by an acid scavenger. This 
assumption was proven to be correct and the major product of the reaction was 
identified as methyl 2_trifluoromethyl-I-H-benzimidazole-.+-carboxylate 46, albeit in 
low yield CUOo). 
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The synthesis of the 2-trifluoromethylbenzimidazole was also achieved by reacting 
methyl 2-amino-3-nitrobenzoate 39 with trifluoroacetic anhydride to form the N-acyl 
derivative 47, in a similar procedure as had been performed previously from a l-amino-
2-nitrophenyl starting material. 98, 109 In accordance with previous results, reduction of 
the nitro group should be followed by nucleophilic attack of the amino at the activated 
carbonyl, allowing the benzimidazole to be isolated directly from the reaction. 
Analysis of the material isolated from this procedure again confirmed that the desired 
benzimidazole 46 had been synthesised and that this pathway was more suitable since 
the product was recovered in 70% yield from 47, and 67% overall from the starting 
material 39. 
o 
\ o o 
o o 
46 45 
39 
Methyl 2_trifluoromethyl-I-H-benzimidazole-4-carboxylate 46 was stirred with 
aqeuous ammonia solution and 2_trifluoromethyl-I-H-benzimidazole-4-carboxamide 
45 was recovered in 75% yield after purification. 
,1 
,-
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4.3 Alkyl Verses Aryl Subsitutents 
Having successfully synthesised and assayed the 2-alkylbenzimidazole-4-carboxamides 
for P ARP inhibitory activity it was now deemed necessary to synthesise a 2-aryl 
derivative for comparison in a structure activity series. The synthesis of the simplest 
aryl derivative, 2-phenyl-l-H-benzimidazole-4-carboxamide 48, was undertaken and is 
described in the next section, along with the subsequent development of the structure-
activity directed synthesis in the benzimidazole series. 
4.4 Methods of 2-Aryl Benzimidazole Synthesis 
Compounds in the 2-alkyl benzimidazole series were found to exhibit good activity 
against poly (ADP-ribose)polymerase; all the biological results are discussed fully in 
Chapter Seven. To compare the inhibitory properties of 2-alkyl versus 2-aryl 
substituents, the synthesis of a 2-phenyl benzimidazole derivative was required, and 
initially the approach that was successful for the 2-alkyl compounds was attempted. 
Following the same method as adopted for alkyl benzimidazole synthesis, 2,3-
diaminobenzoic acid 32 was treated with benzoic acid and 4M hydrochloric acid. The 
reaction was refluxed for several hours but no evidence of benzimidazole formation 
could be observed. It has been reported that 2-arylbenzimidazoles can be synthesised 
using polyphosphoric acid (PPA) as the mineral acid solvent/catalyst, and that this 
reagent is highly favourable for such reactions. lOO In this case it was reasoned that 
2,3-diaminobenzoic acid 32 could react with benzoic acid, in the presence of 
polyphosphoric acid, to obtain the desired 2-phenyl-I-H-benzimidazole-4-carboxylic 
acid 49. This was successfully attempted albeit in a low yield of 200/0. 
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0 0 0 6" OH i. SOCI2 NH2 OH ii. NH3 
• N .. N 
PPA HN ~ HN /, 
NH2 
32 
49 48 
A possible explanation for the low yield of this reaction IS a lowering of the 
concentration of benzoic acid present in the reaction via its sublimation into the 
reaction condenser. However, increasing the amount of benzoic acid to excess showed 
no significant improvements in the yield of this reaction. 
4.4.1 Synthesis of 2-Phenyl-l-H-benzimidazole-4-carboxamide 
To achieve this conversion the previously successful method via the acid chloride was 
adopted. The acid chloride was generated by dissolving the acid in THF and treating 
with an equivalent of thionyl chloride, and a catalytic amount of dimethylformamide, to 
facilitate formation of the acid chloride as demonstrated infigure -1.2. 
08 o 
1/ 
O-S 
I 
\ @ t-?'CI 
----i .. ~ N CI --
/ H 
\ 0 N--{ 
/ H 
+ \@ < 'CI 
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Treatment of the acid chloride with ammonia, followed by purification afforded the 
amide 48 in 620/0 yield. The 2-phenyl derivative 48 was found to be the most active 
inhibitor identified to date in this series and so it was clear that this molecule would 
need further elaboration. 
In order to determine the optimum inhibitor in a situation such as this a structure , 
activity relationship is always useful and requires the synthesis of a number of varied 
molecules with an overall similar core structure. Hence, a series of substituted 2-
phenyl derivatives was proposed. Introducing electron donating groups and electron 
withdrawing groups at various positions around the 2-phenyl ring, and comparing the 
effect of varying the electronic and steric nature of the phenyl substitutents on 
inhibitory activity would help us build up such a structure-activity relationship for the 
2-arylbenzimidazole compounds. The synthetic approach to the construction of such a 
series is described subsequently. 
4.4.2 Analogues of 2-Phenyl-t-H-benzimidazole-4-carboxamide 49 
Following the synthesis of the 2-phenylbenzimidazole 49, consideration was given to 
the elaboration of the compound to obtain a structure-activity relationship as 
previously discussed. Initially, the syntheses of 4'-nitro- and 4'-methoxy-
phenyl benzimidazole derivatives were proposed, as these compounds would represent 
benzimidazoles with an electron deficient and an electron rich aryl group at the 2-
position, respectively. In order to synthesise these benzimidazoles, 2 ~-,-
diaminobenzoic acid 32 was treated with either 4-nitrobenzoic acid or 4-
methoxybenzoic acid (anisic acid) in polyphosphoric acid under reflux. Although the 
reactions were heated for long periods of time, and the addition of an excess of 
carboxylic acid reactant \vas investigated, no evidence could be found for the 
formation of a benzimidazole derivative under these conditions This was a surprising 
obser\'ation, especially \vith the reaction involving 4-nitrobenzoic acid. as one would 
assume this to be a \'ery reactive compound Due to the failure of this chemistry, 
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alternative routes to the target benzimidazoles had to be considered. The handling of 
polyphosphoric acid is problematical due to its extremely viscous nature, and this was 
a contributing factor to the need for alternative methods and reagents for aryl 
benzimidazole synthesis. 
Reactions with PP A can be improved by conducting the reactions in a heterogeneous 
phase using a co-solvent. The reaction is heated with vigorous stirring and the product 
can be easily extracted from the organic phase at the end of the reaction. Xylene is a 
particularly effective co-solvent for these reactions. 110 This procedure was applied to 
the synthesis of 49 but, unfortunately, no benzimidazole product could be extracted 
from the reaction. 
o 
o 
OMe 
c~KJ-R 
TEA, DMAP, THF 
X ~ 
R = H, N02 
o 
OMe 
o 
R 
The possibility that the synthesis of aryl benzimidazoles could be approached via an 
alternative synthesis from a different starting material was investigated. Following the 
procedure of Chapman and Stephen 10:' 2-amino-3-nitrobenzoic acid 36 was 
successfully acet~'lated, the product 50 being obtained in 7..+% yield. It was proposed 
that 50 could be reduced and cyc1ised to a benzimidazole, although attempting this 
procedure appeared unsuccessful. 
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In an analogous manner, it was proposed that the methyl ester derivative 39 could be 
reacted with aryl acid chlorides to produce amino substituted derivatives. As such the 
reaction of 39 with 1.1 equivalents of benzoyl chloride or 4-nitrobenzoyl chloride was 
attempted, in the presence of triethylamine and a catalytic amount of 4-
dimethyl amino pyridine (DMAP). Under these conditions no reaction was observed at 
room temperature, and the starting material was recovered from the solution. This 
was again a surprising result, especially in the case of the highly reactive 4-
nitrobenzoyl chloride. This outcome is probably due to the presence of two electron 
withdrawing groups adjacent to the amino group, and possibly the steric crowding 
around this centre is less than favourable. 
To overcome this problem the aryl benzimidazole synthesis from methyl 2,3-
diaminobenzoate 33 was attempted. This material could now be reacted with an acid 
chloride in THF with triethylamine and DMAP. The absence of a deactivating nitro 
group may allow the reaction to occur more readily. There may be a problem of 
selectivity due to the presence of two amino groups but it was reasoned, on the 
grounds of electronic and steric factors that the 3-amino group should be more 
reactive and hence a single acylation reaction should occur. 
0 0 
0 6' OMe OMe OMe ~I CH3C02H ~ 
~ .-
TEA, DMAP, 11-1F ~ 
NH2 
33 
51 52 
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Initially the reaction of methyl 2,3-diaminobenzoate 33 with benzoyl chloride was 
attempted and a product, methyl 2-amino-3-N-benzoylbenzoate 51, was successfully 
isolated in 74% yield. This was an extremely encouraging result, made even more so 
by the observation that the mono-acylated compound could be readily cyclised to 
methyl 2-phenyl-l-H-benzimidazole-4-carboxylate 52 by heating at 120°C in glacial 
acetic acid. With a synthesis of an aryl benzimidazole finally achieved, conversion of 
the methyl ester to the amide should be facile and so the path was now set for the 
synthesis of a series of 2-aryl benzimidazoles. 
4.5 Synthesis of 4'-Substituted 2-Aryl Benzimidazoles 
Under the newly established reaction conditions, the synthesis of the original targets 41-
methoxyphenyl- and 4 1-nitrophenyl-l-H-benzimidazole-4-carboxamide was embarked 
upon. Methyl 2,3-diaminobenzoate was treated with 1 equivalent of 4-
methoxybenzoyl chloride ( anisoyl chloride) or 4-nitrobenzoyl chloride, respectively, in 
the presence of triethylamine, and a catalytic amount of DMAP in THF. This was 
stirred under an inert gas atmosphere overnight at room temperature. After 
purification of the products of these reactions it became clear that two differing 
compounds had been obtained from each reaction. With 4-methoxybenzoyl chloride a 
monoacylated product, methyl 2-amino-3-N-( 41-methoxyphenyl)arninobenzoate 53 was 
isolated, whereas with 4-nitrobenzoyl chloride a diacylated product 54 was isolated. 
The structural assignment of these compounds was confirmed by analysis of the NMR 
and mass spectra. 
The successfully synthesised .t-methoxyphenyl derivative 53 was subsequently sho\vn 
to cyclise readily when heated in glacial acetic acid at 120°C for J 0 minutes. The 
benzimidazole 55 was isolated as an acetate salt in high yield (75 0/0), in concordance 
\\ith the sllcccssfill s!'nthesis of a 2-phenyl benzimidazole 52 by this route described 
previously. 
o 
CI~R 
TEA, DMAP, THF 
0 1 
OMe 
o 
CI~ 
N~ 
TEA, DMAP, ll-lF 
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R 
55R=OMe 
59R = CF3 
Acid / Base N~ 
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The conversion of the methyl ester group to an amide, the functionality required to 
render the molecule active against P ARP, was now investigated. The methyl ester 55 
was initially treated with ammonia solution at room temperature but stirring over 24 
hours did not seem to yield any product in significant amounts. In an attempt to drive 
the reaction to completion harsher conditions were adopted, reacting the methyl ester 
with liquid ammonia under high pressure in a sealed pressure vessel. Initially 55 was 
treated with an excess of ammonia at 20 atm pressure and 50°C for 4 hours. TLC 
analysis after this time showed evidence that product could have formed, although the 
methyl ester starting material was still in excess. The reaction mixture was returned to 
the vessel and heated for a further 20 hours, after which time the desired product was 
isolated in low y'ield (2 1% ). Investigation of these conditions sho\\'ed that \\hen the 
methyl ester compound was subjected to heating in the \'essel \\ith liquid ammonia at 
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80°C under 40 atm pressure for 24 hours, the desired amide product could be isolated 
in the far more acceptable yields of 800/0. Although quantitative conversion was not 
observed, the reaction proceeded cleanly and the methyl ester starting material could 
be recovered and recycled. The compound 2-( 4'-methoxyphenyl)-1-H-benzimidazole-
4-carboxamide 56 was fully characterised and hence demonstrated that analogues of 
this nature could be prepared by this route. 
4.5.1 Synthesis of an Electron Withdrawing 2-Aryl Analogue 
As it was obvious that there may be difficulties concerned with the synthesis of a 
nitrophenyl derivative, probably due to the high reactivity of the nitrobenzoyl chloride, 
the synthesis of a benzimidazole with an alternative electron withdrawing substituent 
was proposed. 2-( 4'-TrifluoromethylphenyI)-1-H-benzimidazole-4-carboxamide 57 
was chosen as the target molecule in this case because although the -CF 3 group is less 
electron withdrawing than -N02, the initial reactant 4-trifluoromethylbenzoyl chloride 
should be less reactive than its nitro equivalent and hence more likely to yield the 
desired monoacylation product. Following the standard procedure, methyl 2,3-
diaminobenzoate 33 was treated with 4-trifluoromethylbenzoyl chloride to yield the 
desired monoacylated product methyl 2-amino-3-N-( 4'-trifluoromethylphenyl) 
aminobenzoate 58. This compound also readily cyclised to the benzimidazole 59 upon 
heating in glacial acetic acid. Treatment of 59 with liquid ammonia in the pressure 
vessel yielded the desired benzimidazole carboxamide 57. Thus, this synthetic 
procedure had successfully furnished two aryl benzimidazoles with differing electronic 
properties, forming the start of a series that should probe the electronic requirements 
of the P ARP active site. 
It has been observed pre\'iously in a related research project that treatment of certain 
structurally related benzoxazole methyl esters 60 with ammonia under high pressure 
conditions etTectl'd a rearrangement to a quinazolinone compound 61 84 It was 
important to establish whether such a reaction could occur when benzimidazoles were 
xo 
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subjected to these harsh conditions. In order to investigate this it was decided to 
prepare 2-( 4'-methoxyphenyl)-1-H-benzimidazole-4-carboxamide 56 indirectly from its 
methyl ester precursor 55 via the corresponding carboxylic acid 62. 
0 
0 
OMe 
NH3 (I), 40 atm NH 
• 
NAcH3 N O~ 
OH CH3 
60 61 
0 0 0 
OMe OH NH2 
i. SOCI2, DMF 
NaOH N ii. NH3, (aq) N HN I. HN I. • .. 
OMe OMe OMe 
55 62 56 
The methyl ester 55 was hydrolysed with sodium hydroxide and the acid obtained 
treated with thionyl chloride to generate the acid chloride. Treatment of this with 
ammonia solution yielded a compound that was analytically identical to 56 prepared 
via the liquid ammonia high pressure route. Since a rearrangement was unlightly to 
occur under these milder conditions it was deemed that the benzimidazole carboxamide 
had been synthesised as proposed. 
4.5.2 The Synthesis of 2-(Nitrophenyl) Benzimidazoles 
As previously described the reaction of methyl 2,3-diaminobenzoate with 4-
nitrobenzoyl chloride produced methyl X,lV-bis( 4'-nitrobenzoyl)-2,3-diaminobenzoate 
54 as the product of reaction, this probably being due to the highly reactive nature of 
XI 
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4-nitrobenzoyl chloride. A nitrophenyl benzimidazole carboxamide derivati\'e is a 
highly important target compound in the series since its powerful electron withdrawing 
properties could provide important structure-activity data. Although the nitro group is 
used frequency in drug design as an electron withdrawing moiety, it is mainly utilised 
for investigative purposes only. In vivo, aromatic nitro groups exhibit considerable 
toxicity as they are readily metabolised to nitro so aromatic compounds known to be 
carcinogenic and cause liver damage. I I I A number of different routes to the important 
4'-nitrophenyl benzimidazole were investigated. 
The possibility that the diacylated derivative 54 could be cyclised to a nitrophenyl 
benzimidazole was investigated. The compound was subjected to various acidic and 
basic conditions; it was stirred at room temperature in glacial acetic acid and O.SM 
sodium hydroxide solution for several hours but no reaction was observed. The 
solutions were then both heated to 100 °C and stirred for several more hours but no 
evidence of reaction could be gained from these experiments. A different approach to 
the problem of synthesising the nitrophenyl benzimidazole involved the use of an 
alternative starting material 8-aminoisatoic anhydride 63, essentially a protected 2,3-
diaminobenzoic acid. This compound is not available commercially but a possible 
synthesis was proposed from 2-amino-3-nitrobenzoic acid 36 by reacting this with 
phosgene and reducing the nitro group. 
This compound would only have one free amino group that could be reacted with 4-
nitrobenzoyl chloride, subsequent treatment with ammonia should effect amide 
formation with subsequent decarboxylation and cyclisation to the nitro phenyl 
benzimidazole 64. 
:-:2 
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Initially, 2-amino-3-nitrobenzoic acid was stirred at room temperature with 0.4 
equivalents of triphosgene and 2.2 equivalents of dry triethylamine in dry THF. 
Triphosgene 65 is a convenient solid trimer of phosgene that is relatively safe and easy 
to use, one equivalent of triphosgene yielding three equivalents of phosgene under 
basic conditions. Because of its ease of use it has recently seen much use as a 
phosgene substitute. 112,1 13,114 It has also been demonstrated that triphosgene can be 
used in the preparation of quinazolinediones l15 and N-carboxy amino acid anhydrides, 
structurally similar to the desired target molecule, and so this experimental procedure 
was utilised. 116 In addition to the starting material another product was isolated from 
the reaction, and analysis of this compound showed that it was not the desired 8-
nitroisatoic anhydride 66 but \vas identified as compound 67. 
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o 
67 
The NMR spectra was consistant with this structure, and the mass spectrum showed a 
peak at 328 corresponding to loss of water and cyclisation of 67. This suggests that 
the isatoic anhydride 66 was forming in the reaction, but was subsequently reacting 
with the starting material. Essentially, the formation of the unwanted product 67 
demonstrates that the proposed route to benzimidazoles via an isatoic anhydride may 
have proved fruitful but is complicated by the formation of a side product. In view of 
this observation further investigations using isatoic anhydrides were discontinued. 
0 0 
OMe OMe (RCOhO 
~ 
N 
NH2 HN-( 
R 
33 
0 0 
0 
02N N02 
68 
The synthesis of a 2-trifluoromethylbenzimidazole had already been achieved by 
reacting an activated anhydride, trifluoroacetic anhydride with methyl 2,3-
diaminobenzoate 33. 
Chapter Four: Syntheses In The Benzimidazole Series 
4-Nitrobenzoic anhydride 68 should also be very reactive and so a reaction of this 
anhydride with the diamino compound 33 to yield a benzimidazole was suggested. 
Since the required 4-nitrobenzoic anhydride was not commercially available a synthesis 
was required. There are a number of methods for the synthesis of anhydrides and most 
commonly a carboxylic acid and an acid chloride are reacted together. The preparation 
of 4-nitrobenzoic anhydride from 4-nitrobenzoic acid has been reported using thionyl 
chloride,117 and using triphosgene and triethylamine. lI8 However in all attempts to 
synthesise 4-nitrobenzoic anhydride, 4-nitrobenzoic acid impurities were present. 
These could not be removed despite several attempts, and consequently a crude 
mixture of anhydride and acid in excess was added to methyl 2,3-diaminobenzoate 33. 
Unfortunately, although some benzimidazole product formation was observed, the 
yields were low and this approach was abandoned. 
An experiment was performed that showed that when the standard conditions for the 
synthesis of methyl 2-amino-3-N-( 4'-methoxybenzoyl)aminobenzoate 53 were repeated 
in the absence of a catalytic amount of DMAP the major product isolated from the 
reaction was a diacylated derivative, analogous to 54, obtained when methyl 2,3-
diaminobenzoate 33 was treated with 4-nitrobenzoyl chloride under these conditions. 
This observation suggested that the presence of DMAP had a profound effect on the 
reactivity of the acid chloride and it was reasoned that the reactivity of 4-nitrobenzoyl 
chloride could be lowered by repeating the reaction with methyl 2,3 -diaminobenzoate 
in the absence of DMAP. When attempted however this reaction still yielded the 
unwanted diacylated product 54. It was then proposed to lower the reactivity of the 
acid chloride further still by cooling the reaction down to -10 °e. This reaction finally 
yielded a suitable amount of the desired monoacylated product 69, and although it \vas 
only in low yield (200 0), enough product could be recovered to continue to the 
cyclisation step of the synthesis 
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As expected the cyclisation of 69 to the nitrophenyl benzimidazole 70 proceeded 
readily, the reaction going to completion in 15 minutes, i. e. half the time required for a 
cyclisation involving an electron donating substitutent such as a methoxy group. When 
70 was stirred with ammonia solution no evidence for amide formation could be found. 
However under the standard conditions in the pressure vessel, the amide 64 was 
formed in good yield. A problem hampering the synthesis of these nitro derivatives at 
all stages is their extreme insolubility. This not only presented handling problems but 
also made purification of these compounds difficult. 
4.5.3 Synthesis of Further 2-Aryl Benzimidazole Analogues 
4'-Cyanophenyl would be a useful benzimidazole substituent SInce it contains an 
electron withdrawing group that can be elaborated further. Initially, reacting 4-
cyanobenzoyl chloride, that was readily prepared from its acid,119 with methyl 2,3-
diaminobenzoate 33 had resulted in the formation of a mixture of mono- and diacylated 
products, with the latter as the major product. However, when the reduced 
temperature method sucessful for synthesising the nitrophenyl benzimidazoles was 
applied, a sample of methyl 2-amino-~-N-( 4'-cyanobenzoyl)aminobenzoate was 
successfullv isolated from the reaction with much lower contamination by the 
dial'ylated byproduct The benzimidazole precursor was readily cyc\ised when heated 
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with glacial acetic acid, and treatment under pressure with liquid ammonia yielded the 
target benzimidazole carboxamide 71. 
o o 
NaOH, EtOH 
eN 
71 72 
The hydrolysis of the cyano group of 71 was attempted under basic conditions, in 
order to synthesise the useful 4'-carboxylic acid derivative 72. The carboxylic acid 
group is an isostere of the nitro group since it is electronically and sterically similar. 
However, the main advantage of the acid group is its relative lack of toxicity, and it is 
also a site of possible elaboration and prodrug modification. The cyano compound 71 
was suspended in a mixture of sodium hydroxide and ethanol and refluxed for five 
hours to yield a carboxylic acid product 72.120 
o o 
1 M BBr3 / OeM 
OMe OH 
56 73 
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A 4'-hydroxyphenyl benzimidazole was an important derivative for the series, since it 
has an electron rich aryl group and it may possibly increase the solubility of the 
benzimidazole compounds. The molecule also possesses a potential prodrug handle. 
When 2-( 4'-methoxyphenyl)-1-H-benzimidazole-4-carboxamide 56 was treated with a 
five-fold excess of boron tribromide solution, and refluxed for 24 hours, a 
demethylation in high yield was observed, affording the desired compound 73Y~ 1 
o 
OMe 
Pd/C I H2 
69 • 
i. CH3C02H 
ii. NH3 (I) 
o 
74 
It had been originally proposed to synthesis 2-( 4'-aminophenyl)-I-H-benzimidazole-4-
carboxamide 74 in one step from the nitro analogue via a reduction. However, due to 
the insolubility of the nitro compounds a reduction of 69 was performed using 
atmospheric hydrogenation to produce 75, since the product is more soluble and easier 
to handle and purify. The amino derivative 75 cyclised readily under acidic conditions, 
and the bemzimidazole product was treated with ammonia to produce the required 
carboxamide compound 74. 
4.5'" Acylation Step Impurities 
In the synthesis of 2-aryl benzimidazoles, the crucial step consists of the reaction of 
methvl 2J-diaminobenzoate 33 with YarioLls acid chlorides. As we have seen, the 
more reacti\'l~ acid chlorides required a modification of reaction conditions in order to 
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successfully achieve mono acylation of the 3-amino group. Even when using the less 
reactive 4-methoxybenzoyl chloride, low yields of the desired product were obtained 
and the two major impurities isolated from the reaction are the diacylated derivative 
and the methyl ester derivative of the acid chloride. In all reactions a diacylated 
impurity was observed to a varying degree, but this could be readily separated by 
column chromatography and/or recrystallisation. 
0 
0 
0 
ArCOCI OMe OMe OMe 
.. + + ArC~Me NH 
TEA, DMAP , THF 
HNyO 0yNHA NH2 _10°C o Ar 
Ar Ar 33 
40-60% 15-20% 5-10% 
4.5.5 Attempted One Pot Method 
An experiment was performed to establish the possibility of synthesising a 
benzimidazole directly from a precursor such as methyl 2-amino-3-nitrobenzoate 39. 
In one flask 39 was dissolved in glacial acetic acid and to this was added 5 mol% 
DMAP, one equivalent of 4-methoxybenzoyl chloride and a catalytic amount of 100/0 
palladium on carbon catalyst. The reaction was stirred under a hydrogen atmosphere 
for 24 hours, but TLC analysis identified the products of the reaction as methyl 2,3-
diaminobenzoate 33 and 4-methoxybenzoic acid. 
4.6 Synthesis of 2'- and 3'-Substituted 2-Aryl Benzimidazoles 
With the synthesis and biological evaluation of a number of 4'·substituted phenyl 
benzimidazoles complete, it was decided to explore the synthesis of inhibitors 
containing electronically different groups at different positions around the 2-phenyl 
ring. On the basis of ease of synthesis and availability, methoxy- and tritluorometh~·1 
R9 
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were chosen as suitable electron donating and withdrawing groups, respectively, for 
use in these experiments. 
4.6.1 3'-Substituted Benzimidazoles 
o o 
OMe 
76 77 
Adopting the now well refined standard procedure, methyl 2,3-diaminobenzoate 33 
was treated with a suitable acid chloride at -10°C. A monoacylated product was 
isolated from this reaction in reasonable yield and some diacylated impurity also 
separated. The product cyclised upon treatment with hot glacial acetic acid, and the 
required benzimidazole carboxamides 76 and 77 were produced by reacting the methyl 
ester with liquid ammonia in a pressure vessel. 
~.6.2 2'-Substituted Benzimidazoles 
Using the standard procedures as described, treatment of methyl 2,3-diaminobenzoate 
33 with 2-methoxybenzoyl chloride and 2-trifluoromethylbenzoyl chloride yielded as 
expected the monoacylated products 78 and 79. However, when the cyclisation of 
these compounds was attempted with glacial acetic acid, no benzimidazole product 
could be isolated from the reaction. In an attempt to effect the cyclisation, methyl 2-
arnino-] -X-(:'-tritluoromethylphenyl)aminobenzoate 79 was treated with a stronger 
acid, tritluoroacctic acid, although no trace of an~' benzimidazole products \\"ere 
90 
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isolated from this reaction either. However on treatment of 78 with -+~1 HCI, 
reminiscent of the traditional methods of benzimidazole synthesis, the compound 
cyclised, and a benzimidazole carboxylic acid 80 was identified as the product of the 
reaction, the harsh nature of the reagents causing hydrolysis of the ester. A possible 
explanation for these results is that the acetic acid and trifluoroacetic acid were 
acetylating the free amino group, and hence blocking cyclisation. N1v1R evidence 
exists for this, since treating 78 and 79 with glacial acetic acid yielded compounds 
containing a singet in their spectra at 0 2.61, that integrated for three protons, and 
hence could be assigned to an acetyl methyl group. Additionally, these spectra did not 
contain the downfield signal typical of a benzimidazole, suggesting that cyclisation had 
not occured. Treatment of 79 with 4M HCI readily gave a benzimidazole carboxylic 
acid. 
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A conversion of the acid 80 to the corresponding amide was attempted. This was 
achieved via the acid chloride, using thionyl chloride and catalytic DMF by the method 
previously adopted. This successfully yielded a sample of 2-(2'-
methoxyphenyl)benzimidazole-4-carboxamide 81. 
4.7 Synthesis of I-N-Substituted Benzimidazoles 
An important extension to the benzimidazole senes involved elaboration of the 
compounds by alkylation and acylation of the imidazole moiety of 2-( 4'-
methoxyphenyl)-1-H-benzimidazole-4-carboxamide 56. 
H 56 
0 
Me 82 
NH2 0 
84 
/N R= 
R 
0y 
85 
OMe 0 
Z 
This compound was chosen for elaboration because of its relative ease of synthesis, 
good handling characteristics and high inhibitory activity. It was intended to increase 
the size of imidazole N-substitutents to gauge the size of groups that may be tolerated 
at this site of the molecule. 
4.7.1 Benzimidazole Alkylation 
:\ simple methylation was chosen as the first substitution to attempt, since the methyl 
~rollp is small and the alkylated product should not be significantl~' larger than the 
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parent compound. The methylation of 2-methylbenzimidazole was first attempted as a 
model reaction, by treatment with potassium hydroxide and methyl iodide in acetone, 
and the desired product was isolated in reasonable yield (500/0).122 
Exactly the same conditions were used to treat 2-( 4'-methoxyphenyl)-1-H-
benzimidazole-4-carboxamide 56, and although at 300/0 the yields were slightly lower 
than previously experienced, enough product 82 was isolated pure to use for the 
biological evaluation of the compound. 
4.7.2 Benzimidazole Benzoylation and Z-Protection 
The benzoylation and benzyloxycarbonyl- (Z) protection of the benzimidazole 56 was 
proposed since these represent side chains of increasing bulk from methyl to Z, and are 
convenient reactions to perform. 
Model Studies 
As with the alkylation reaction, a model benzoylation was attempted initially with the 
treatment of 2-methylbenzimidazole with benzoyl chloride and triethylamine in 
DMF.123 This reaction proceeded well, although, again, the yields were considerably 
lower than those reported. 
83 
An alternatin:- reagent for the Z protection of amines, a stable solid carbamate 
deri\'ati\'e of benzyl chloroformate 83 is a useful alternative which is stable and does 
not contain impurities l~-l This was synthesised bv the reaction of benzyl 
chloroformate and 4-nitrophenol. 
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A large number of primary and secondary amines have been successfully protected 
using this reagent but when 2-methylbenzimidazole was treated following the 
recommended procedure, only starting materials were isolated from the reaction. The 
Z protection of 2-methylbenzimidazole was attempted using the procedure applied for 
its benzoylation, and although obtained in low yield, the protected benzimidazole was 
successfully prepared via this alternative method. 
2-( 4'-Methoxyphenyl)-1-H-benzimidazole-4-carboxamide 56 was treated with benzoyl 
chloride and triethylamine in DlVtF under the literature conditions but no product could 
be isolated from the reaction, and no evidence that any reaction had occurred could be 
found. In an attempt to obtain a product, the procedure was attempted again using 
DMAP as a catalyst, but this had no effect on the outcome of the reaction. Similarly, 
when 56 was treated under these conditions with benzyl chloroformate, or with the Z 
protecting carbamate reagent 83, only starting materials were isolated from the 
reaction. 
It was decided that the benzimidazole 56 probably required ionisation for its efficient 
protection,125 and therefore the conditions that were utilised for the successful 
alkylation were applied to the problem of benzoyl at ion. The substrate was dissolved in 
acetone and an equivalent of potassium hydroxide added followed by an equivalent of 
benzoyl chloride and after stirring this procedure afforded the protected benzimidazole 
84 in 44% yield. Although this was not an entirely efficient process, sufficient product 
was obtained for characterisation and biological evaluation. Substituting benzyl 
chloroformate for benzoyl chloride in this reaction yielded the Z protected 
benzimidazole 85 in 5~% yield. 
It is worth noting that 85 \\'as deprotected in quantitative yield to the parent 
benzimidazole 56 upon treatment with 1 ~1 boron tribromide in OC\1 
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This chemistry yielded three important compounds of increasing steric bulk. Their 
ability to interact with the active site of P ARP will yield important structure-activity 
data. 
4.8 Combinatorial Approaches To PARP Inhibitors 
As has been described in the prevIOUS sections, a senes of structurally similar 
benzimidazole inhibitors has been synthesised to explore the requirements of the active 
site of P ARP. Although this study has produced some positive results and highly 
potent compounds, progress has been hampered by the repetitive nature of the 
chemistry required for the synthesis of each inhibitor. This has long been recognised as 
a limiting factor in drug design generally, and recently the novel technique of 
combinatorial chemistry has gained favour as a solution to such time-consuming 
problems. 66,126,127 Essentially, combinatorial techniques can be used to rapidly 
synthesise a large 'library' of structurally related molecules. It is related to the 
Merrifield method of peptide synthesis, and carried out in the solid phase using 
polymer or resin beads as supports, to which an identified core compound is attached. 
This can then be treated sequentially with a variety of reactants, excesses of which are 
removed at each stage by a washing procedure. Once the synthetic procedure is 
completed, active compounds can be isolated from the mixture by cleavage from the 
supports, and undergo bulk screening for the required biological activity. Although 
such generation of mixtures goes against traditional organic chemistry, interest in 
combinatorial chemistry is growing rapidly, especially in the pharmaceutical industries, 
where the hardware and software for the automation of this technique is rapidly 
becoming available. 
Combinatorial chemistry has two principal applications; the synthesis of large libraries 
for broad screening to identif)t a lead compound, or the fast synthesis of a large 
number of analogues of an identified active molecule. The latter \vas sllccessfully 
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applied to the generation of a 1,4-benzodiazepine library and heralded the use of 
combinatorial techniques to introduce small molecule diversity. 128 
The elaboration of the benzimidazole series of P ARP inhibitors presents possibilities 
for the application of combinatorial techniques, to increase the variety of active 
compounds and the speed at which they can be synthesised. Performing a 
'retrocombinatorial analysis' upon a 2-aryl benzimidazole suggests the elements 
required to achieve a suitable synthesis. The 2,3-diamino benzoate / benzamide core is 
a suitable candidate for attachment to a solid support, this linkage would need to be 
readily convertible to an amide upon cleavage. 
0 
0 
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NH2 y)support] CI 
=> Ra + 
/N 
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Rc NH2 
Rb 
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Rb 
Y = 0 or NH + Rc-X C 
The procedure could be carried out in a 2-dimensional matrix of wells, in a heating 
block. Initially, a 2,3-diamino precursor attached to a solid support (A) could be 
placed in each well and be treated with reactants of type B, and any other required 
reagents, for example, an acid scavenger. After suitable reaction time, excess reagents 
could be removed by a wash, and each well could be treated with an acid, including 
heating if necessary, to cyclise to a benzimidazole. Following a washing procedure, 
some or all of the wells could be treated with reagent C before cleavage from the 
support and recovery of the inhibitors The series could be extended further still if an 
Rb substituent, capable of elaboration, was protected for the formation of the 
benzimidazole, then deprotected and reacted further subsequent to the c!ea\·age of the 
96 
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support. Using such a technique, a large number of benzimidazole P ARP inhibitors 
could be generated essentially in one experimental procedure. Much work would be 
required to develop such a process, and unfortunately is outside the scope of this 
thesis, for combinatorial chemistry promises an exciting future for medicinal chemistry 
and drug design. 
4.9 Summary 
This chapter has reported the synthesis of a series of compounds, that have been tested 
for their inhibitory activity against the enzyme poly (ADP-ribose)polymerase. The 
results of these inhibitor studies have influenced the identification of subsequent 
benzimidazole targets, which to clarify matters are discussed fully in Chapter Seven. 
The linear synthetic routes to the 2-alkyl and 2-aryl benzimidazoles are summarised in 
scheme -1.1 and scheme -1.2 respectively. The 2-alkyl benzimidazoles were synthesised 
with a poor overall yield, for example, 6% for 2-methylbenzimidazole-4-carboxamide 
.. 4 from 3-nitrophthalic anhydride 37. This figure would be higher if the final amide 
conversion had proceeded in a higher yield. The overall yields of the 2-aryl 
benzimidazoles were marginally better. The 4-methoxyphenyl benzimidazole 56, that 
was synthesised readily, yielded 14% overall from the anhydride starting material. 
However, a less efficient yield of only 3% overall from 37 was recorded for the 4-
trifluoromethylphenyl derivative 57. Yields in this synthesis could be improved by 
increasing the efficiency of the acylation of methyl 2,3-diaminobenzoate 33. 
The synthetic route described has been sucessful for the synthesis of a series of novel 
benzimidazole-4-carboxamide derivatives as inhibitors of P:-\RP, although some 
refinements to the procedure could benefit the overall yields of these compounds 
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Scheme 4.1: Synthesis of 2-Alkyl Benzimidazole-4-Carboxamides 
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Scheme 4.2: Synthesis of 2-Aryl Benzimidazole-4-Carboxamides 
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5.1 Introduction 
To successfully develop a drug suitable for use in the clinic, consideration must be 
given to its in vivo solubility, bioavailability and formulation . For example, a 
compound may have high potency in vitro but if it is unlikely to be soluble in aqueous 
conditions as experienced in the body, then it will be of limited use as a drug. 
A common method used to overcome this problem is the prodrug approach, where an 
active compound is chemically modified to make it suitable for clinical administration, 
and once in the circulation it is enzymically reconverted to the parent drug. A prodrug 
modification can be carried out on a compound with a suitable functionality, commonly 
an amine or hydroxyl group. 129, 130 The parent drug should be of high activity, and the 
prodrug derivative should be chemically stable, non toxic and normally inactive.131 
The adminstration of anti-cancer agents as slow release prodrugs, may have the 
advantage of reducing the toxicity of chemotherapy. Most importantly, the prodrug 
should have good aqueous solubility characteristics. Once administered, the prodrug 
hould be ab orbed well and under in vivo conditions normally via enzymatic 
h droly is, will be clea ed to deliver the active drug to the circulation. Additionally, 
the lea ing group of thi reaction should be non toxic and readil eliminated from the 
b d . 
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For the purposes of the benzimidazole project, the choice of inhibitor to de\'eJop as a 
potential prodrug was 2-( 41-hydroxyphenyl)-1-H-benzimidazole-4-carboxamide 73, 
since it was found to have high activity and also contained a phenolic hydroxyl group 
as a prodrug modification site. 
5.2 Prod rug Modifications 
A clinically useful drug, must possess a good level of aqueous solubilty. A simple 
solution to this problem is the conversion of the compound in question to a salt in 
order to improve aqueous solubility properties. Sodium or potassium salts of 
carboxylic acids, and hydrochloride salts of amines can increase the solubility of the 
parent molecules, although these are not regarded as prodrug modifications. 
Glycosides have been reported as effective phenolic prodrug modifications, although 
they are not readily cleaved and do not always confer increased solubility. Sulphates 
have also been synthesised as phenolic prodrugs, although their poor stability, and 
rapid clearance from the body may cause problems with this class of compounds. 132 
5.2.1 Carbamate Prodrug Modifications 
Carbamate esters are well known as important prodrug modifications used to increase 
the solubility of a compound. They can be used to modify hydroxyl and amine groups, 
and in the latter case this has proved especially useful for drugs needed to cross the 
blood-brain barrier, since not only are they prodrugs, but they also protect the amine 
against metabolism by monoamine oxidases (MAO's) before they reach the brain. 
MAO's are present in all brain capillaries, and destroy many amines, including 
dopamine, before they can enter into the brain. Carbamoylation protects the amine 
from degradation, and hence facilitates its transport into brain tissue. l J J Carbamate 
linkages are known to be highly chemically stable and yet are often readily hydrolysed 
ill l'il'(} by plasma cholinesterases.lJ~ 
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Amine Carbamate Ester 
0 Enzyme, 0 
R-NH2 
R, )l /R' H2O R'N)lOH ~ N 0 ~ ~ R-NH2 H H 
+ CO2 + R'-OH 
Hydroxyl Carbamate Ester 
R-OH R-OH + 
Figure 5.1 .. Carbamate Ester Hydrolysis 
Both amme and hydroxyl carbamate prodrug modifications are hydrolysed 
enzymatically to an alcohol and a carbamic acid, which is unstable under physiological 
conditions and decomposes to carbon dioxide and an amine. The amine or the alcohol 
produced in this reaction may be the active drug, depending on which group was 
originally modified. The leaving group, which may be an amine or an alcohol 
depending on the parent compound, must be non toxic and readily cleared from the 
body. 
Many carbamate esters with numerous substituents have been reported, and they vary 
from simple short alkyl chains to bulky aromatic groups. The 4-iso-
propylphenylcarbamate derivative, (figure 5.2), is an example that is particularly 
resistant to first pass metabolism, and can hence lead to high plasma levels of 
prodrug.135 
figure 5.:: -I-ls(}pr(}r~1ca,.hamale F'sler Prodrllg 
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5.2.2 Phosphate Prodrug Modifications 
Phosphates and their salts are common water soluble prodrug modifications of 
hydroxyl groups. They are often chemically very stable, and are known to be 
hydrolysed enzymatically in vivo to yield the parent compound. 132 Numerous 
examples exist of phosphates, either free or as their sodium or potassium salts, as 
prodrug modifications, and a number of phosphorylating reagents have been reported, 
generally affording benzyl protected phosphate derivatives, that undergo deprotection 
to yield the prodrug, (figure 5.3).132,136,137 
Phosphorylation 
ROH • ....... 0, 'i0 R P 
/ ' BnO OBn 
Figure 5.3; Phosphate Prod rug Modifications 
Deprotection 
2 Na+ / K+ 
It was decided to attempt the synthesis of a carbamate ester and a phosphate prodrug 
of the benzimidazole-4-carboxamide 73, and the chemistry required for these syntheses 
is discussed in the following section. 
5.2.3 Antibody-Directed Enzyme Prodrug Therapy: ADEPT 
Carbamate ester prodrugs have been utilised in the recently proposed novel treatment 
for cancer, ADEPT. This is a two-step approach designed to overcome the unwanted 
toxicity generally experienced with conventional chemotherapy treatments. 138.139 
In the first step of ADEPT treatment, an antibody-enzyme conjugate is administered. 
The enzyme component of the conjugate is capable of converting a specific prodrug to 
its active parent drug, \-vhile the antibody coupled to it has been raised against certain 
10J 
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tumour associated antigens. Following introduction to the circulation, the conjugate 
accumulates predominantly at the site of the tumour, and any excess is allowed to clear 
from the system. A non-toxic prodrug is subsequently administered, and enzyme 
mediated cleavage to the active drug occurs selectively at the tumour, resulting in little 
or no systemic toxicity. To prevent any non-specific hydrolysis occurring prior to the 
prodrug reaching the tumour, the prodrug is designed to undergo activation 
specifically by the ADEPT enzyme, which is invariably of bacterial origin. 
ADEPT 
Enzyme 
Conjugate 
CI 
~ 
CI~N~ ~ 86 OH 
+ 
A glutamic acid carbamate ester prodrug of the known alkylating agent, 4-[N,N-Bis(2-
chloroethyl)amino ]phenol 86, has been identified as a suitable prodrug for ADEPT 
therapy.139,140 In vitro experiments with a suitable conjugate and 86, have shown a 
reduced survival of human colonic carcinoma cell lines, and such treatments are 
currently undergoing clinical evaluation. 
5.3 Benzimidazole Prodrugs 
The benzimidazole inhibitor 73, while highly actIve in l'itro, has a 10\v aqueous 
solubility making it an ideal candidate for prodrug modification. Such a modification 
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to Improve solubility, and hence bioavailabilty, is essential to develop further the 
benzimdazole inhibitors as clinically useful agents. 
5.3.1 Carbamate Ester Derivatives 
There are many examples of the use of carbamate esters as prodrugs of phenolic 
compounds that are readily synthesised from isocyanate derivatives,135 so an attempt 
was made to synthesise such a benzimidazole analogue. A glycine carbamate ester 87 
was proposed as it should be water soluble as a salt, undergo hydrolysis readily in vivo 
to the active drug 73, and give rise to a non toxic leaving group. 
o 
73 
OH 
Et02CCH2NCO 
TEA J THF 
o 
88 R = Et 
NaOH[ 
87 R = H 
The synthesis involved reacting 73 with ethyl isocyanatoacetate in the presence of 
triethylamine to yield an ethyl ester 88. The carbamate obtained could then be 
hydrolysed to the carboxylic acid to yield the prod rug, which may be formulated as the 
sodium salt. Although there \vas evidence that the isocyanate was reacting \vith the 
phenol, it was clear from NMR and mass spectral data that the product rapidly 
decomposed to the parent benzimidazole 73, e\'en when stored under reduced 
10) 
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temperatures. Consequently, the synthesis of these prodrugs was abandoned in favour 
of the phosphate analogues that were expected to exhibit a much greater stability. 
5.3.2 Phosphate Derivatives 
The phosphorylation of alcohols is another common prodrug modification. Dibenzyl 
chlorophosphonate 89 is a good phosphorylation reagent and has been used 
extensively. 141 The dibenzyl groups are readily cleaved by hydrogenation after 
phosphorylation has occurred. Although a number of methods for the preparation of 
89 have been reported, the reagent can be readily synthesised from dibenzyl phosphite 
by treatment with N-chlorosuccinamide (NCS).l-U This procedure was carried out in 
dry ether to give 89 as an oil, and this was reacted directly with the benzimidazole 73 
in acetonitrile, in the presence ofHunig's base. 
o ~ 89 
P 
CI/ ........ (OCH2Phb 
Hunigs Base, MeCN 
OH 
73 
o 
O-R 
90 R = P(O)(OBn)2 , R' = H 
91 R = R' = P(O)(OBn)2 
The reaction did not seem to go to completion, and two further products besides 
recovered starting material were isolated from the reaction. The major component was 
recovered in 100/0 yield, and shown to be the desired mono phosphorylated product 90. 
The second product (40/0) was shown to be the diphosphorylated product 91 This 
reaction was most unsatisfactory in terms of yield, and may possibly be due to a 
succinimide impurity reacting with the dibenzyl chlorophosphonate. .-\ more efficient 
lOll 
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phosphorylation has been reported which involves the generation of the 
phosphorylating reagent from dibenzyl phosphite in situ. The phosphorylation of 
alcohols can be achieved in a one pot reaction with dibenzyl phosphite, carbon 
tetrachloride and DMAP in dry acetonitrile. lOon 
o 
73 
NH2 
(BnO)2P(O)H, CCI4 , 
DMAP, MeCN 
• 
OH 
o 
Pd/C I H2 
0 
II 
O-P 
I' BnO OBn 
90 
o 
0 
II 
O-P 
I' HO OH 
92 
This reaction was attempted successfully with the benzimidazole 73, and although still 
generated in low yield (290/0), the required protected phosphate 90 was isolated from 
the reaction together with unreacted starting material. Under these conditions only a 
trace amount of the diphosphorylated impurity 91 was observed. 
Conversion to the phosphate 92 was achieved by catalytic hydrogenation at 
atmospheric pressure to remove the benzyl protecting groups. This reaction required 
the use of THF redistilled from lithium aluminium hydride to remove a contaminant 
that otherwise appears to inhibit this reaction.l~~ The reaction proceeded well, with 
complete conversion of 90, although the phosphate derivative obtained appears to 
exhibit only moderate water and organic solvent solubility, which hampered the 
purification of the compound. 
107 
Chapter Five: Design of Benzimidazole Prodrugs 
5.4 Summary 
The synthesis of a potential benzimidazole carboxamide prodrug has been achieved 
with the phosphate derivative 92 of the hydroxyphenyl benzimidazole 73. However, 
from initial observations it appears that the aqueous solubility of the compound 92 is 
only moderate. Further refinements, such as formulation as the sodium or potassium 
salt of 92, may be necessary if the potential of this compound to act as a prodrug is to 
be investigated, and will be essential if the benzimidazole P ARP inhibitors are to 
progress towards clinical trials and beyond. 
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An important structural feature of the benzimidazole carboxamide inhibitors is the 
amide functionality, restricted by an intramolecular hydrogen bond into a conformation 
that is essential for the activity of this series of compounds. 
o 
OMe 
56 
Evidence from a number of analytical techniques has been used to confirm that the 
structure of these molecules is as drawn, for example 56. This chapter presents a 
ummary of the information obtained in support of the proposed structure. 
6.2 Benzimidazole-4-carboxamide Analysis 
6.2.1 X-Ray tructure 
T d t rmin ri ntation of the carb xamide group the X-ra tructure of 56 \Va 
btain d It r al d that th arbo amide gr up i r train d in the anfl-confi rmati n 
Illl) 
Figure 6.1 .. X-Ray Crystal Structure of 56 
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Figure 6.2; Solid Phase Intermolecular Interactions of 56 
III 
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by an intramolecular hydrogen bond, and that there is also a strong intermolecular 
interaction in the crystal lattice. This observation must be treated with caution whilst , 
this structure may be preferential in the crystal lattice it may not reflect the true 
structure that exists, and binds to the enzyme in the solution phase. 
6.2.2 NMR Spectra 
Nuclear magnetic resonance experiments have yielded the most useful structural 
information on benzimidazole P ARP inhibitors. The proton spectra obtained were 
readily interpreted in favour of the structure assigned to the benzimidazole 
carboxamides. The most important features of the spectra are the three singlets; Ha, 
Hb and He (see figure 6.4), exchangeable upon addition of D20, that can be assigned 
as two amide protons and one imidazole amine proton. 
The presence of two amide proton signals suggests that they must be inequivalent and 
this is evidence for the presence of an intramolecular hydrogen bond in solution. The 
upfield protons Ha and Hb can be assigned as the two carboxamide protons, since in 
the N-substituted benzimidazole series (jor example 82), the most downfield signal He 
is absent. Proton Hb can be assigned as the most downfield carboxamide signal due to 
deshielding relative to Ha. 
When the relative shifts of proton signals for various inhibitors are compared, as 
shown in figure 6.3, an interesting observation can be made. The carboxamide protons 
Ha and Hb have relatively constant OH values throughout the series, not varying by 
more than about 0.3 ppm. In contrast, the 0H values for the imidazole proton He vary 
considerably; nearly 1 ppm difference is observed between compounds with an electron 
rich 2-aryl substituent, and those with an electron deficient substituent. This provides 
further evidence that this downfield signal is arising from the imidazole proton as it is 
sufficiently close to be influenced b~' the electronic nature of the 2-substituent The 2-
substituent may therefore be important in determining the abilitv of the imidazole 
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proton to interact with the active site of the enzyme. The most striking example of this 
is the proton spectrum for 2-trifluoromethyl-l-H-benzimidazole-4-carboxamide 45 
where a powerful electron withdrawing group is attached directly to the benzimidazole 
ring, and the He shift is far downfield. Additionally, the Hb signal is 
uncharacteristically upfield, suggesting the effect of the trifluoromethyl group has 
weakened the intramolecular hydrogen bond. These observations suggest the 
electronic nature of the 2-aryl benzimidazole substituent could influence the ability of 
an inhibitor to bind at the active site of the enzyme. 
o 
R OHa (ppm) OHb (ppm) OHc (ppm) 
H (43) 7.8-8.0* 9.40 13.1 
CF3 (45) 7.97-8.01 * 8.70 14.4 
4'-NH2Ph (74) 7.84 9.S 13.0 
3'-OMePh (76) 7.85-8.01 * 9.4 13.5 
4'-N02Ph (64) 8.0 9.3 13.9 
* Ha Signal Under Multiplet 
Figllre 6.3,' Relative N-H Shifts of PARP Inhibitors 
The DC spectrum shown in figllre 6.5 is typical of those obtained and is consistent 
with the benzimidazole structure proposed. 
To verify the assignment of the three N-H protons a proton nuclear Overhauser effect 
(nOe) correlation ROESY spectrum was obtained for 56. It was hoped that this 
technique \vould yield further information with regard to the conformation of the 
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Figure 6.5; Carbon-13 Spectrum of 56 
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carboxamide group, and hence the nature of the intramolecular hydrogen bond. While 
the spectrum (see figure 6.6) reconfirmed the assignment of He' the most downfield 
peak, as the imidazole proton, it does not prove that the carboxamide group is 
restrained in the anti-conformation. The extreme downfield nature of the signal for the 
He proton suggests, on the basis of chemical shift data, that it is involved in a hydrogen 
bond interaction. If this is the case, then the carboxamide group could adopt the SYIl-
conformation, and one might expect an nOe signal from the interaction of Hb with C6-
H, although this was not observed. 
N Hi 
o 
56 anti 
OMe 
--
OMe 
56 syn 
In the solution phase, the orientation of the carboxamide group remams to be 
established. The fact remains, however, that the benzimidazole carboxamide inhibitors 
do exhibit a high inhibitory activity against P ARP. Possibly, in the solution phase both 
conformers are present in equilibrium, and while the syn conformer may predominate 
as the spectral data suggest, only the anti conformer binds to and inhibits the enzyme. 
Alternatively, .\)'11 56 may be binding upside down to the active site of PARP. The 
answers to these questions may be provided by the crystal structure of an inhibitor 
bound to the catalytic region ofPARP, an exciting possibility for the future. 
1 1 -; 
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6.2.3 Mass Spectra 
The benzimidazole-4-carboxamides compounds were invariably analysed usmg 
electron impact mass spectrometry, and for most of the compounds a common 
fragmentation pattern was observed. The molecular ion (M+) was always identified, 
and usually was of high intensity. The fragments observed corresponded to the loss of 
ammonia, followed by the loss of carbon monoxide. A peak originating from the 2-
phenyl substituent was commonly observed. Examples of these observations are 
presented below (figure 6.7). 
Comp_ound M+ 
-
NH3 -CO 2-Substituent 
0 
Y;H' 
262 245 217 +< }-CN HNq 
71 ~ # 102 
eN 
0 
ctNH' 
253 236 208 +< }-OH HNq 
73 ~ # 93 
OH 
Figure 6. 7; Mass Spectral Data 
6.3 Conclusions 
The empirical structure of the benzimidazole carboxamides has been confirmed by a 
number of techniques, but the exact orientation of the carboxamide group has not been 
proven. In the solid phase, X-ray crystallography has established the existence of an 
intramolecular hydrogen bond, but while this result is in favour of the proposed 
structure of the benzimidazole inhibitors, it must be remembered that the crystal 
structure represents the most stable orientation in the solid phase, and the same may 
IIX 
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not be true in the liquid phase as experienced under NMRIexperimental conditions, or 
in vivo. The view of the solution structure is less clear, but the benzimidazole 
inhibitors are highly active, and if an equilbrium does exist in the liquid phase, 
restricting the carboxamide rotation chemically to the anti conformation could produce 
an increase in activity. In summary, additional studies of the structure of the 
benzimidazole inhibitors in the solution phase, may lead to new synthetic targets to 
enhance the potency of the benzimidazole P ARP inhibitors still further. 
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7.1 Introduction 
The benzimidazole P ARP inhibitors are the product of a drug design programme that 
started originally with the structural modification of 3-hydroxybenzamide,8-l and 
continued via rationally synthesised molecules to reach the present compounds. The 
development of these inhibitors has largely relied upon the feedback of biological 
activity data in order to determine subsequent synthetic targets . As well as 
determining the activity of these compounds against P ARP, other experiments have 
been performed, including potentiation studies to demonstrate the clinical potential of 
the benzimidazole inhibitors . This chapter outlines the results of these investigations, 
that were carried out in collaboration with colleagues in the Cancer Research Unit, 
University of Newcastle upon Tyne. 
7.2 PARP Inhibition Studies 
7.2.1 Permeabilised Cell Assay 
The assay for P ARP inhibition was carried out in permeabilised munne leukaemia 
L 1210 cells using a modification of the method first reported by Halldors on e t aI. 14 ~ 
The cells were permeabilised b exposure to h potonic buffer and co ld hock and 
in ubated for 5 minute at 26°C \ ith a synthetic palindromic nucleotide 
[( TT G), \ hi h form a double tranded hairpin \vith a blunt end to acti\ ate 
P RP] , the inhibit r lind r in e tigati n, and ., ~P AD+ in i otoni buffer In ubati n 
1-1 
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was terminated by addition of 1 % TCA, and polymer precipitation was effected by 
cooling on ice. The precipitate was collected by filtration, washed with 1 % TCA and 
1 % sodium phosphate, dried, and the incorporation of 32p into the precipitate 
measured with a scintillation counter. Activity is recorded as the percentage of 32p 
uptake in drug treated cells relative to control experiments, and is expressed as an IC50 
value, the concentration of inhibitor required to reduce the activity of the enzyme to 
50% of a control. 52 
7.2.2 Activities of P ARP Inhibitors 
The 2-alkyl benzimidazole carboxarnides were the first P ARP inhibitors to be assayed 
for inhibition against P ARP. The results of these experiments are detailed in figure 
7.1, and benzamide 6 and 3-hydroxybenzarnide 20, assayed under the above 
conditions, are included for comparison. The 2-alkyl benzirnidazoles showed good 
inhibition of PARP, being ten-fold more active than benzarnide, although no clear 
requirement for activity could be defined from these results. For example, the 
inhibitors 44 and 45 are sterically similar and yet electronically very dissimilar but there 
is only a marginal difference in activity between them (and 43). This suggested that a 
bulkier 2-substituent may be needed for active site interactions, which lead to the 
synthesis of the 2-aryl benzimidazole series. As a control experiment, the carboxylic 
acid derivative 41 was shown to be inactive as a P ARP inhibitor, demonstrating the 
requirement of the 4-carboxamide group for activity. Introducing a 2-aryl substituent, 
onto the benzimidazole carboxarnide produced a significant increase in inhibition over 
the 2-alkyl inhibitors, with activity now being observed at nanomolar concentrations. 
The development of this series of compounds, varying the electronic nature of the aryl 
substituent to investigate any electronic requirement that may exist at the active site, 
continued to yield highly potent P ARP inhibitors. The inhibitory activity (Ie 50) assay 
values for these compounds are shown infigure 7.:;. in decreasing order of potency 
122 
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Figure 7.1 
Number Structure 1Cso (Jll"I) 
Benzamide o 
6 12.4 
3-Hydroxy- 0 
benzamide NH2 8.0 
20 
OH 
0 
41 OH Inactive 
NUI067 
0 
43 NH2 1.02 
NU1066 
N 
HNJ 
0 
44 NH2 1.09 
NUI064 
N 
HN~ 
CH3 
0 
45 NH2 1.6 
NUI086 N 
HN~ 
CF3 
12, 
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For this senes of compounds it is difficult to make a clear statement regarding 
structure-activity requirements, except that inhibitors with a highly electron deficient 2-
aryl substituent, such as 64 and 71, appear to exhibit the highest inhibitory activity 
against PARP. However, they are only less than ten-fold more active than electron 
rich 2-aryl benzimidazoles, such as 74, so steric factors could also be important. The 
bulkier 2-aryl benzimidazoles are clearly more active than the 2-alkyl series, and the 
steric nature of the aryl substituent itself may also be important. Compound 64 
contains a relatively bulky nitro group that may have the correct geometry to interact 
with an active site residue. To investigate this proposal the carboxylic acid derivative 
72 was synthesised as an isostere of 64. The activity determined for this inhibitor was 
surprising low, although purification difficulties were encountered with this compound 
and an accurate CHN analysis could not be obtained. The result suggests that the 
shape of the substituent could not be important, but should be viewed with caution. 
All the other inhibitors tested for activity have been characterised successfully at high 
levels of purity. 
The series of imidazole N-substituted inhibitors, derivatives of 56, demonstrates that a 
small increase in steric bulk can be tolerated at the enzyme active site, since compound 
82 is only marginally less active than its analogous unsubstituted benzimidazole 56. As 
the size of the imidazole substituents is increased, the resulting compound is less well 
received by the enzyme, shown by a rapid decrease in potency. Steric factors are 
certainly vital to activity in this region of the molecule, as illustrated in figure 1.3, so 
any further successful elaboration of the imidazole nitrogen would need to be of low 
steric bulk. 
12.t 
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Figure 7.2 
o 
N HN-Z 
R 
Number R ICso (n1\l) 
64 
-+Q-N02 19 
NU109l 
71 
-+Q--cN 27 
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Figure 7.3 
OMe 
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The recent crystal structure data obtained for the catalytic region of P ARP suggests 
that an active site interaction with the imidazole proton could contribute to activity due 
to its closeness to important amino acid residue Glu-988. 85 The high potency of the 
methyl benzimidazole 82 in comparison with 56 argues, however, that the imidazole 
proton itself may not be involved in significant substrate-active site interactions 
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In terms of producing novel, potent P ARP inhibitors, these results show this project 
has been highly successful. The most active inhibitor identified, 64 (NU 1 091), is 
highly active and represents an increase of over 420-fold in potency from 3-
hydroxybenzamide 20, the original lead compound in these investigations. 
7.2.3 Increased Potency of Benzimidazole Inhibitors 
Figure 7.4 
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A comparison of the activities of a selection of inhibitors from the benzoxazole and 
benzimidazole serIes, demonstrates the increased inhibitory potency of the 
benzimidazole carboxamides. In all cases the benzimidazole is considerably more 
active than its isosteric benzoxazole, and in the case of the two 41-methoxyphenyl 
compounds, allows the evaluation of 56 due to increased solubility. In this case, a 
simple isosteric replacement has had a profound effect upon the chemical nature and 
biological activity of these compounds. 
7.3 Potentiation Studies 
Experiments have been performed to demonstrate that P ARP inhibitors potentiate the 
effects of cytotoxic drugs in vitro, and could possibly be developed for use in the clinic 
as resistance modifying agents. For these experiments, the methylating agents 
temozolomide 93 and MTIC 94 have been employed. 
7.3.1 Mechanism of Action of Temozolomide 
Temozolomide, 8-carbamoyl-3-methylimidazo[5, I-d]-l ,2,3,5-tetrazin-4(3H)-one 93, is 
an alkylating agent currently undergoing clinical trials. 1-l7 It is a chemically stable 
molecule that once administered is activated to a linear triazene, MTIC 94, that has 
been identified as the active species of the drug, although the precise mechanisms are 
unclear. 148 
0 
~ Me Clinical E--N N/ Activation 
N I • ~N ') N 
H2N CO2 H2N 
~u = 0:-':.-\ Base 
93 94 
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Temozolomide has been shown to be highly cytotoxic against munne and human 
tumour cell lines in vivo in the clinic, and is known to methylate at the 0 6 position of 
guanine, a lethal event. 149 
7.3.2 Potentiation Experimental Results 
Two types of experiments have been carried out USing the P ARP inhibitor 2-
methylbenzimidazole-4-carboxarnide (44, NUl064), in conjuction with and the 
cytotoxic agent temozolornide 93. The first potentiation experiments involved the 
incubation of L 121 0 cells with varying concentrations of NU 1 064, in the presence or 
absence of a fixed concentration of temozolornide (1 00 ~M). The results of these 
experiments are displayed in figure 7.5, and demonstrate clearly that benzimidazole 
PARP inhibitors potentiate the cytotoxicity of the DNA damaging agent in a dose 
dependent manner. There is also evidence to suggest that at high concentrations 
NU I 064 itself is marginally cytotoxic. 
The second assay was similar, but with a fixed dose of the P ARP inhibitor NU 1064 
and increasing concentrations of the cytotoxic agent MTIC. These experiments, 
shown in figure 7.6, demonstrate that a concentration of 200 J.lM of the inhibitor 
NUI064 potentiates the in vitro cytoxicity ofMTlC (94) in LI2l0 cells. The extent of 
potentiation can be expressed as a dose enhancement factor (EF 10)' calculated by 
comparing the IC 10 (the concentration of drug causing 900/0 cell death) of the 
cytotoxic agent alone with the IC 10 in the presence of a P ARP inhibitor, i. e. :-
EF 10 = lC 10 (Control) / lC 10 (+ NUl 064) 
For NUI064 a dose enhancement factor of 3.09 \vas observed, i.e., 200 ~l~l :.JUI064 
increases the cytotoxicity of ~ ITle by' approximately three-fold. 
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Figure 7.5; Potention Experiment With Varying NU1064 Concentrations With or 
Without 100 pM Temozolomide 
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Figure 7.6; Potentiation Experiment With Varying MTIC Concentration With or 
Without 200 )1lvf NUl 064 
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7.4 Kinetic Studies 
Kinetic studies of inhibitor one-site binding to the active site of P ARP have 
demonstrated that the benzimidazole carboxamide 44 acts as a competitive inhibitor as 
expected. As displayed in figure 7.7, using a hyperbola plot, the rate of 32p 
incorporation into permeabilised L 1210 cells was plotted against increasing labelled 
NAD+ concentrations in the presence or absence of 1 IlM ofNU1064. The V max and 
KM have been calculated for both curves, and since the former was unchanged and the 
latter varies considerably competitive inhibition can be assumed 
Vmax (IlM) KM* 
Control 735.22 407.76 
1 IlM NUI064 728.97 1036.94 
* Rate expressed as: pmoVI06 cells/5 min 
If the opposite result had been observed, i. e. the V max seen to vary between the curves 
while the KM remained constant, this would have suggested that the inhibitor may be 
asserting its effect by binding at a site other than the catalytic region, therefore 
allosterically inhibiting P ARP. From the results presented, one can assume that this is 
good evidence that NU 1 064 is binding competitively to P ARP at the catalytic site. 
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Figure 7.7; Kinetic Experiment Showing The Rate of Cellular 32 P NAD-:-
Incorporation With or Without 1 J.1M NUl 064 
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7.5 Summary 
• Control 
A l~ NUI064 
From the results of a variety of experiments, it is evident that the benzimidazole 
carboxamides are among the most potent inhibitors of P ARP reported to date. 150 
They are clearly considerably more active than the structurally related benzoxazole 
series, 1~6 and in common with that series, the 2-aryl derivatives exhibit the greatest 
potency. The results of these investigations suggest that the electronic nature of the 2-
aryl substituents may only have a small influence upon the overall ability to bind to the 
enzvme active site, and it appears that the size and shape of the compound may be 
important. 
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The P ARP inhibitor 2-methyl-l-H-benzimidazole-4-carboxamide (44) has been 
demonstrated to potentiate the cytotoxicity of DNA damaging agents while being 
relatively non cytotoxic itself. Given the high activity of the benzimidazole series these 
compounds have exciting potential as clinically useful resistance modifying agents, for 
use in combination with DNA-damaging agents to improve the efficiency of existing 
cancer chemotherapy regimes. 
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8.1 General Experimental Details 
Chemicals and Solvents 
All chemicals used were purchased from Aldrich Chemical Company or Lancaster 
Synthesis Ltd . The important starting material 3-nitrophthalic anhydride required 
careful storage in anhydrous conditions because of the ready hydrolysis observed . 
Experimental work was carried out under a positive pressure of argon or nitrogen as 
appropriate. Ethyl acetate, dichloromethane and petrol were redistilled before use. 
Dry solvents were prepared as required. Tetrahydrofuran and ether were distilled from 
sodium and benzophenone, and used immediately. Methanol was dried with 
magnesium and iodine and distilled. Acetonitrile and triethylamine were dried over 
calcium hydride and distilled. Hunigs base was distilled from ninhydrin . Unless 
otherwise stated, solvents were stored until needed over 4A molecular sieves under an 
inert gas atmosphere. lSI 
Chromatography 
Reactions were monitored using thin layer chromatography (TLC) employing Merck 
1.05554 aluminium plates coated with silica gel 60F25+, and a variety of mobile phase 
solvents. TLC plates were visualised using using short wave (254 nm) and long wa e 
(365 nm) ultra iolet light. All benzimidazole derivatives gave a characteri tic blue 
fluore ence under hort \ a e UV light Fla h' column chromatograph wa carried 
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out using Fison' s Matrix Silica 60 at medium pressure. Mixtures to be separated v,ere 
absorbed onto a small quantity of silica before loading onto the column. 
Pressure Reactions 
The reactions using liquid ammonia at 40 atm required the use of a sealed pressure 
vessel. The apparatus used was designed and built in the mechanical engineering 
workshops of the Department of Chemistry, University of Newcastle upon Tyne. 
Analytical Techniques 
Melting points were determined with a Kofler hot stage apparatus and are uncorrected. 
Elemental combustion analyses were recorded with a Carlo-Erba Instrumentazione 
1106 analyser or were performed by Butterworths Laboratories Ltd, 54-56 
Waldegrave Road, Teddington, Middlesex, TWII 8LG. 
Infra-red spectra were obtained using a Nicolet 20PC Fourier Transform spectrometer 
and the samples were mounted on potassium bromide disks. 
All proton (1 H) and carbon (l3C) nuclear magnetic resonance spectra were obtained in 
deuteriated dimethylsulphoxide (d6-DMSO) and exchangeable protons observed using 
a deuterium oxide (D20) 'shake'. Chemical shift values are quoted in parts per million 
(ppm). Proton spectra were recorded at 200 MHz and carbon spectra were recorded 
at 50 MHz, both using a Bruker WP 200 spectrometer. Carbon spectra are broad band 
decoupled. Additional proton spectra and nucleur Overhauser effect ROESY spectra 
were carried out at 500 MHz using a Bruker AMX 500 spectrometer. Coupling 
constants, (.I), are given in Hertz (Hz). Multiplicity of peaks in proton spectra are 
abbreviated as follows: s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), br 
(broad); and combinations thereof, for example dd (double doublet). 
Using either electron impact (EI) or fast atom bombardment (F AB) techniques as 
indicated in the text, mass spectra were recorded on a Kratos 0.1S80RF spectrometer. 
\Vhere a molecular ion was observed the symbol f\1+ is included in parentheses. FAB 
spectra \vere obtained using a l11t.'fu-nitrobenzyl alcohol matrix 
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8.2 Standard Procedures 
Similar procedures were employed for three important reactions concerned with the 
synthesis of 2-arylbenzimidazole precursors and derivatives. Since there was little 
variation of these procedures from compound to compound, they have been quoted in 
the main text as standard procedures, with the exact experimental details given below. 
The purification methods did differ, however, and the exact details are outlined in the 
main text. 
Standard Procedure A 
Reaction of Methyl 2,3-diaminobenzoate With Aryl Acid Chlorides. 
An ice/salt bath cooled solution of methyl 2,3-diaminobenzoate (1 equivalent), dry 
triethylamine (1. 5 equivalents) and 4-dimethylaminopyridine (DMAP; 5 mol%) in half 
the required volume of dry tetrahydrofuran (THF) was prepared. The required acid 
chloride (1 equivalent) was dissolved in the remaining dry tetrahydrofuran (THF) and 
added to the cooled solution with stirring over 30 minutes. The reaction was allowed 
to warm to room temperature and stirred overnight under an inert gas atmosphere. 
The solvent was filtered to remove a precipitate, which was suspended in ethyl acetate, 
washed twice with water, followed by saturated brine, and the organic layer was dried 
(MgSO-l). The organic layer was added to the initial reaction filtrate, and the solvents 
removed under reduced pressure. The solid residue was redissolved in ethyl acetate, 
washed twice with water followed by saturated brine, and dried with i\.lgS0-t. 
Removal of the solvents under reduced pressure left a solid residue, which could be 
purified by column chromatography and/or recrystallisation from suitable solvents 
Standard Procedure B 
Benzimidazole Ring Formation by Acid Cata~r."jcd (rclisation 
The stal1ing material was dissoh'ed in glacial acetic acid and immersed into a pre-
heated oil bath at I :woC. The solution \vas heated for the appropriate time and then 
I .., ~ _, I 
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allowed to cool to room temperature. The acetic acid was removed under reduced 
pressure, and the solid residue purified by column chromatography and/or 
recrystallisation from suitable solvents. 
Standard Procedure C 
Amide Formation by Reaction With Liquid Ammonia 
The starting material was dissolved in an excess of freshly condensed liquid ammonia. 
This was heated to 80°C within a sealed vessel, generating a pressure of 40 
atmospheres, for 24 hours. The ammonia was evaporated, and the solid residue 
obtained purified by column chromatography and/or recrystallisation from suitable 
solvents. 
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8.3 Experimental Procedures 
2-Carboxamido-3-nitrobenzoic Acid (3-Nitrophthalamic acid) 38 105 
o 3-Nitrophthalic anhydride (10 g, 50 mmol) was added with 
stirring to warm ammonia solution (15 m!) to produce a pale 
yellow solution. On cooling the solution yielded crystalline 
ammonium phthalamate. The crystals were dissolved in a 
minimum of water, with slight warming to ensure complete 
dissolution. Concentrated hydrochloric acid (4.5 m!) was added dropwise with stirring 
to produce a white crystalline paste. This was washed with water until free of 
ammonium chloride, and the product was dried under high vacuum, to give 3-
nitrophthalamic acid, as a fine white powder, (9.01 g, 830/0). 
mp 217-218 °C; Anal. Found: C 45.76, H 2.79, N 13.21. C8~N205 Requires: C 
45.71, H 2.86, N 13.33 0/0; umax(cm-1) 3467 (OH), 3322 (NH), 1685 (CO), 1669 
(CO), 1526 (N02); bH 7.71 (IH, br s, NH), 7.76-7.84 (IH, t, Ar5H), 8.11 (IH, br s, 
NH), 8.19-8.23 (IH, d, Ar4H), 8.25-8.29 (1H, d, Ar6H); be 127.32, 130.06, 132.38, 
133.49, 134.78, 147.70, 166.23, 166.60; m: (El) 192 (M+-H20), 148 (-C02), 103 (-
N02), 75 (Ph+). 
2-Amino-3-Nitrobenzoic Acid ( 3-Nitroanthranilic Acid) 36 105 
o 
OH 
Potassium Hydroxide pellets (2..+. 1 g) were dissolved in water 
(110 m!) and the solution was cooled to 0 °e. Bromine (2.46 
ml) was added slowly \vith stirring to the cooled solution, to 
complete dissolution. 3-Nitrophthalamic acid 38 (lOg, 0.05 \1) 
\vas added, and when dissolved, the reaction was warmed to 60 0 
(' for -' h. The reaction \\'as then allowed to cool to room temperature, and stirred 
overnight The orange precipitate of potassium nitroanthranilate formed \\as dissoh'ed 
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in a minimum of water to give a red solution. Concentrated hydrochloric acid was 
added dropwise to pH 4, precipitating a yellow solid. This was removed by filtration. 
and recrystallised from hot water to yield yellow crystals of 3 -nitroanthranilic acid, 
(6.42 g, 74%). 
mp 208-209 °C~ Anal. Found: C 45.83, H 3.07, N 15.21. C7~N20-l Requires: C 
46.15, H 3.29, N 15.38 %; urnax( cm-1) 3476 (OH), 3345 (NH2), 1688 (CO), 1518 
(N02)~ bH 6.79-6.87 (1H, t, Ar5H), 8.31-8.35 (1H, d, Ar6H), 8.40-8.44 (1H, d, 
Ar4H), 8.61 (2H, s, NH2), 13.65 (IH, br s, C02H)~ be 113.19, 13l.97, 140.02, 
115.02, 132.77, 147.09, 168.95; mlz (El) 182 (M+), 164 (-H20), 118 (-N02), 90 (-
CO). 
2,3-Diaminobenzoic Acid 32 93,103 
o LIGHT SENSITIVE! 3-Nitroanthranilic acid 36 (2.44 g, 13 
OH mmol) was dissolved in methanol (120 ml) and Pd/C catalyst 
(100/0 Pd, 200 mg) was added as a slurry in methanol (10 ml). 
The mixture was hydrogenated under atmospheric pressure for 2 
h until no more hydrogen was absorbed. The crude product was 
purified by column chromatography on silica with dichloromethane : methanol, 85: 15 
as elutent. 2,3-Diaminobenzoic acid was obtained as a red solid, (1.34 g, 660/0). 
mp 204-206 °C~ urnax(cm- 1) 3434 (NH), 1659 (CO); bH 5.8-7.4 (4H, br S, 2x NH2) 
6.44-6.52 (IH, t, Ar5H), 6.79-6.83 (1H, d, Ar4H), 7.20-7.25 (1H, d, Ar6H); be 
110.31,11545,118.33,120.55,135.03,140.36,170.68; m= (El) 152 (M+), 134 (-
H20), 106 (-CO). 
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Methyl 2,3-diaminobenzoate 33 
o 
OMe 
LIGHT SENSITIVE! Methyl 2-amino-3-nitrobenzoate 39 (I.12 
g, 5.73 mmol) was dissolved in methanol (80 ml) and to this 
was added, with stirring under argon, a slurry of 200 mg 100/0 
Pd catalyst on activated charcoal in methanol (20 ml). The 
resulting suspension was hydrogenated under atmospheric 
pressure for 3 h until no further hydrogen gas was absorbed. The catalyst was 
removed by filtration through Celite® and the solvent evaporated under reduced 
pressure to yield the product as a brown solid, (0.9 g, 94%). 
mp 63-64 DC; umax(cm- 1) 3427.76 (NH), 1693 (CO); bH 3.86 (3H, s, C02CH3), 4.8-
5.0 (2H, br s, NH2)' 6.2-6.4 (2H, br s, NH2)' 6.45-6.53 (IH, t, Ar5H), 6.78-6.84 (IH, 
d, Ar4H), 7.17-7.23 (lH, d, Ar6H); be 51.60 (C02CH3), 109.29, 115.67,117.72, 
119.12,136.17,139.98,169.03 (C02CH3);mlz(EI) 166 (M+), 134 (-MeOH), 106(-
CO). 
The title compound was also prepared via the esterification of 2,3-diaminobenzoic acid 
32 using the HCI gas and methanol method described below. Generally, the yields of 
this process were reasonable, (50-550/0). 
Methyl 2-amino-3-nitrobenzoate 39 
o 
OMe 
A solution of 2-amino-3-nitrobenzoic acid 36 (5 g, 0.027 {od) in 
methanol (80 ml) was cooled to ice bath temperature. Drv 
hydrogen chloride gas was bubbled through the solution for 20 
minutes, and the solution was allowed to warm to room 
temperature. The reaction mi~ture \vas heated at reflu~ for 6 h 
with a calcium chloride drying tube in place. The reaction mixture was allowed to cool 
overnight, and the vl'lIo\\ precipitate formed was collected, and recrvstallised from 
l-ll 
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petrol - ethyl acetate to yield the product as a bright yellow crystalline product, (3.6 g, 
60%). 
mp 95-96 °C; Anal. Found: C 49.09, H 3.78, N 14.03. C8H8N20~ Requires: C 4898, 
H 4.08, N 14.29 %; umax(cm- 1) 3452.45 (NH), 1702 (CO), 1573 (N02); bH 3.96 (3H, 
s, C02CH3), 6.80-6.88 (lH, t, Ar5H), 8.29-8.34 (lH, d, Ar4B), 8.41-8.46 (lH, d, 
Ar6H), 8.46 (2H, s, NH2); be 52.63 (C02CH3), 114.12, 114.37, 132.29, 132 94, 
139.52, 146.61, 167.10 (C02CH3); mlz (EI) 196 (M+), 164 (-MeOH), 118 (-N02), 90 
(-CO). 
I-H-Benzim idazole-4-carboxylic acid (NU 1 067) 41 103 
o 2,3-Diaminobenzoic acid 32 (500 mg, 3.29 mmol) was dissolved 
OH in 4 M HCl (10 ml) and to this was added formic acid (405 Ill, 
9.87 mmol). The reaction was refluxed for 1 h, allowed to cool 
to room temperature, and the precipitate produced was collected 
by filtration. This was redissolved in boiling methanol, activated 
charcoal was added, and the solution filtered hot. Removal of the solvent yielded the 
required product 41, (408 mg, 770/0). 
mp >300 °C lit; Anal. Found: C 46.11, H 3.63, N 13.27. C8H6N202.HC1.0.5H20 
Requires: C 46.28, H 3 38, N 13.490/0; umax(cm- 1) 3125 (OH), 1715 (CO); bH 7.7-
7.8 (IH, t, Ar6H), 8.2-8.3 (2H, dd, Ar517H), 9.65 (lH, s, 20); m:: (El) 162 (\1+), 
144 (-H20), 116 (-CO). 
I-H-Benzimidazole-4-carboxamide (NUI066) 43 
o 
Benzimidazole-4-carboxylic acid ·n (398 mg, 2 45 mmol) \\as 
NH2 refluxed in thionyl chloride (10 ml) for 3.5 h. The thionyl 
chloride was removed hy \·acuum distillation, and the residual 
solid \\ as suspended in dry THF (10 ml) This was added to 
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ammonia solution (50 ml) and stirred. Excess solvent was removed, and the residue 
redissolved in water (20 ml). The product was extracted with ethyl acetate, the solid 
recovered redissolved in 0.1 M HCI (20 ml), and the insoluble impurity was removed 
by filtration. The solution was adjusted to pH 7, and then to pH 12. in increments of 
one pH units. Ethyl acetate extractions were taken at each pH unit change, combined, 
and dried (MgS04)' The product was recrystallised from ethyl acetate to yield 43 as 
off white crystals, (50 mg, 13%). 
mp 214-218 °C; Anal. Found: C 59.95, H 3.90, N 24.59. C9H7NJ O Requires: C 
59.63, H 4.35, N 26.09 0/0; umax(cm- 1) 3322 (NH), 31S0 (NH), 1680 (CO)~ 8H 7.34-
7.42 (IH, t, Ar6H), 7.75 (1H, s, CONH), 7.81-7.85 (1H, d, Ar7H), 7.89-7.93 (1H, d, 
ArSH), 8.46 (IH, br s, 2H), 9.4 (1H, br s, COND), 13.1 (1H, br s, INH); m = (EI) 
161(M+), 116 (-NH3/CO). 
2-Methyl-l-H-benzimidazole-4-carboxylic acid 42 
o 
OH 
2,3-Diaminobenzoic acid 32 (200 mg, 1.32 mmol) was dissolved 
in 4 M HCI (3.2 ml), and acetic acid (226 ~I) was added. The 
mixture was refluxed for 1 h then allowed to cool to room 
temperature. The solvent was removed, and the solid residue 
dissolved in boiling methanol. Activated charcoal was added, 
and the solution was filtered hot The solvent was removed, and 
the resulting solid was washed with boiling ethyl acetate followed by a minimum of hot 
methanol, yielding the product, (167.5 mg, 72%). 
mp 188-191 °C; umax(cm- 1) 2853 (OH), 1720 (CO); 8H 2.95 (3H, s, CH3), 7.66-7.7~ 
(1H, t, Ar6H), 8.10-8.1~ (2H, dd, ArS/7H); rnIz (EI) 176 (M+), IS8 (-H20), 130 (-
CO). 
1 .. l3 
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2-Methyl-I-H-benzimidazole-4-carboxamide (NUI064) 44 
o 2-Methylbenzimidazole-4-carboxylic acid 42 (500 mg, 2 8-+ 
NH2 mmol) was retluxed in thionyl chloride (10 ml) for 2 hours, 
which was removed by vacuum distillation. The solid residue 
was dissolved in dry THF, added dropwise to ammonia solution 
(50 ml), and stirred for 30 minutes. The ammonia was removed 
under vacuum, and the solid residue dissolved in a minimum of 
water. A little heat was needed for complete dissolution, and undissolved material was 
removed by filtration. The product was extracted from the aqueous solution with ethyl 
acetate (3x 15 ml). The resultant brown residue was recrystallised from boiling ethyl 
acetate, yielding 44 as a white solid, (70.1 mg, 140/0). 
mp 233-238 °C; Anal. Found: C 61.47, H 4.96, N 23.39. C9H9N30 Requires: C 
61.71, H 5.14, N 24.0 0/0; umax(cm- 1) 3297 (NH), 3071 (NH), 1684 (CO); bH 2.68 
(3H, s, CH3)' 7.30-7.38 (lH, t, Ar6H), 7.72-7.76 (IH, d, Ar7H), 7.86,7.90 (1H, d, 
Ar5H), 7.72-7.90 (lH, br s, CONn), 9.4 (IH, br s, CONH), 12.8 (lH, br s, INH); 
In= (El) 175 (M+), 158 (-NH2 +), 130 (-CO). 
Methyl 2-Trifluoromethyl-l-H-benzimidazole-4-carboxylate 46 
o 
OMe 
A solution of tritluoroacetic anhydride (86.9 Ill, 0.62 nunol) in 
dry THF (5 mt) was added dropwise with stirring to a solution 
of methyl 2,3-diaminobenzoate 33 (92.9 mg, 0.56 mmol) and 
triethylamine (85.6 Ill, 0.62 mmol) in THF (10 ml) The 
reaction was stirred at room temperature for 36 h Water (0.2 
ml) was added to the reaction, and the solvents removed under 
reduced pressure. The ~olid residue was dis~oh'ed in water (10 ml) and the product 
extracted into ethyl acetate (2x 5 ml). The organic layer was washed with water (2x 5 
1111) and sodium bicarbonate solution (5 ml) and dried (\lgS0~) Column 
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chromatography, with dichloromethane as eluent, afforded the product, (48.9 mg, 
330/0). 
mp 86-88 °C; umax(cm-1) 1712 (CO), 1200 (CF); 0H 4.07 (3H, s, C02eB3), 7.56-7.63 
(lH, t, Ar6H), 8.11-8.15 (lH, d, Ar7H), 8.19-8.23 (lH, d, Ar5H), 13.8 (lH, br s, 
NH); mlz (EI) 244 (M+), 212 (-MeOH), 185 (-HCN), 116 (-CF3)' 
Methyl 2-trifluoromethyl-1-H-benzimidazole-4-carboxylate 46 was also prepared by 
treating methyl 2-N-(trifluoroacetyl)amino-3-nitrobenzoate 47 (100 mg, 0.21 mmol) 
and 10% palladium catalyst on activated carbon (20 mg), dissolved in methanol (10 
ml), with hydrogen gas at atmospheric pressure for 4 hours. Filtration through Celite 
® and removal of the solvents under reduced pressure gave a clear oil, which 
crystallised under petrol to yield the title compound, (38 mg, 750/0). 
Methyl 2-N-(Trifluoroacetyl)amino-3-nitrobenzoate 47 
o 
OMe 
o 
N....-ll--CF H 3 
Methyl 2-amino-3-nitrobenzoate 39 (100 mg, 0.51 mmol) 
and triethylamine (234 ~t1, 1.68 mmol) were dissolved in 
THF (10 ml). To this was added, dropwise, a solution of 
trifluoroacetic anhydride (237.9 Ill, 1.68 mmol) in dry THF 
(5 ml), followed with stirring at room temperature for 12 h. 
Water (0.5 ml) was added to the solution and the solvents were removed under 
reduced pressure to yield a yellow oil. Ice cold water (0.5 ml) was added to the oil 
and a white crystalline precipitate was formed. This was collected by filtration, washed 
with ice cold water, and dried to yield the title product, (94.7 mg, 64%). 
mp 126-129 °C; umax(cm- 1) 3295 (NH), 1726 (CO), 1701 (CO), 1551 (N02)' 1191 
(CF): 0H 3.94 (3H, s, C02CH3), 782-7.90 (IH, t, Ar5H), 8.28-833 (lH, d, Ar6H), 
836-84:2 (IH, d, Ar4H), 11.8 (IH, br s, NH): 111 ~ (EI) 29:2 (:\1+),260 (-\leOH), 233 
(-CO), 214 (-F+), 136 (-COCF2+)· 
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2-Trifluoromethyl-l-H-benzimidazole-4-carboxamide (NU 1 086) 45 
Methyl 2 - trifluoromethyl - 1 - H - benzimidazole - 4 -
carboxylate 46 (25.6 mg, 0.01 mmol) was dissolved in aqueous 
ammonia solution (5 ml) and stirred at room temperature for 12 
h. The excess ammonia was removed under reduced pressure 
and the remaining aqueous solution washed with ethyl acetate 
(3x 5 ml) to extract the product. The organic layer was dried 
(MgS04) and the solvent removed under reduced pressure to yield 45, (18.1 mg, 
75%). 
mp 228-230°C~ Anal. Found: C 47.16, H 2.62, N 18.34. C9~F3N30 Requires: C 
46.89, H 2.52, N 18.01 %; umax(cm- 1) 3351 (NH), 1669 (CO), 1157 (CF): 8H 7.57-
7.65 (IH, t, Ar6H), 7.97-8.01 (2H, d, Ar7H and CONH), 8.06-8.10 (lH, d, Ar5H), 
8.70 (lH, br s, CONH), 14.4 (IH, br s, INH); m/z (El) 229 (M+), 212 (-NH3)' 185 (-
HCN), 116 (-CF3)' 
2-Phenyl-l-H-benzimidazole-4-carboxylic Acid 49 
o 
N 
HN~ 
Ph 
OH 
2,3-Diaminobenzoic acid 32 (100 mg, 0.66 mmol) was placed in 
a flask with benzoic acid (80.2 mg, 0.66 mmol), and 
polyphosphoric acid (5 rnI) was added. This was heated to 150-
160 °C for 30 minutes and allowed to cool. When still slightly 
warm, crushed ice was added to dilute the acid. The dark 
solution was filtered to remove insoluble material, and the filtrate 
washed twice with ethyl acetate (5 ml) to remove unreacted benzoic acid. The acidic 
solution was neutralised with sodium hydroxide (10 i\ 1), \vhich after cooling yielded a 
large quantity of salt. which was removed by filtration. The salt and the neutral 
solution \\'ere each washed separately with ethyl acetate (2x 10 ml), and the washings 
combined and dried (:\ IgS0~). Final purification of the product was achieved by 
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column chromatography using dichloromethane : methanol 85: 15 as elutent, (32 mg, 
20%). 
mp 287-288 °C; umaxCcm-l) 3336 (OH), 1680 (CO); bH 7.35-743 (1H, t, Ar6H), 
7.62-7.68 (3H, m, Ar31/4'/5'H), 7.87-7.91 (1H, d, Ar7H), 7.95-7.99 (1H, d, Ar5H), 
8.38-8.44 (2H, d, Ar2'/6'H), 12.5 (IH, br s, NH); mz (El) 238 (M+), 220 (-H20), 192 
(-CO). 
2-Phenyl-l-H-benzimidazole-4-carboxamide (NUI070) 48 102 
o 
N HN-( 
Ph 
2-Phenyl-l-H-benzimidazole-4-carboxylic acid 49 (50 mg, 0.21 
mrnol) was dissolved in THF (10 ml) and to this was added 
thionyl chloride (16.8 I .. d, 0.23 mmol) and a catalytic amount of 
DMF (2 drops). This was stirred overnight at room 
temperature, forming a white precipitate. The suspension was 
added dropwise to aqueous ammonia (10 ml) and the solution stirred for 0.5 h. Water 
(20 ml) was added and the solution neutralised with hydrochloric acid (4 M). The 
desired product precipitated upon cooling and was collected by filtration to yield 48 as 
a white solid, (31 mg, 620/0). 
mp 239-241 °C; umax(cm-1) 3184 (NH), 1669 (CO); bH 7.43-7.51 (1H, t, Ar6H), 
7.69-7.72 (3H, m, Ar3'/4'/5'H), 7.86-7.90 (IH, d, Ar7H), 7.97 (IH, br s, CONH), 
7.98-8.01 (lH, d, Ar5H), 8.37-8.41 (2H, d, Ar21/6'H), 9.5 (IH, br s, CONH); m = (EI) 
237 (M+), 220 (-NH3)' 192 (-CO), 165 (-HCN). 
2-Acetylamino-3-nitrobenzoic Acid 50 105 
o 
OH 
2-Arnino-3-nitrobenzoic acid 36 (1.87 g, 0.01 \ 1) was 
suspended in acetic anhydride (40 ml), heated to 40 ::: C for 5 
minutes, and allowed to cool The resulting precipitate was 
collected and dried, (17 g. 74(0). 
147 
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mp 179-180 °C~ umax(cm- l ) 1723 (CO), 1640 (CO), 1538 (N02); 0H 2.53 (3H, s, 
COCH3), 7.80-7.88 (lH, t, Ar5H), 8.42-8.51 (2H, dd, Ar4/6H)~ 0c 21. 76 (COCH:;), 
118.68, 128.42, 129.56, 130.03, 131.68, 138.38, 145.58, 157.85, 163.65; m,= (El) 206 
(M+-H20), 191 (-CH3), 164 (-HCN). 
Methyl 2-Amino-3-N-benzoylbenzoate 51 
o 
OMe 
Following standard procedure A, methyl 2,3-diaminobenzoate 
33 (50 mg, 0.30 mmol) was dissolved in THF (5 ml) and 
triethylamine (46 ~l, 0.33 mmol) and DMAP (1.8 mg, 5 mol%) 
were added. Benzoyl chloride (38 ~l, 0.33 mmol) was 
dissolved in THF (5 ml) and added slowly to the reaction. 
Using petrol : ethyl acetate, 3:2 column chromatography, 
followed by recrystallisation from petrol and ethyl acetate, the 
pure title compound was isolated, (60 mg, 740/0). 
mp 156-157 °C; umax(cm- l ) 3379 (NH), 1702 (CO), 1649 (CO), 0H 3.93 (3H, s, 
C02CH3), 6.64 (2H, s ,NH2), 6.69-6.77 (lH, t, Ar5H), 7.46-7.50 (lH, d, Ar4H), 
7.59-7.70 (3H, m, Ar3'/4'/5'H), 7.81-7.85 (lH, d, Ar6H), 8.11-8.14 (2H, d, Ar2'/6'H), 
9.85 (lH, s, NH); m = (El) 270 (M+), 253 (-NH3), 105 (-PhCO+). 
Methyl 2-amino-3-N-( 4' -methoxybenzoyl)aminobenzoate 53 
o 
OMe 
OMe 
Following standard procedure A, methyl 2,3-diaminobenzoate 
33 (460 mg, 2.77 mmol), triethylamine (385.5 ~t1, ~ 77 mmol), 
and 4-dimethylaminopyridine (17 mg, 5 mol%) \,vere dissolved 
in dry THF (20 ml). 4-Methoxybenzoyl chloride (3"78 pI, ~ 77 
mmol) in dry THF (20 ml) \\·as added drop\\·ise to the reaction. 
The product \\as recrystallised from methanol and \vater The 
resulting white crystals were recovered bv tiltration, washed 
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with a minimum of ice cold water, and dried under high vacuum to yield the title 
compound, (513 mg, 620/0). 
mp 179-180 °C~ Anal. Found: C 64.26, H 5.31, N 9.17. C16H16N20~ Requires: C 
64.0, H 5.33, N 9.33 0/0; umax(cm-1) 1699 (CO), 1632 (CO)~ bH 3.92 (3H, s, 
ArOCB3), 3.94 (3H, s, C02CB3), 6.59 (2H, br s, NH2), 6.68-6.75 (lH, t, Ar5H), 
7.13-7.17 (2H, d, J 8.8. AI3'/5'B), 7.43-7.46 (lH, d, Ar4H), 7.79-7.83 (IH, d, 
Ar6H), 8.07-8.12 (2H, d, J~8.8, Ar2'/6'H), 9.7 (lH, br s, NH)~ be 51.98, 55.76, 
110.62, 113.79, 114.67, 125.0, 126.84, 129.12, 130.14, 133.20, 147.36, 16~ 2 L 
165.74, 168.33; mlz (El) 300 (M+), 283 (-NH3), 135 (MeOPhCO+), 107 (MeOPh+). 
Methyl 2-( 4'-methoxyphenyl)-1-H-benzimidazole-4-carboxylate Acetate Salt 55 
o 
OMe 
OMe 
Following standard procedure B, methyl 2-amino-3 -,V-( -+'-
methoxybenzoyl)benzoate 53 (480 mg, 1.6 mmol) was 
dissolved in glacial acetic acid (15 ml), and the mixture was 
heated for 0.5 h. The product was obtained by 
recrystallisation from petrol and ethyl acetate to yield a 
white crystalline solid, (409 mg, 750/0). 
mp 141-142 °C; Anal. Found: C 63.68, H 4.79, N 7.88. 
C16Hl~N203.CH3C02H Requires: C 63.16, H 5.26, N 8.19 
%~ umax(cm- 1) 1718 (CO), 1697 (CO)~ bH 2.02 (3H, s, CH3C02H), 3.97 (3H, s, 
ArOCH]), 4.09 (3H, s, C02CB3), 7.21-7.25 (2H, d, J=8.6, Ar3'/5'H), 739-7.46 (IH, 
t, Ar6H), 7.90-7.93 (IH, d, AI7H), 8.00-8.04 (lH, d, Ar5H), 8.36-8.40 (2H, d, J=8.6, 
Ar2'/6'H), 12.1 (IH, s, INH), 12.3-12.4 (IH, br s, CH3C02H)~ be ~1.35, 5237, 
55.64,11-+.41, 121.68,12235,124.34,129.56, 153.63, 161~7, 166.13, 17~ 37: m: 
(EI) 282 (l\r~- -CH3C02H), 250 (-rvleOH), 22~ (-CO), 60 (CH ]C02H). 
1-+9 
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2-(4'-Methoxypheny)-1-H-benzimidazole-4-carboxamide (~rl076) 56 
o 
OMe 
Following standard procedure C, the acetate salt of methY'l 
2-( 4'-methoxyphenyl)benzimidazole-4-carboxylate 55 (361 
mg, 1.06 mmol) was dissolved in excess liquid ammonia (40 
ml). The solid residue recovered was washed with ice cold 
water (3x 5 ml). The solid was dissolved in excess boiling 
methanol, filtered hot, and the solvent volume was reduced 
by a half by boiling. Ice cold water (0.5 ml) was added, and 
the solution turned cloudy. Cooling overnight yielded the 
product as large, off-white prisms, that were collected by filtration and dried, (226.4 
mg,80%). 
mp 261-263 °C; Anal. Found: C 67.85, H 5.00, N 15.78. ClSH13N302 Requires: C 
67.42, H 4.87, N 15.73 0/0; umax(cm-1) 3321 (NH), 3141 (NH), 1656 (CO); DH 3.96 
(3H, s, OCB3), 7.23-7.27 (2H, d, J=8.6, Ar3'/5'H), 7.37-7.45 (lH, t, Ar6H), 7.78-
7.82 (lH, d, Ar7B), 7.87 (lH, br s, COND), 7.93-7.96 (lH, d, Ar5H), 8.27-8 31 (2H, 
d, J=8.6, Ar2'/6'B), 9.4-9.5 (lH, br s, CONB), 13.3-134 (IH, br s, IND); DC 60.64 
(OCH3), 119.78, 119.93, 126.80, 127.15, 127.35, 127.97, 133.81, 140.58, 146.91, 
157.34,166.42,171.63; m,z (EI) 267 (M+), 250 (-NH3), 222 (-CO). 
2-( 4'-Methoxyphenyl)-1-H-benzimidazole-4-carboxylic Acid 62 
o 
OH 
Methyl 2 - (4' - methoxyphenyl) - 1 - H - benzimidazole - 4 -
carboxylate 55 (150 mg, 0.53 mmol) was dissolved in 
methanol (5 ml), and to this was added sodium hydroxide 
(-+6.8 mg, 1.17 mmol) dissolved in water (5 ml) The mixture 
was heated at 50 '~c for -+ h, follov/ed bY' removal of the 
solvents under reduced pressure. The solid residue was 
OMe redissl)\ved in water (10 ml) and the pH adjusted to 7 with 
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concentrated HCI. The resulting precipitate was collected, washed with water and 
dried to yield the title compound as a white amorphous solid, (78.4 mg, 55(%). 
mp 289-295 °C~ 8H 3.96 (3H, s, C02CB3), 7.20-7.24 (2H, d, J=8.7, Ar3'/5'B), 7.37-
7.45 (lH, t, Ar6H), 7.87-7.91 (lH, d, Ar7B), 7.95-7.99 (lH, d, Ar5H), 8.36-8.40 
(2H, d, J=8. 7, Ar2'/6'H)~ mlz (EI) 268 (M+), 250 (-H20), 222 (-CO). 
2-( 4'-HydroxyphenyI)-1-H-benzimidazole-4-carboxylate (NUI085) 73 
o Under an argon atmosphere 1M boron tribrornide in 
dichloromethane (3.8 ml, 3.79 mmol) was transfered to a flask 
containing 2-( 4'-methoxyphenyl)benzirnidazole-4-
carboxamide 56 (202.4 mg, 0.76 mmol). The resulting 
solution was refluxed for 24 h using an air condenser, and the 
solvent was removed by distillation. The solid residue was 
OH treated with 100/0 NaOH (10 ml), followed by the dropwise 
addition of concentrated hydrochloric acid to neutralise the 
solution. The resulting white precipitate was collected by filtration and dissolved in 
ethyl acetate (10 mil. The organic layer was washed with water (2x 3 ml) and dried 
(MgS04). The product was obtained by removal of the solvent under reduced 
pressure, (109.5 mg, 57%). 
mp 266-267 °C~ Anal. Found: C 63.27, H 4.37, N 15.67. C14HllN302·0.75MeOH 
Requires: C 63.04, H 4.69, N 15.76 010; umax(cm-1) 3424 (NH), 3156 (NH), 1642 
(CO); 8H 7.03-7.07 (2H, d, J=8.5, Ar3'/5'B), 7.34-7.42 (lH, t, Ar6H), 7.75-7.79 (lH, 
d, Ar70), 7.85 (IH, brs, CONH), 7.90-7.94 (IH, d, Ar5H), 8.15-8.19 (2H, d,J=8.5, 
Ar2'/6'H), 9.4-9.6 (lH, br s, CONB), 10.0-10.4 (lH. br s, OH), 13.0-13 4 (lH, br s. 
INH); m = (El) 253 (1\1+), 236 (-NH:;), 208 (-CO). 93 (HOPh~). 
I ~ I 
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Methyl 2-amino-3-N-( 4' -trifluoromethylbenzoyl)aminobenzoate 58 
o 
OMe Following standard procedure A, methyl 2,3-diaminobenzoate 
33 (300 mg, 1.81 mmol), triethylamine (2514 Ill, 1.81 mmol) 
and 4-dimethylarninopyridine (11 mg, 5 mol%) were dissolved 
in dry THF (15 ml). 4-Trifluoromethylbenzoyl chloride (268.4 
Ill, 1.81 mmol) was dissolved in dry THF (15 ml) and added 
dropwise to the reaction. Recrystallisation from aqueous 
CF3 methanol yielded the title compound as a white solid, (83.6 mg, 
140/0). 
mp 180-181 °C; Anal. Found: C 56.75, H 3.50, N 8.28. C16H13F3N203 Requires: C 
56.80, H 3.85, N 8.28 %; umax( cm- I) 3292 (NH), 1701 (CO), 1653 (CO), 1330 (CF); 
bH 3.93 (3H, s, C02C03), 6.70-6.76 (3H, m, Ar5H / NU2), 7.46-7.49 (1H, d, :\r40), 
7.81-7.85 (lH, d, Ar60), 7.99-8.03 (2H, d, Ar2'/6'H), 8.29-8.33 (2H, d, Ar3'/5'0), 
10.05 (IH, s, NH); mlz (EI) 338 (M+), 321 (-NH3), 289 (-MeOH), 173 (CF3PhCO+), 
145 (CF3Ph+). 
Methyl 2-( 4 '-trifluoromethylphenyl)-I-H-benzimidazole-4-carboxylate - Acetate 
Salt 59 
o 
OMe 
Following standard procedure B, methyl 2-arnino-3-N-(4'-
trifluoromethyl benzoyl)aminobenzoate 58 (75.7 mg, 0.224 
mmol) was dissolved in glacial acetic acid (5 ml) and heated 
for 0.5 h. The solvent was removed and the white solid 
obtained was recrystallised from petrol-ethyl acetate to yield 
the title compound, (59.6 mg, 70%). 
mp 138-140 "C, Anal. Found: C 56.78, H ~.98, \: 736. 
C16HIIF~N202CH~C01H Requires: C 56.84, H ~ 9 .. L :\ 
7 3: o~, U
1
1\;\\((I11- I) 1709 (CO), 1694 (CO), 1327 (CF); bH:2 01 (lH,~, CH~C02H), 
1~2 
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7.44-7.52 (IH, t, Ar6H), 7.97-8.14 (4H, m, Ar5/7/2'/6'H), 8.62-8.66 (2H, d, 
Ar3'/5'H), 12.1 (br s, NH), 12.7-12.8 (1H, br s, CH3C02H); m = (El) 320 (\1+-
CH3C02H), 288 (-MeOH), 260 (-CO), 145 (CF3Ph+), 60(CH3C02H). 
2-( 4' -Trifluoromethyl)-I-H-benzimidazole-4-carboxamide (NU 1 077) 57 
o 
Following standard procedure C, the acetate salt of methyl 2-
(4'-trifluoromethylphenyl)-I-H-benzimidazole-4-carboxylate 
59 (50 mg, 0.13 mmol) was dissolved in excess liquid 
ammonia and placed in the pressure vessel. Evaporation of 
the ammonia yielded a solid residue that was washed with ice 
cold water (3x 5 ml). Recrystallisation from boiling methanol 
and ice cold water yielded the product as fine white needles, 
(19.1 mg, 480/0). 
mp 301-305 °C; Anal. Found: C 56.45, H 3.50, N 12.41. ClsHlOF3N30.CH30H 
Requires: C 56.97, H 4.18, N 12.46 %; umax(cm- l ) 3155 (NH), 1668 (CO), 1318 
(CF); 8H 7.45 (lH, t, Ar6H), 7.88-7,92 (1H, d, Ar7H), 7.99 (1H, br s, CONH), 8.03 
(lH, d, Ar5H), 8.06-8.10 (2H, d, J=8.1, Ar2'/6'H), 8.55-8.59 (2H, d, J=8.1, Ar3'/5'H), 
9.3-9.4 (lH, br s, CONH), 13.7-13.8 (lH, br s, INH); m = (El) 288 (M+-NH3), 260 (-
CO), 69 (CF3 +). 
lVlethyl 2-amino-3-1V-( 4'-nitrobenzoyl)aminobenzoate 69 
o 
OMe Following standard procedure A, methyl 2,3-diaminobenzoate 
33 (300 mg, 1.81 mmol), dry triethylamine (276.6~t1, 1.99 
mmol) and Oi\1AP (11 mg) were dissolved in dry THF (12 ml) 
and cooled To this 4-nitrobenzO\·! chloride (3 3 ~ 2 mg, 181 
mmol) in THF ( 12 ml) was added dropwisc o\cr o. ~ h and the 
resulting mixture stirred for 12 h. Column chromatograp!l\ 
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with dichloromethane : methanol 99: 1 as eluent, followed by recrystallisation from 
methanol yielded the product, (259 mg, 450/0). 
mp 196-197 °C; Anal. Found: C 57.08, H 3.78, N 13.25. C1SH13N30S Requires: C 
57.14, H 4.12, N 13.33 0/0; u max( em-I) 3382 (NH), 1702 (CO), 1658 (CO), lS25 
(N02); 8H 3.94 (3H, s, C02CH3), 6.70-6.78 (lH, t, Ar6H), 6.66 (2H, br s, 7':H2)' 
7.48-7.51 (lH, d, Ar7H), 7.83-7.87 (lH, d, ArSH), 8.33-8.38 (2H, d, J=8.8, 
Ar2'/6'H), 8.46-8.51 (2H, d, J=8.8, Ar3'/S'H), 10.IS (lH, br s, NH); m = (EI) 315 
(M+), 297 (-H20), 265 (-MeOH), 165 (02NPhCONH+). 
Methyl 2-(4' -Nitrophenyl)-1-H-benzimidazole-4-carboxylate 70 
o 
OMe 
Following standard procedure B, methyl 2-amino-3-N-( 4'-
nitrobenzoyl)arninobenzoate 69 (340.2 mg, 1.08 mmol) was 
heated in glacial acetic acid (10 ml) for IS minutes. The 
product was obtained pure by recrystallisation from 
methanol, (208 mg, 6S%). 
mp 208-210 °C; Anal. Found: C 60.69, H 3.S7, N 13.96. 
N0
2 
CIsHllN304 Requires: C 60.61, H 3.70, N 1..+ 14 0/0; U 
max(cm- I) 1720 (CO), 1513 (N02); bH 4.21 (3H, s, 
C02CH 3), 7.57-7.65 (lH, t, Ar6H), 8.10-8.12 (lH, d, Ar7H), 8.23-8.27 (lH, d, 
Ar5H), 8.60-8.64 (2H, d, J=8.8, Ar2'/6'H), 8.78-8.82 (2H, d, J=8.8, Ar3'/5'H), 13.04 
(1 H, br s, NH); III = (El) 297 (M+), 265 (-MeOH), 219 (-N02)' 
15..+ 
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2-( 4'-Nitrophenyl)-I-H-benzimidazole-4-carboxamide (~Ul 091) 64 
o 
Following standard procedure C, methyl 2-( 4'-nitrophenyl)-
I-H-benzimidazole-4-carboxylate 70 (l00 mg, 0.34 mmol) 
was dissolved in liquid ammonia and heated under constant 
volume in the pressure vessel. The solid recovered was 
purified by column chromatography using dichloromethane : 
N02 methanol 99: 1 as eluent, and was recrystallised from 
methanol, (70 mg, 740/0). 
mp >310 °C; umax(cm- 1) 3436 (NH), 1661 (CO), 1585 (N02); bH 7.48-7.56 (IH, t, 
Ar6H), 7.90-7.94 (IH, d, Ar7H), 8.00 (lH, s, CONH), 8.00-8.04 (lH, d, Ar5H), 
8.52-8.56 (2H, d, 1=8.8, Ar2'/6'H), 8.60-8.64 (2H, d, 1=8.8, Ar3'/5'H), 9.3-9.4 (lH, br 
s, CONH), 13.8-14.0 (IH, br s, INH); 1n= (El) 282 (M+), 265 (-NH3)' 219 (-N02)' 
191 (-CO). 
Methyl N, N'-bis(4'-nitrobenzoyl)-2,3-diaminobenzoate 54 
o 
OMe 
o 
Methyl 2,3-diaminobenzoate 33 (200 mg, 
1.02 mmol), 4-nitrobenzoyl chloride (378.6 
mg, 2.04 mmol), triethylamine (284 IJ.I, 2.04 
mmol) and DMAP (6.2 mg) were dissolved in 
N02 THF (20 ml), and stirred under an inert gas 
atmosphere, at room temperature, for 12 h. 
A precipitate was collected, stirred in boiling 
acetic acid (10 ml) for 5 minutes, and was 
allowed to cool. The resulting solid was 
recovered, washed \\'ith eth~'1 acetate (5 ml) and dried, (167.4 mg, 35%) 
mp 260-2«, "C: bH 3.84 (~H, s, C02CH~), 7.56-7.64 (IH, t, Ar50), 781-7.84 (lH, 
d, :\r4H), 8.05-8.08 (Ill. d, :\r6H), S 2-+-8 .. ,0 (-+H, dd, 2x .-\r2','(1'll), S 46-8 52 (4H, 
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dd, 2x Ar3'/5'B), 10.45 (lH, br s, NH), 10.55 (lH, br s, NO); m = (EI) 464 (~1+). 432 
(-MeOH), 266. 
4-Cyanobenzoyl Chloride 119 
CN 
C I 4-Cyanobenzoic acid (2.11 g, 20 mmo!) was suspended in thionyl 
chloride (10 ml). The solid dissolved upon warming and the reaction 
was refluxed for 2 h, and allowed to cool to room temperature. The 
excess thionyl chloride was removed by distillation at the water pump, 
followed by short path drying at high vacuum, to yield a white solid, 
(2.26 g, 95%). mp 64-65 °C. For NMR analysis the product was 
converted to the methyl ester by dissolving the acid chloride (10 mg) in dry THF (2 
ml), adding dry methanol (1 rnI), and stirring for 10 minutes. Removal of the solvents 
under reduced pressure followed by drying yielded methyl 4-cyanobenzoate as a white 
solid. 
mp 63-64 °C; oR 3.99 (3H, s, C02CB3), 8.08-8.12 (2H, d), 8.17-8.21 (2H, d). 
Methyl 2-amino-3-N-( .t'-cyanobenzoyl)aminobenzoate 
CN 
o Following standard procedure A, methyl 2,3-diaminobenzoate 
OMe 33 (300 mg, 1.81 mmol), triethylamine (251 !-tl, 1.81 mmol) and 
DMAP (II mg) were dissolved in THF (7.5 ml) and cooled to -
10°C. 4-Cyanobenzoyl chloride (299 mg, 1.81 mmol) 
dissolved in THF (7.5 ml), \vas added dropwise. The product 
was purified by column chromatography using dichloromethane 
: methanol 99: 1 as eluent, followed by recrystallisation from 
boiling methanol, (196 mg, 37° 0). 
mp 198-202 "C. Anal. Found: C 64.07, H 4 4~, N 13 69 
CI6HI.,N,03.04~leOH Requires: C ()~94, H 47), 0.: 1364°'0; uma.\(cm- I ) 3486 
1~6 
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(NH)" 2231 (CN), 1688 (CO), 1647 (CO); bH 3.93 (3H, s, C02eB3), 6.68-6.76 (lH, 
t, ArSH), 6.72 (2H, br s, NH2), 7.45-7.49 (1H, d, Ar4B), 7.81-7.86 (1H, d, Ar6H), 
8.11-8.1S (2H, d, J=8.4, Ar2'/6'H), 8.25-8.29 (2H, d, J=8.4, Ar3'/5'B), 10.1 (1H, br s, 
NH); m/z (EI) 29S (M+), 278 (-NH3), 246 (-MeOH), 130 (CNPhCO+), 102 (CNPh~) 
Methyl 2-( 4'-cyanophenyl)-1-H-benzimidazole-4-carboxylate 
o 
N 
OMe 
Following standard procedure B, methyl 2-amino-3-N-( 4'-
cyanobenzoyl) aminobenzoate (301 mg, 1.02 mmol) was 
heated in glacial acetic acid (10 ml). The product was 
HN Ii obtained by recrystallisation twice, from petrol-ethyl acetate, 
(203 mg, 720/0). 
mp 19S-198 °C; Umax(cm- 1) 2229 (CN), 1692 (CO); bH 4.09 
CN (3H, s, C02CH3), 7.44-7.53 (1H, t, Ar6H), 7.97-8.01 (1H, 
d, Ar7H), 8.10-8.13 (1H, d, Ar5B), 8.13-8.17 (2H, d, J=8.4, 
Ar2'/6'H), 8.S8-8.62 (2H, d, J=8.4, Ar3'/5'B), 12.8 (1H, br s, NH); m = (EI) 277 
(M+), 245 (-MeOH), 217 (-CO). 
2-( 4'-Cyanophenyl)-1-H-benzimidazole-~-carboxamide (NU1092) 71 
o Following standard procedure C, methyl 2-( 4'-cyanophenyl)-
I-H-benzimidazole-4-carboxylate (169.5 mg, 0.61 mmol) was 
treated with ammonia under pressure. The crude product 
was recrystallised from boiling methanol to yield the title 
compound, as white crystals, (116.5 mg, 730/0). 
mp >.:no °C, Anal. Found: C 67.81, H 3 89. ;-..; 20.87. 
CN C 15H ION40.02MeOH Requires: C 67 l)~, H 4 0\ ~ 20.8~ 
0 0; uma:x(cm- 1) 31-:'8 ()':H), 2231 (C~), 1659 (CO): 8H 7.45-
157 
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7.49 (IH, t, Ar6H); 7.87-7.91 (lH, d, Ar7H), 7.91 (lH, br s, CONH), 7.98-8.02 (lH, 
d, Ar5H); 8.13-8.17 (2H, d, J=8.3, Ar2'/6'H), 8.50-8.54 (2H, d, J=8 3, :\r3'/5'H), 9.2-
9.4 (lH, br s, CONH), 13.6-13.8 (lH, br s, INH); Oe 112.80, 115.81 (-CN), 118.83. 
123.42, 123.76, 127.82, 133.31, 133.55, 141.6, 141.8, 150.32, 166.37; m = (EI) 262 
(M+), 245 (-NH3), 217 (-CO), 102 (CNPh+). 
2-( 4' -Carboxyphenyl)-1-H-benzimidazole-4-carboxamide (NU 1107) 72 
o 
o 
OH 
2 - ( 4' - Cyano phenyl) - 1 - H - benzimidazole - 4 -
carboxamide 71 (150 mg, 0.57 mmol) was dissolved in 
ethanol (5 ml), and sodium hydroxide solution (200/0 HI v, 
2 ml) was added. The solution was heated at reflux 
overnight and the organic solvent was removed under 
reduced pressure, to yield a brown oil. This was diluted 
with water (2 ml), and concentrated hydrochloric acid was 
added dropwise to the solution, adjusting to pH 7, and 
precipitating a white solid. The precipitate was washed 
with water and recrystallised from methanol, (75 mg, 470/0) 
mp >300 °C; uma,,(cm- l ) 3342 (NH), 1711 (CO), 1649 (CO); OH 7.45-7.52 (lH, t, 
Ar6H), 7.87-7.91 (lH, d, Ar7H), 7.95 (lH, s, CONH), 7.98-8.02 (lH, d, Ar5H), 
8.22-8.26 (2H, d, J=8.2, Ar2'/6'H), 8.46-8.50 (2H, d, J=8.2, Ar3'/5'H), 9.35 (lH, S, 
CONH), 13.39 (IH, br S, INH); III = (EI) 281 (M+), 264 (-NH3)' 236 (-CO). ~lass 
Observed For C15HllN303 281.0792, Calc. 281.270. 
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Methyl 2-amino-3-N-(4' aminobenzoyl)aminobenzoate 75 
o Methyl 2-amino-3-N-(4'-nitrobenzoyl)aminobenzoate 69 (246 
OMe mg, 0.78 mmol) was suspended in methanol (40 ml) and a 
slurry of 10% palladium catalyst on activated carbon (-50 mg) 
in methanol (10 ml) was added with stirring under argon. The 
solution was hydrogenated under atmospheric conditions for 2 
h. After filtration through Celite® to remove the catalyst, the 
product was obtained by evaporation of the solvent under 
NH2 reduced pressure to give a white solid, (204 mg, 92%). 
mp 197-200 °C; Anal. Found: C 62.95, H 5.30, N 14.39. 
ClsHlSN303 Requires: C 63.16, H 5.26, N 14.73 %; umax(cm- 1) 3473 (NH), 3375 
(NH), 1695 (CO), 1635 (CO); bH 3.94 (3H, s, C02CH3), 5.87 (2H, s, NH2), 6.54 
(2H, s, NH2), 6.68-6.73 (2H, d, Ar3'/5'H), 6.73-6.76 (1H, t, Ar5H), 7.42-7.47 (1H, d, 
Ar4H), 7.78-7.82 (lH, d, Ar6H), 7.83-7.87 (2H, d, Ar2'/6'H), 9.4 (lH, s, NH); m:: 
(EI) 285 (M+), 267 (-H20), 235 (-MeOH), 207 (-CO), 120 (H2NPhCO+), 92 
(H2NPh+). 
Methyl 2-( 4'-aminophenyl)-1-H-benzimidazole-4-carboxylate Acetate Salt 
o 
OMe 
Following standard procedure B, the treatment of methyl 2-
amino-3-N-( 4'-aminobenzoyl) amino benzoate 75 (186.5 mg, 
0.66 mmol), with hot glacial acetic acid (8 ml) for 30 
minutes, yielded the title compound following 
recrystallisation from petrol-ethyl acetate, (113 4 mg, 91 ~/o). 
mp 162-164 °C; Anal. Found: C 62.60, H 5 04, \: 1273 
C15H13N~02.CH~C02H Requires: C 62.39, H 520, N 
1284 %; umax(cm-') 3451 (NH), 1692 (CO), 1648 (CO)~ b 
H:2 02 (3H, s, CH~C02H), 408 {3H, s, C02CH.~), 581 (2H, S, 7\H 2), 6.75-6 80 (:~H, 
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d, J=8.6, Ar3'/5'H), 7.32-7.40 (IH, t, Ar6H), 7.83-7.86 (lH, d, Ar7H), 7.93-7.97 (lH, 
d, 5H), 8.08-8.13 (2H, d, J=8.6, Ar2'/6'H), 11.9 (lH, s, NH), 12.1 (lH, br s, C02B); 
mlz (EI) 267 (M+-CH3C02H), 235 (-MeOH), 207 (-CO), 92 (H2NPh+), 60 
(CH3C02H). 
2-( 4'-Aminophenyl)-1-H-benzimidazole-4-carboxamide (NUII03) 74 
o 
Folowing standard procedure C, the acetate salt of methyl 2-
( 4'-aminophenyl)-I-H-benzimidazole-4-carboxylate ( 113 
mg, 0.35 mmol) was treated with liquid ammonia under 
pressure for 24 h. The title compound was isolated by 
column chromatography of the crude material usmg 
dichloromethane : methanol 9: 1, (21.4 mg, 250/0). 
mp 237-240 °C; Anal. Found: C 66.22, H 495, N 21.41. 
C 1-lH12N40.O.2CH30H Requires: C 65.94, H 4.95, N 21.67 0/0; umax(cm- 1) 3338 
(NH), 1651 (CO); 8H 5.90 (2H, s, NH2)' 6.79-6.83 (2H, d, J=8.3, Ar3'/5'H), 7.31-
7.39 (lH, t, Ar6H), 7.71-7.75 (IH, d, Ar7H), 7.84 (lH, s, CONH), 7.88-7.92 (IH, d, 
Ar5H), 8.00-8.04 (2H, d, J=8.3, Ar2'/6'H), 9.5-9.6 (lH, br s, CONH), 13.0 (lH, br s. 
INH); m = (EI) 252 (M+), 235 (-NH3), 207 (-CO), 92 (H2NPh+). 
Methyl 2-amino-3-N-(3'-trifluoromethylbenzoyl)aminobenzoate 
o 
OMe 
Following standard procedure A, methyl 2,3-diaminobenzoate 
33 (200 mg, 1.21 mmol), dry triethylamine (704 ~L 5.06 mmol) 
and DMAP (7.3 mg) were dissolved in dry THF (7 5 ml). 3-
Tritluoromethylbenzoyl chloride (183 ~lL 1.21 mmol) in dry 
THF (7 5 ml) was added. Column chromatography with 
dichloromethane . methanoL 99: 1 as eluent, removed impurities 
and the polar product \\as eluted \\ ith dichloromethane 
160 
Chapter Eight: Experimental 
methanol, 97:3. Recrystallisation from methanol yielded the product as a white solid, 
(160.4 mg, 260/0). 
mp 157-159°C; Anal. Found: C 57.14, H 3.57, N 8.10. C16H13F3N203 Requires: C 
56.80, H 3.85, N 8.28 %; umax(cm-1) 3368 (NH), 1706 (CO), 1651 (CO), 1250 (CF); 
DH 3.93 (3H, s, C02CB3), 6.69-6.77 (lH, t), 6.73 (2H, s, NH2), 7.45-7.49 (1H, d), 
7.82-7.92 (2H, m), 8.06-8.10 (lH, d), 8.40-8.44 (lH, d), 8.48 (lH, s, Ar2'B), 10.1 
(lH, s, NH); mlz (EI) 338 (M+), 320 (-H20), 288 (-MeOH), 260 (-CO), 173 
(CF3PhCO+), 145 (CF3Ph+). 
Methyl 2-(3'-trifluoromethylphenyl)-1-H-benzimidazole-4-carboxylate Acetate 
Salt 
o 
OMe 
HN 
Following standard procedure B, a glacial acetic acid (6 
ml) solution of methyl 2-amino-3-N-(3'-
trifluoromethylbenzoyl) aminobenzoate (143 mg, 0.42 
mmol) was heated for 15 minutes. Removal of the 
solvent under reduced pressure, followed by drying at 
high vacuum, yielded the product as a white solid, (154 
mg,960/0). 
mp 105-107 °C: Anal. Found: C 56.93, H 3.78, N 7.32. 
C16HllF3N202.CH3C02H Requires: C 56.84. H 3.95, N 7.37 0/0; umax(cm- 1) 1708 
(CO), 1328 (CF); DH 2.01 (3H, s, CH3C02H), 4.09 (3H, s, C02CH3), 7.44-7.51 (lH, 
t), 7.79-8.13 (4H, m), 8.71-8.75 (lH, d), 8.82 (1H, S, Ar2'B), 11.8-12.2 (1H, br s. 
NB), 12.8-13.0 (IH, br s, C02B): m:: (EI) 320 (M+-CH3C02H), 288 (-MeOH). 260 
(-CO), 145 (CF ~Ph+). 
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2-(3'-Trifluoromethylphenyl)-I-H-benzimidazole-4-carboxamide (~U 1 093) 77 
o Following standard procedure C, the acetate salt of 
methyl 2-(3'-trifluoromethylphenyl)-I-H-benzimidazole_ 
4-carboxylate (134.8 mg, 0.36 mmol) was treated with 
excess liquid ammonia in a sealed vessel. The crude 
product was purified by recrystallisation from methanol, 
C F 3 to yield off-white needles, (78 mg, 72%). 
mp 268-270 °C; Anal. Found: C 57.68, H 3.82, N 1296. 
ClsHlOF3N30.0.6CH30H Requires: C 57.74, H 3.82, N 12.95 %; vma,,(cm- l ) 3349 
(NH), 3176 (NH), 1668 (CO), 1330 (CF); DH 7.44-7.52 (1H, t), 7.88-8.04 (5H, m), 
8.66-8.70 (IH, d), 8.70 (1H, s, Ar2'H), 9.3 (lH, br s, CONH), 13.6 (lH, br s, INH); 
DC 48.92 (CF3), 115.63, 121.87, 123.11, 123.57, 127.23, 129.89, 130.55, 130.66, 
131.23, 135.73, 135.98, 150.71, 166.45; m/z (EI) 305 (M+), 288 (-NH3), 260 (-CO), 
145 (CF3Ph+). 
Methyl 2-amino-3-N-(3'-methoxybenzoyl)aminobenzoate 
o 
OMe 
OMe 
Following standard procedure A, a solution of methyl 2,3-
diaminobenzoate 33 (670.3 mg, 4.04 mmol), dry triethylamine 
(842.6 ~t1, 6.06 mmol) and DMAP (25 mg) in THF (20 m!) was 
prepared. A solution of 3-methoxybenzoyl chloride (567 ~d, 
4.04 mmol) in THF (20 ml) was added dropwise and stirred. 
The resulting solid residue was purified by column 
chromatography using dichloromethane : methanol 99: 1, and 
recrystallisation twice from petrol and ethyl acetate to yield the title compound, (282.6 
") ... 0 ) mg, _.' 0 . 
mp 124-12~ "C, Anal Found: C 63.90, H 5.1 L N 9.24 CI6HI6:\20 .. Requires: C 
()-l.0, II) 33, N l) 33 0 o, uma\(cm- 1) 3386 (:':H), 1698 (CO), 16-l() (CO), 125027; DH 
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3.92 (3H, s, ArOCB3), 3.93 (3H, s, C02CB3), 6.61 (2H, s, ;-''B2) , 6.68-6.76 (lH, t), 
7.22-7.27 (IH, d), 7.44-7.47 (lB, d), 7.49-7.57 (lB, t), 7.66 (lB, s, 2'-B), 7.67-7.71 
(lB, d), 7.79-7.84 (lB, d), 9.8 (lB, s, NB); m = (EI) 300 (i\r~), 283 (-NH3)' 135 
(MeOPhCO+), 107 (MeOPh+). 
Methyl 2-(3'-methoxyphenyl)-1-H-benzimidazole-4-carboxylate Acetate Salt 
o 
OMe 
OMe 
Following standard procedure B, methyl 2-amino-3-N-
(3'-methoxybenzoyl) aminobenzoate (356.9 mg, 1.19 
mmol) was heated in glacial acetic acid (12 ml). The 
removal of the solvent under reduced pressure, followed 
by recrystallisation from petrol and ethyl acetate, 
afforded the title compound, (235.6 mg, 58%). 
mp 93-94 °C; Anal. Found: C 62.66, H 5 13, N 8.06. 
C16H14N203.CH3C02B Requires: C 63.16, B 5.26, N 
8.18 %; umax(cm-1) 1707 (CO); OH 1.99 (3B, S, CB3C02B), 3.96 (3B, s, ArOCH3), 
4.06 (3H, s, C02CB3), 7.15-7.21 (lB, d), 7.38-7.46 (lB, t), 7.51-7.59 (lB, t), 7.91-
8.00 (3B, m), 8.04-8.08 (IH, d), 12.0 (lB, s, NH), 12,5 (IH, s, C02B); m = (EI) 282 
(M+-CB3C02H), 250 (-MeOH), 60 (CH3C02H). 
2-(3'-Methoxyphenyl)-1-H-benzimidazole-4-carboxamide (NUI098) 76 
o Following standard procedure C, a liquid ammoma 
solution of methyl 2-(3 '-methoxyphenyl)-I-H-
benzimidazole-4-carboxylate (203 mg, 0.6 mmol) was 
heated at 80 C( under constant volume. The solid 
residue \vas recrystallised from methanol to afford the 
OMe product. (73.5 mg, -+6° 0). 
mp 223-225 °C; Anal. Found: C 67.5:. H -+.91, ;\ l:\()2 
163 
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ClSH13N302 Requires: C 67.42, H 4.87, )J 15.73 %; umax(cm- 1) 3409 C\11) , 3169 
(NH), 1662 (CO); bH 3.99 (3H, s, OCB3), 7.22-7.27 (IH, d), 7.43-:51 (lH, t), 7.58-
7.66 (IR, t). 7.85-8.01 (5H, m), 9.4-9.5 (lH, br s, COND), 13.5 (lH, br s, INH); m = 
(EI) 267 (M+), 250 (-NH3)' 
Methyl 2-amino-3-N-(2'-trifluoromethylbenzoyl)aminobenzoate 79 
o 
OMe 
Following standard procedure A, methyl 2,3-diaminobenzoate 
33 (564 mg, 3.4 mmol) was dissolved in THF (20 ml), with 
triethylamine (709 ~l, 5.1 mmol) and DMAP (21 mg). A THF 
(20 ml) solution of 2-trifluoromethylbenzoyl chloride was 
added dropwise and the mixture stirred. The resulting oily 
residue was absorbed onto silica and subjected to column 
chromatography with 99: 1 dichloromethane : methanol as 
eluent. The pure product was obtained after recrystallisation 
from petrol and ethyl acetate, (303 mg, 260/0). 
mp 163-166 °C; Anal. Found: C 56.91, H 3.75, N 8.29. C16H13F3N203 Requires: C 
56.80, R 3.85, N 8.28 0/0; umax(cm-1) 1697 (CO), 1664 (CO), 1313 (CF); bH 3.94 
(3R, s, C02CB3), 6.58 (2R, s, NH2), 6.74-6.82 (lH, t), 7.57-7.62 (lH, d), 7.79-8.03 
(5H, m), 10.0 (lR, s, NH); m/= (EI) 338 (M+), 321 (-NH3), 289 (-MeOH), 173 
(CF3PhCO+), 145 (CF3Ph+). 
2-(2'-Trifluoromethylphenyl)-1-H-benzimidazole-4-carboxylic acid 
o 
OH A suspenSIOn of methyl 2-amino-3 -X-(2'-trifluoromethyl) 
aminobenzoate 79 (150 mg. 0 . .+,+ mmol) in '+~I Hel (5 ml) 
was prepared and retluxed for 3 h. The clear solution was 
allowed to cool to 25 cC and using 2\ 1 N aOH solution was 
adjusted to pH 5 The product was extracted with ethyl 
16.+ 
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acetate (3x 15 ml) and the organic layer was dried (1\a2S0~). Removal of the solvent 
under reduced pressure yielded a white solid that was recrysallatised from petrol and 
ethyl acetate, (81.47 mg, 600/0). 
mp 266-267 °C; umax(cm- 1) 1676 (CO), 1316 (CF); bH 7.41-7.49 (lH, t), 7.89-8.08 
(6H, m), 12.8 (lH, br s, NH), 13.0-13.6 (IH, br s, CO2 B); m = (EI) 306 (M+), 288 (_ 
H20), 260 (-CO). 
2-(2' -Methoxyphenyl)-1-H-benzimidazole-4-carboxylic Acid 80 
o 
OH 
Following standard procedure A, methyl 2,3-
diaminobenzoate 33 (460 mg, 2.77 mmol) was dissolved in 
THF (15 ml), and triethylamine (579 Ill, 4.16 mmol) and 
DMAP (17 mg) were added. 2-Methoxybenzoyl chloride 
(413 Ill, 2.77 mmol) was dissolved in THF (15 ml) and added 
dropwise to the reaction. After stirring for 12 h, a 
precipitate was collected, partitioned between ethyl acetate 
(20 ml) and water (20 ml), and washed with water (20 ml) and saturated brine (10 ml). 
The organic solvents were removed under reduced pressure, the solid recovered was 
added to 4M HCI (10 ml), and the solution refluxed for 3 h. The solution was allowed 
to cool to 25°C and an off white precipitate was collected by filtration. This was 
recrystallised twice from methanol to yield the title product, (110.7 mg, 200/0). 
mp 263-265 °C; umax(cm- 1) 1686 (CO); bH 4.16 (3H, s, OCB3), 73-+-7.-+1 (lH, t), 
7.49-7.53 (IH, d), 7.70-7.78 (IH, t), 7.79-7.8-'+ (lH, t), 8.1-+-8.17 (lH, d), 8.21-8.24 
(IH, d), 8.35-839 (lH, d): m = (EI) 268 (~l+), 250 (-H20), 222 (-CO). 
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2-(2' -Methoxyphenyl)-1-H-benzimidazole-4-carboxamide 81 
o 2-(2'-Methoxyphenyl)-1-H-benzimidazole-4-carboxylic acid 
80 (56 mg, 0.21 mmol) was suspended in THF (2 ml) and 
thionyl chloride (50.4 j..ll, 0.69 mmol) and a catalytic amount 
of DMF (2 drops) were added. The reaction was stirred 
under an inert gas atmosphere for 48 h, after which time 
ammonia solution (5 ml), was added to the reaction and the 
mixture was stirred overnight. Water (1 ml) was added and 
the pH of the solution adjusted to 7 with 4M HCl. The white precipitate was 
collected, washed with water, and recrystallised from methanol to yield 81, (l2 mg, 
22%). 
mp 219-220 °C; umax(cm- l ) 3421 (NH), 1674 (CO); bH 4.15 (3H, s, OCB3). 7.27-
7.28 (lH, t), 7.37-7.45 (2H, m), 7.63-7.65 (lH, t), 7.87-7.89 (lH,d), 7.92 (lH, br s, 
CONH), 7.95-7.98 (lH, d), 8.47-8.50 (lH, d), 9.50 (lH, br s, CONH), 12.60 (1H, br 
s, INH); mlz (EI) 267 (M+), 250 (-NH3)' 222 (-CO). 
2-('" -Methoxyphenyl)-1-methylbenzimidazole-4-carboxamide (NU1090) 82 
o 
OMe 
2 - (4' - Methoxyphenyl) - 1 - H - benzimidazole - 4 -
carboxamide 56 (l05.3 mg, 0.4 mmol) and powdered 
potassium hydroxide (22mg, 0.4 mmol) were suspended in 
acetone (of ml) and stirred until all the solids had dissolved. 
1\ {ethyl iodide (24.6 j..ll, 0.4 mmol) was added and the 
mixture stirred at room temperature overnight. The 
solvent was removed under reduced pressure and the white 
solid residue was purified by column chromatography \\ith 
dichloromethane : methanol 95 5 as eluent, to ~ive fine \\hite crystals of the title 
compound. en 2 mg. 300,0,) 
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mp 289-292 °C~ Anal. Found: C 68.62, H 5.36, ?\ 14.67. C16H15\:302 Requires: C 
68.33, H 5.34, N 14.95 %~ umax(cm-1) 3309 (NH), 1671 (CO), 0H 3.95 (3H, s, 
ArOCll3), 4.02 (3H, s, NCll3), 7.22-7.27 (2H, d, Ar3'/5'H), 7.44-7.52 (1 H, t, :\r6H), 
7.86-8.00 (5H, m), 9.4 (lH, br s, CONH)~ 0e 37.31 (NCH3), 60.65 (OCH3), 119.45, 
119.52, 126.62, 127.09, 127.50, 128.30, 136.32, 142.15, 145.40, 158.85, 165.98, 
171.28~ mlz (El) 281 (M+), 264 (-NH3), 250 (MeO+). 
Benzyl 4-Nitrophenylcarbonate 83 124 
4-Nitrophenol (3.4 g, 0.02 M) was dissolved in dry THF (16 ml), and triethylamine 
(3. S ml) was added to form a yellow solution. A solution of benzyl chloroformate 
(3.33 ml) in THF (8 ml) was added and the solution was stirred under an inert gas 
atmosphere for 12 h. A yellow precipitate of triethylamine hydrochloride was removed 
by filtration and a solid residue obtained by the removal of the solvent under reduced 
pressure. The solid residue was dissolved in ether, and washed with O.IM NaOH (10 
ml) until the washings were colourless. The organic layer was washed twice with 
water (10 ml), dried (MgSO -l), and the solvents removed under reduced pressure to 
yield a white solid, (2.5 g, 39%). 
mp 76-78 °C, umax(cm- 1) 1755 (CO), 1527 (N02); 0H 5.42 (2H, s, -CH2-), 7.49-7.59 
(SH, m, Ph), 7.66-7.70 (2H, d), 8.40-8.44 (2H, d); m= (EI) 139 (HOPhN02), 108 
(PhCH20H), 91 (PhCH2 +). 
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2-( 4'-Methoxyphenyl)-1-N-benzoylbenzimidazole-4-carboxamide (~r II 01) 84 
o 
OMe 
A solution of 2-( 4'-methoxyphenyl)-I-H-
benzimidazole-4-carboxamide 56 (75.1 mg, 0.28 
mmol) and powdered potassium hydroxide (15.8 
mg, 0.28 mmol) was prepared in acetone (3 ml) 
and was stirred until all the solids had dissolved. 
Benzoyl chloride (32.6 Ill, 0.28 mmol) was added 
and the solution stirred for 12 h, at room 
temperature, with the production of a white 
precipitate. The solvents were removed under reduced pressure, and the white residue 
was purified by column chromatography using dichloromethane : methanol, 95: 5. The 
resulting solid was recrystallised from petrol and ethyl acetate to yield the product as 
white prisms, (15.6 mg, 15%). 
mp 207-210 °C; Anal. Found: C 70.45, H 4.60, N 10.99. C22H17N303·025CH30H 
Requires: C 70.45, H 4.47, N 11.08 0/0; uma,,(cm- 1) 3446 (NH), 1690 (CO), 1666 
(CO); 0H 3.86 (3H, s, OCB3), 7.02-7.06 (2H, d, Ar3 '/5'H), 7.50-7.65 (4H, m), 7.72-
7.82 (3H, m), 7.88-7.92 (2H, d), 8.08 (lH, s, CONH), 8.10-8.14 (IH, d, Ar5H), 9.1-
9.2 (lH, br s, CONB); m z (El) 371 (M+), 105 (PhCO+). 
2-( 4' -Methoxyphenyl)-I-N-benzyloxycarbonylbenzimidazole-4-carboxamide 
o 
N O-{ 
o 
(NUII05) 85 
NH2 2-( 4'-Methoxyphenyl)-I-H-benzimidazole-4-
carboxamide 56 (-U 7 mg, 1.64 mmol) \\·as 
suspended in acetone (18 ml), po\vdered 
potassium hydroxide (91 ~ mg) \\as added 
and the solution was stirred until all the 
OMe solids had dissoh"ed. Benzyl chloroformate 
16S 
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(234 j.ll, 1.64 mmol) was added and the solution was stirred at 25 8 C for 2 h, with the 
formation of a white precipitate. The solid was collected, washed with water, and 
purified using column chromatography with dichloromethane : methanol, 24: 1, as 
eluent. Recrystallisation from methanol afforded the product as a white solid, (3982 
mg,61%). 
mp 202-204 °C; Anal. Found: C 67.59, R 4.53, N 10.55. C23R19N30~.0.35H20 
Requires: C 67.76, R 4.83, N 10.31 0/0; umax(cm- l ) 3379 (NH), 3164 (NH), 1746 
(CO), 1687 (CO); CH 3.92 (3R, s, OCR3), 5.51 (2R, s, -CRr), 7.05-7.10 (2R, d, 
J=8.8, Ar3'/5'R), 7.37-7.48 (5R, m, Ph), 7.57-7.65 (lR, t, Ar6H), 7.68-7.86 (2H, d, 
J=8.8, Ar2'/6'H), 8.01 (IR, br s, CONH), 8.08-8.13 (lH, d, Ar7R), 8.23-8.27 (1H, d, 
Ar5R), 9.02 (lR, br s, CONH); mlz (EI) 401 (M+), 267 (-Z), 250 (-NH3), 222 (-CO). 
Dibenzyl chlorophosphonate 89 1~1,1~2 
N-Chlorosuccinamide freshly recrystallised from glacial acetic 
acid (365.4 mg, 2.74 mmol) was suspended in dry ether (10 
mI). Dibenzyl phosphite (604 j.ll, 2.74 mmol) was added, and 
the solution stirred overnight at room temperature under argon, yielding a white 
precipitate of succinamide. The solid was removed by filtration, and the solvents 
removed under reduced pressure. If white crystals of succinamide persisted in the 
yellow oil obtained, it was redissolved in a small quantity of dry ether (3 ml) and 
filtered. This was repeated until the oil was free of solid contaminants and was 
colourless, (352 mg, 65%). 
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2-( 4' -Dibenzylphosphophenyl)-1-H-benzimidazole-4-carboxamide 90 
Method 1 
o Under an argon atmosphere 2-( 4'-hydroxy 
phenyl) - I - H - benzimidazole-4-carboxamide 
73 (300 mg, 1.87 mmol) was suspended in dry 
acetonitrile (20 ml) with Hunigs base (24 7 ~t1, 
1.42 mmol). Dibenzyl chlorophosphonate 89 
(352 mg, 1.19 mmol), dissolved in dry 
acetonitrile (10 ml), was added to the reaction 
dropwise over 0.5 h. The reaction was allowed 
to stir for 4 h, before quenching with 
isopropanol (8 ml), and stirring for a further 0.5 h. Removal of the solvents under 
reduced pressure yielded a yellow oil, that was partitioned between dichloromethane 
and water. The solution was filtered to remove unreacted starting material, and the 
organic layer was washed with excess water, and dried (Na2S0-l). Removal of the 
solvents under reduced pressure, and purifying by column chromatography usmg 
dichloromethane: methanol, 95:5, yielded the product, (70.5 mg, 10% ). 
mp 175-177 °C; Anal. Found: C 65.26, H 4.66, N 7.80. C28H2-lN30SP Requires: C 
65.50, H 4.68, N 8.19 %; umax(cm-1) 3227 (NH), 1666 (CO); bH 5.30-5.34 (4H, d, 2x 
-CHr ), 7.46-7.53 (3H, m), 7.50 (lOH, s, 2xPh), 7.92-7.93 (IH, d, Ar7H), 7.97 (lH, 
s, COND), 8.00-8.01 (lH, d, Ar5D), 8.34-8.38 (2H, d), 9.4 (IH, s, CONH), 13.5 
(lH, s, INH); Dp -5.78 (s); Il1':: (FAB) 514 (M++l), 497 (-NH3), 91 (PhCHr )· 
lVlethod 2 
2-( -l'-Hydroxyphenyl)-I-H-benzimidazole-4-carboxamide 73 (698 mg, 2 76 mmol) was 
suspended in dry acetonitrile (40 ml). The solution was cooled to -10°C and under an 
inert gas atmosphere carbon tetrachloride (1 :)3 ml, 0.01-+ mmol). Hunigs base (1.01 
ml, 5 79 mmol) and DrvlAP (33.7 mg. 0.28 mmol) \\·ere added to the solution, which 
\\as then stirred for one minute before the addition of dibenzyl phosphite (1.22 ml 
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5.52 nunol). The mixture was stirred at -10°C for 1. 5 h, after which time potassium 
dihydrogen-ortho-phosphate (0.5 M, 25 ml) was added and the flask was allo\ved to 
warm to room temperature. The solution was washed with ethyl acetate (20 ml), and 
the organic layer was washed twice with water (40 ml), and once with saturated brine 
(20 ml). The organic layer was dried (Na2S04), and the solvents removed under 
reduced pressure. The resulting oil was purified using column chromatography with 
dichloromethane : methanol, 95 :5, to elute the product as a white amorphous solid, 
(334.1 mg,290/0). 
2-( 4' -Phosphophenyl)-I-H-benzimidazole-4-carboxamide 92 
The benzyl protected phosphate 90 (300 mg, 0.59 
mmol) was dissolved in a mixture of water (30 ml) 
and THF freshly distilled from lithium aluminium 
hydride (30 ml). Palladium (10%) on carbon catalyst 
(100 mg) was added as a slurry in water. The mixture 
was hydrogenated under atmospheric pressure for 1 h. 
/9 Methanol (60 ml) was added to the solution to 
O-p I 'OH dissolve all the solids, and the catalyst was removed 
HO 
by filtration through filtration through Celite®. The 
solvents were removed under reduced pressure, and recrystallisation from methanol 
yielded the phosphate 92, (47.2 mg, 240/0). 
mp 248-250 °C; umax(cm-1) 3387 (NH), 1668 (CO), 1611 (PO); bH 7.42-7.46 (3H, m, 
Ar3 1/5 1/6H), 7.81-7.85 (IH, d, Ar7H), 7.88 (IH, s, CONH), 7.93-7.97 (1H, d, Ar5H), 
7.97-831 (2H, d, Ar21/6'H), 9.4 (IH, s, CONH), 13.5 (1H, br s, INH); bp -5.32 
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8.4 Index of Compounds Synthesised 
2,3-Diaminobenzoic Acid 32 
Methyl 2,3-diaminobenzoate 33 
2-Amino-3-Nitrobenzoic Acid ( 3-Nitroanthranilic Acid) 36 
2-Carboxamido-3-nitrobenzoic Acid (3-Nitrophthalamic acid) 38 
Methyl 2-amino-3-nitrobenzoate 39 
l-H-Benzimidazole-4-carboxylic acid (NUI067) 41 
2-Methyl-I-H-benzimidazole-4-carboxylic acid 42 
l-H-Benzimidazole-4-carboxamide (NUl 066) 43 
2-Methyl-l-H-benzimidazole-4-carboxamide (NUl 064) 44 
2-Trifluoromethyl-I-H-benzimidazole-4-carboxamide (NUl 086) 45 
Methyl 2-Trifluoromethyl-l-H-benzimidazole-4-carboxylate 46 
Methyl 2-N-(Trifluoroacetyl)amino-3-nitrobenzoate 47 
2-Phenyl-I-H-benzimidazole-4-carboxamide (NU 1 070) 48 
2-Phenyl-l-H-benzimidazole-4-carboxylic Acid 49 
2-Acetylamino-3-nitrobenzoic Acid 50 
Methyl 2-Amino-3-N-benzoylbenzoate 51 
Methyl 2-amino-3-N-( 4'-methoxybenzoyl)aminobenzoate 53 
Methyl N, N'-bis( 4'-nitrobenzoyl)-2,3-diaminobenzoate 54 
Methyl 2-( 4'-methoxyphenyl)-I-H-benzimidazole-4-carboxylate 55 
2-( 4'-Methoxypheny)-I-H-benzimidazole-4-carboxamide (NU 1 076) 56 
2-( 4'-Trifluoromethyl)-I-H-benzimidazole-4-carboxamide (NU 1 077) 57 
Methyl 2-amino-3-N-( 4'-trifluoromethylbenzoyl)aminobenzoate 58 
~lethyl 2-( 4'-trifluoromethylphenyl)-I-H-benzimidazole-4-carboxylate 59 
2-( 4'-l\lethoxyphenyl)-I-H-benzimidazole-4-carboxylic Acid 62 
2-( 4'_Nitrophenyl)-I-H-benzimidazole-4-carboxamide (NtT 1091) 64 
1\ lethvl 2-amino-3-N-( 4'-nitrobenzoyl)aminobenzoate 69 
1\ leth~'1 2-( 4'-;'\itrophenyl)-I-H-benzimidazole-4-carbox~'late 70 
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4-Cyanobenzoyl Chloride page 156 
Methyl 2-amino-3-N-( 4'-cyanobenzoyl)aminobenzoate 156 
Methyl 2-( 4'-cyanophenyl)-I-H-benzimidazole-4-carboxylate 157 
2-( 4'-Cyanophenyl)-1-H-benzirnidazole-4-carboxamide (NU I 092) 71 157 
2-( 4'-Carboxyphenyl)-I-H-benzimidazole-4-carboxamide (NU 11 07) 72 158 
2-( 4'-Hydroxyphenyl)-1-H-benzimidazole-4-carboxylate (NU 1 085) 73 151 
2-( 4'-Aminophenyl)-I-H-benzirnidazole-4-carboxamide (NU II 03) 74 160 
Methyl 2-arnino-3-N-( 4' arninobenzoyl)aminobenzoate 75 159 
Methyl 2-( 4'-aminophenyl)-I-H-benzimidazole-4-carboxylate 159 
Methyl 2-amino-3-N-(3'-trifluoromethylbenzoyl)aminobenzoate 160 
Methyl 2-(3'-trifluoromethylphenyl)-1-H-benzimidazole-4-carboxylate 161 
Methyl 2-amino-3-N-(3'-methoxybenzoyl)aminobenzoate 162 
Methyl 2-(3'-methoxyphenyl)-I-H-benzimidazole-4-carboxylate 163 
2-(3'-Methoxyphenyl)-1-H-benzimidazole-4-carboxamide (NU 1 098) 76 163 
2-(3'-Trifluoromethylphenyl)-I-H-benzimidazole-4-carboxamide (NU 1 093) 77 162 
Methyl 2-amino-3-N-(2'-trifluoromethylbenzoyl)aminobenzoate 79 164 
2-(2'-Trifluoromethylpheny\)-1-H-benzimidazole-4-carboxylic Acid 164 
2-(2'-Methoxyphenyl)-I-H-benzimidazole-4-carboxylic Acid 80 165 
2-(2'-Methoxyphenyl)-I-H-benzimidazole-4-carboxamide 81 166 
2-( 4'-Methoxyphenyl)-I-methylbenzimidazole-4-carboxamide (NU 1 090) 82 166 
Benzyl 4-Nitrophenylcarbonate 83 167 
2-( 4'_Methoxyphenyl)-I-N-benzoylbenzimidazole-4-carboxamide (NU II 0 1) 84 168 
2-( 4'_Methoxyphenyl)-I-N-benzyloxycarbonylbenzimidazole-4-carboxamide 
(NUl 105) 85 
Dibenzyl chlorophosphonate 89 
2-( 4'_Dibenzylphosphophenyl)-I-H-benzimidazole-4-carboxamide 90 
2-( 4'_Phosphophenyl)-I-H-benzimidazole-4-carboxamide 92 
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Appendix: Crystallography Data 
Table 1. Crystal data, structure solution and refinement for btg29. 
Identification code 
Chemical for.mula 
Formula weight 
Temperature 
Radiation and wavelength 
Crystal system, space group 
Unit cell dimensions 
volume 
z 
Density (calculated) 
Absorption coefficient ~ 
F(OOO) 
Reflections for cell refinement 
Crystal colour 
Crystal size 
Data collection method 
e range for data collection 
Index ranges 
Reflections collected 
Independent reflections 
Reflections with I>2a(I) 
Absorption correction 
Structure solution 
Refinement method 
Weighting parameters a, b 
Data / restraints / parameters 
2 Goodness-of-fit on F 
Final R indices [I>2a(I)] 
R indices (all data) 
Extinction coefficient 
Largest and mean shift/esd 
Largest diff. peak and hole 
btg29 
C15H13N302 
267.28 
160(2) K 
MoKa, 0.71073 A 
monoclinic, P2 /n 
1 
a = 8.4535(14) A 
b = 14.076(2) A 
c = 10.914(2) A 
1291.0(3) .3 A 
4 
1. 375 g/cm 3 
0.094 -1 mm 
560 
o 
a = 90 
~ = 96.24(5)0 
"y = 90 0 
o 3146 (9 range 2.37 to 28.07 ) 
Colourless 
0.36 x 0.30 x 0.04 mm 
Siemens SMART CCD diffractometer, 
w rotation with narrow frames 
2.37 to 25.000 
-11 s h s 7, -17 s k s 18, -8 s 1 s 14 
6657 
2267 (R, = 0.0431) 
~nt 
1767 
none 
direct methods 
2 
full-matrix least-squares on F 
0.0379, 0.4255 
2242 / 0 / 192 
1. 076 
R1 = 0.0404, wR2 = 0.0859 
R1 = 0.0605, wR2 = 0.0981 
0.016(2) 
0.000 and 0.000 
. -3 
0.213 and -0.160 eA 
lX3 
Appendix. Crystallograph.',,' Data 
Table 2. Atomic coordinates 4 x 10) and equivalent isotropic displacement 
.2 3 
parameters (A x 10 ) for btg29. U(eq) is defined as one third of the trace of 
the orthogonalized U" tensor. 
~J 
x y z U(eq) 
0(1) 911.9(14) 1109.4(8) 364.2(11) 28.2(3) 
N (1) 1155(2) 298.8(11) -1386(2) 29.2(4) 
e (1) 1505(2) 1026.9(12) -631(2) 23.5(4) 
e(2) 2607(2) 1763.5(12) -1025(2) 23.5(4) 
e(3) 3212(2) 2454.9(13) -189(2) 27.1(4) 
e(4) 4238(2) 3169.8(13) -514(2) 28.8(4) 
e(5) 4672(2) 3237.0(12) -1697(2) 28.1(4) 
e (6) 4063(2) 2548.7(12) -2532(2) 24.7(4) 
e(7) 3067(2) 1809.7(12) -2223(2) 23.4(4) 
N (2) 2735(2) 1201.1(10) -3220.1(12) 24.6(4) 
e (8) 3520(2) 1562.5(12) -4102(2) 24.4(4) 
N (3) 4321(2) 2376.6(11) -3734.3(13) 27.0(4) 
e(9) 3590(2) 1136.7(13) -5313 (2) 25.7(4) 
e(10) 4368(2) 1590(2) -6215(2) 34.0(5) 
e (11) 4502(2) 1165(2) -7333 (2) 37.7(5) 
e(12) 3836(2) 278.4(14) -7601(2) 32.0(5) 
e(13) 3035(2) -180.6(14) -6717(2) 32.2(5) 
e(14) 2939(2) 244.5(13) -5584(2) 29.4(4) 
0(2) 4048(2) -77.8(10) -8728.0(11) 41.7(4) 
e(15) 3259(3) -943(2) -9104(2) 42.4(5) 
Appendix: Crystallography Data 
Table 3. Bond lengths (A) and angles (0) for btg29. 
O(l)-C(l) 1.250(2) N(l) -C (1) 1.329(2) 
C(l) -C(2) 1.488(2) C(2) -C(3) 1.393(2) 
C(2) -C(7) 1.406(2) C(3)-C(4) 1.399(3) 
C(4) -C(5) 1.384 (3) C(5)-C(6) 1.390(2) 
C(6) -N(3) 1.375(2) C(6)-C(7) 1.402(2) 
C(7) -N(2) 1.389(2) N(2)-C(8) 1.328(2) 
C(8) -N(3) 1.369(2) C(8) -C(9) 1.459(2) 
C(9) -C(14) 1.390(3) C(9)-C(10) 1.396(2) 
C(10) -C(11) 1.375(3) C(ll) -C(12) 1.386(3) 
C(12) -0(2) 1.358(2) C(12)-C(13) 1.396(3) 
C(13)-C(14) 1.383 (2) 0(2)-C(15) 1.427 (2) 
0(1) -C(l) -N(l) 121.8(2) 0(1) -C(l) -C(2) 120.6(2) 
N(l) -C(l) -C(2) 117.5(2) C(3) -C(2) -C(7) 117.3(2) 
C(3) -C(2) -C(l) 119.6(2) C(7) -C(2) -C(l) 123.1(2) 
C(2) -C(3) -C(4) 122.0(2) C(5) -C(4) -C(3) 121.3 (2) 
C(4) -C(5) -C(6) 116.6(2) N(3) -C(6) -C(5) 131. 5 (2) 
N(3) -C(6) -C(7) 105.1(2) C(5) -C(6) -C(7) 123.3(2) 
N(2) -C(7) -C(6) 110.2(2) N(2) -C(7) -C(2) 130.3(2) 
C(6) -C(7) -C(2) 119.5(2) C(8) -N(2) -C(7) 104.86(14) 
N(2) -C(8) -N(3) 112.3 (2) N(2) -C(8) -C(9) 124.9(2) 
N(3) -C(8) -C(9) 122.8(2) C(8) -N(3) -C(6) 107.59(14) 
C(14) -C(9) -C(10) 118.0(2) C(14) -C(9) -C(8) 120.6(2) 
C(10) -C(9) -C(8) 121.3 (2) C (11) -C (10) -C (9) 121.1(2) 
C(10) -C(ll) -C(12) 120.5 (2) 0(2) -C(12) -C(11) 115.6(2) 
0(2) -C(12) -C(13) 125.2(2) C(11) -C(12) -C(13) 119.2(2) 
C(14) -C(13) -C(12) 119.8(2) C(13) -C(14) -C(9) 121.3 (2) 
C(12) -0(2) -C(15) 118.2(2) 
185 
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Table 4. Anisotropic displacement parameters (A2 x 10 3 ) for btg29. 
The anisotropic displacement factor exponent takes the form: 
222 -2~ (h a* 0 + ... + 2hka*b*u ). 
11 12 
0(11) U (22) U(33) o (23) 0(13) 
0(1) 31.2 (7) 25.3(7) 30.4(7) 
-2.5(5) 14.0(6) N (1) 35.7(9) 27.3(9) 27.1(9) 
-3.6(7) 14.4(7) C (1) 21.5(9) 22.4(9) 27.1(10) 0.2(7) 5.1(7) C(2) 21.3 (9) 22.1(9) 27.5(10) 2.0(7) 4.6(7) C(3) 24.6(10) 27.4(10) 29.5(10) 
-2.1(8) 3.5(8) C(4) 27.9(10) 23.3(9) 34.5(11) 
-4.0(8) 0.1(8) C(5) 26.4(10) 21.4 (9) 36.2(11) 4.0(8) 2.2(8) C(6) 21.7(9) 24.7(9) 27.6(10) 3.5(8) 2.1(7) C(7) 20.9(9) 21.9(9) 27.4(10) 2.1(7) 2.9(7) N(2) 24.3(8) 25.1(8) 24.7(8) 2.5(6) 4.2(6) C(8) 22.5(10) 25.1(9) 25.3(10) 4.4(8) 1. 3 (7) N (3) 27.8(8) 25.7(9) 28.1(9) 5.3(7) 5.5(7) C(9) 22.2(9) 30.2(10) 24.4(9) 4.2(8) 1.2 (7) C(10) 33.1(11) 39.0(11) 30.2(11) 2.5(9) 5.0(8) C(11) 37.6(12) 50.1 (13) 26.7(11) 4.1(9) 9.3(9) C(12) 28.1(10) 43.3(12) 24.2(10) 
-1.6(9) 1.2 (8) C(13) 34.5(11) 28.9(10) 32.9(11) 
-0.7(8) 2.1(8) C(14) 30.8(10) 28.7(10) 29.2(10) 4.8(8) 6.1(8) 0(2) 42.0(8) 53.5(9) 30.3(8) 
-8.0(7) 7.1(6) 
0(12) 
0.8(5) 
-8.0(7) 
4.0(7) 
2.8(7) 
3.7(8) 
0.2 (8) 
-2.7(8) 
1.0 (8) 
1.8(7) 
-0.5(6) 
-1.0(8) 
-4.7(7) 
1.6(8) 
-8.0(9) 
-8.4(10) 
8.5(9) 
2.3(8) 
1.1(8) 
4.6(7) C(15) 45.9(13) 44.5(13) 35.5(11) 
-8.5(10) 
-1.5 (9) 13.8(10) 
Table 5. Hydrogen atom coordinates x and isotropic displacement 
.2 3) f b 29 parameters (A x 10 or tg . 
x y z 0 
H(lA) 473 (23) -160(14) -1151(17) 35 
H(lB) 1561(23) 285(14) -2137(18) 35 
H(3) 2919(2) 2440.7(13) 627(2) 33 
H(4) 4646(2) 3618.1(13) 91(2) 35 
H (5) 5352(2) 3728.3(12) -1927(2) 34 
H (3A) 4879(22) 2761(14) -4188(16) 32 
H(10) 4812(2) 2203 (2) -6054 (2) 41 
H (11) 5054(2) 1480(2) -7928(2) 45 
H(13) 2558(2) -783.3(14) -6892(2) 39 
H(14) 2416(2) -79.9(13) -4980(2) 35 
H (15A) 3512 (13) -1115(5) -9930(5) 64 
H(15B) 2106(3) -859(3) -9116(12) 64 
H(15C) 3616(12) -1450(3) -8522(7) 64 
ISh 
